
CHAPTER 9

Ischaemic stroke and transient ischaemic attack*

P. A. Ringleb,¹ M.-G. Bousser,² G. Ford,³ P. Bath,⁴ M. Brainin,⁵ V. Caso,⁶ Á. Cervera,⁷ A. I. Chamorro,⁷ Charlotte Cordonnier,⁸ L. Csiba,⁹ A. Davalos,⁷ H.-C. Diener,¹⁰ J. Ferro,¹¹ W. Hacke,¹ M. Hennerici,¹² M. Kaste,¹³ P. Langhorne,¹⁴ K. Lees,¹⁴ D. Leys,⁸ J. Lodder,¹⁵ H. S. Markus,¹⁶ J.-L. Mas,² H. P. Mattle,¹⁷ K. Muir,¹⁴ B. Norrving,¹⁸ V. Obach,⁷ S. Paolucci,¹⁹ E. B. Ringelstein,²⁰ P. D. Schellinger,²¹ J. Sivenius,²² V. Skvortsova,²³ K. Stibrant Sunnerhagen,²⁴ L. Thomassen,²⁵ D. Toni,¹⁹ R. von Kummer,²⁶ N. Gunnar Wahlgren,²⁷ M. F. Walker,²⁸ J. Wardlaw²⁹

¹Heidelberg, Germany; ²Paris, France; ³Newcastle, UK; ⁴Nottingham, UK; ⁵Krems, Austria; ⁶Perugia, Italy; ⁷Barcelona, Spain;

⁸Lille, France; ⁹Debrecen, Hungary; ¹⁰Essen, Germany; ¹¹Lisbon, Portugal; ¹²Mannheim, Germany; ¹³Helsinki, Finland;

¹⁴Glasgow, UK; ¹⁵Maastricht, The Netherlands; ¹⁶London, UK; ¹⁷Bern, Switzerland; ¹⁸Lund, Sweden; ¹⁹Rome, Italy;

²⁰Münster, Germany; ²¹Erlangen, Germany; ²²Kuopio, Finland; ²³Moscow, Russia; ²⁴Göteborg, Sweden; ²⁵Bergen, Norway;

²⁶Dresden, Germany; ²⁷Stockholm, Sweden; ²⁸Nottingham, UK; ²⁹Edinburgh, UK

Preface

This article represents the update of the European Stroke Initiative (EUSI) Recommendations for Stroke Management, which were first published in 2000 [1, 2] and subsequently translated into a number of languages, including Spanish, Portuguese, Italian, German, Greek, Turkish, Lithuanian, Polish, Russian, and Mandarin Chinese. The first update of the recommendations was published in 2003 [2]. In 2006, the EUSI decided that a larger group of authors should prepare the next update. In the meantime, a new European Stroke Society, the European Stroke Organisation (ESO), was established and took over the task of updating the guidelines. Accordingly, the new recommendations have been prepared by members of both the former EUSI Recommendations Writing

Committee and the ESO (see Appendix). The members of the Writing Group met in Heidelberg, Germany, for 3 days in December 2007 to finalize the new recommendations. The members of the Writing Committee were assigned to six groups covering different topics. Each group was co-chaired by two colleagues, and included up to five further experts. To avoid bias or conflict of interest none of the chairs had major involvement in clinical trials or studies discussed in their respective group. In addition, a detailed conflict of interest disclosure form is on file with the editor of the *European Journal of Neurology* and attached to the electronic version of this article. However, due to the large number of authors, the detailed disclosures are not listed in the printed article.

These guidelines cover both ischaemic stroke and transient ischaemic attacks (TIAs), which are now considered to be a single entity. If recommendations differ for the two conditions, this will be explicitly mentioned; otherwise the recommendations are valid for both conditions. Separate guidelines exist or are being prepared for intracerebral haemorrhage [3] and subarachnoid haemorrhage. The classes of evidence and levels of recommendations used in these guidelines are defined according to the criteria of the European Federation of Neurological Societies (EFNS) (table 9.1, table 9.2). The article

*The authors have prepared this guideline on behalf of the European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee

Table 9.1 Classification of evidence for diagnostic and for therapeutic measures (from [583]).

	Evidence classification scheme for a diagnostic measure	Evidence classification scheme for a therapeutic intervention
Class I	A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy	An adequately powered, prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. The following are required: <ul style="list-style-type: none"> a. randomization concealment b. primary outcome(s) is/are clearly defined c. exclusion/inclusion criteria are clearly defined d. adequate accounting for dropouts and crossovers with numbers sufficiently low to have a minimal potential for bias; and e. relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences
Class II	A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy	Prospective matched-group cohort study in a representative population with masked outcome assessment that meets a–e above or a randomized, controlled trial in a representative population that lacks one criterion a–e
Class III	Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation	All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment
Class IV	Evidence from uncontrolled studies, case series, case reports, or expert opinion	Evidence from uncontrolled studies, case series, case reports, or expert opinion

Table 9.2 Definitions for levels of recommendation (from [583]).

Level A	Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least one convincing Class I study or at least two consistent, convincing Class II studies
Level B	Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective, or harmful for a therapeutic intervention; requires at least one convincing Class II study or overwhelming Class III evidence
Level C	Established as useful/predictive or not useful/predictive for a diagnostic measure or established as effective, ineffective or harmful for a therapeutic intervention; requires at least two Class III studies
Good Clinical Practice (GCP) points	Recommended best practice based on the experience of the guideline development group. Usually based on Class IV evidence indicating large clinical uncertainty, such GCP points can be useful for health workers

covers referral and emergency management, Stroke Unit service, diagnostics, primary and secondary prevention, general stroke treatment, specific treatment including acute management, management of complications, and rehabilitation.

Changes in the guidelines necessitated by new evidence will be continuously incorporated in the online version that can be found on the ESO website (eso-stroke.org). The reader is advised to check the online version when making important treatment decisions.

Introduction

Stroke is one of the leading causes of morbidity and mortality worldwide [4]. Large differences in incidence, prevalence, and mortality have been noted between Eastern and Western Europe. This has been attributed to differences in risk factors, with higher levels of hypertension and other risk factors resulting in more severe stroke in Eastern Europe [5]. Notable regional variations have also been found within Western Europe. Stroke is the most important cause of morbidity and long-term disability in Europe, and demographic changes will result in an increase in both incidence and prevalence. It is also the second most common cause of dementia, the most frequent cause of epilepsy in the elderly, and a frequent cause of depression [6, 7].

Many guidelines and recommendations for stroke management or specific aspects of stroke care have been published during the past decade [2, 8–18]. Most recently, the updated Helsingborg Declaration focused on standards of stroke care and research needs in Europe [19]. In the future, the global harmonization of stroke guidelines will be the focus of the World Stroke Organisation, supported by the ESO and other national and regional stroke societies.

Public awareness and education

Recommendations

- Educational programmes to increase awareness of stroke at the population level are recommended (Class II, Level B).
- Educational programmes to increase stroke awareness among professionals (paramedics/emergency physicians) are recommended (Class II, Level B).

The ‘time is brain’ concept means that treatment of stroke should be considered as an emergency. Thus, avoiding delay should be the major aim in the pre-hospital phase of acute stroke care. This has far-reaching implications in terms of recognition of signs and symptoms of stroke by the patient or by relatives or bystanders, the nature of first medical contact, and the means of transportation to hospital.

Delays during acute stroke management have been identified at different levels [20]:

- at the population level, due to failure to recognize the symptoms of stroke and contact emergency services
- at the level of the emergency services and emergency physicians, due to a failure to prioritize transport of stroke patients
- at the hospital level, due to delays in neuroimaging and inefficient in-hospital care.

A large amount of time is lost outside the hospital [21]: for stroke patients at a Portuguese university hospital this accounted for 82% of the delay in treatment [22]. Studies that identify demographic, social, cultural, behavioural, and clinical factors associated with longer pre-hospital time may provide targets for educational campaigns [23, 24].

The interval from symptom onset to first call for medical help is the predominant part of pre-hospital delay [25–28]. Major reasons for delayed contact include lack of awareness of stroke symptoms and recognition of their severity, but also denial of the disease and the hope that symptoms would resolve. This suggests that educating the population to recognize stroke symptoms, and changing people’s attitudes to acute stroke, may reduce the delay from stroke onset to emergency medical service (EMS) involvement.

Medical attention is rarely sought by the patient: in many cases contact is initially made by a family member [28–30]. Information and educational initiatives should therefore be directed both to persons at high risk of stroke and also to those around them.

Stroke awareness depends on demographic and socio-cultural factors, and on personal medical knowledge. Knowledge of stroke warning signs varies considerably, depending on the symptoms, and is dependent on the way questions are asked (e.g. open-ended or multiple-choice questions [31, 32]).

While most people agree that stroke is an emergency, and that they would seek medical help immediately, in

reality only up to 50% call EMS. In many cases the first contact is with a family member or with a general practitioner; in some studies between 45% and 48% of patients were referred via a general practitioner [29, 33–36].

Most studies show that only approximately 33–50% of patients recognize their own symptoms as stroke. There are considerable discrepancies between theoretical knowledge of stroke and the reaction in case of an acute stroke. Some studies have shown that patients with better knowledge of stroke symptoms do not always arrive earlier at hospital.

The most frequently used sources of stroke information are mass media [37–39] and friends and relatives who have knowledge of stroke; only rarely is information derived from general practitioners or books [40–44]. The sources accessed vary with age: older people more often obtain information from health campaigns or their general practitioner, whereas younger people gain more information from TV [38–40].

Interventional studies have measured the effect of education on stroke knowledge. Eight non-randomized studies measured the impact of educational measures on pre-hospital time delay or thrombolysis use [45–52]. In six studies, the intervention was a combined educational programme directed at the public, paramedics, and health professionals, while in two studies education was directed only to the population. Only the TLL Temple Foundation Stroke Project included a concurrent control group [50, 51]. All studies had a pre-post design. Thrombolysis usage increased after education in the intervention group of the TLL study, but only for up to 6 months after intervention ended [51]. This suggests that public education has to be maintained to sustain stroke awareness in the population.

Education should also be directed to paramedics and emergency department (ED) staff to improve the accuracy of stroke identification and speed up transfer to the hospital [53]. Education of paramedics increases stroke knowledge, clinical skills, and communication skills, and decreases prehospital delays [54].

Educating medical students in basic stroke knowledge during their first year at medical school has been shown to be associated with a high degree of knowledge retention [55]. The value of postgraduate training is universally acknowledged, but training programmes for stroke specialists are still heterogeneous throughout Europe. To

overcome such heterogeneity and to increase the number of specialists available for stroke care, some countries (e.g. France, UK) have developed and implemented national curricula. In contrast, other countries rely on training specialization within neurology training programmes. With a view towards harmonization of training, a European Masters' Programme for Stroke Medicine (www.donau-uni.ac.at/en/studium/strokemedicine/index.php) and annual Stroke Summer Schools (www.eso-stroke.org), have been established.

Referral and patient transfer

Recommendations

- Immediate EMS contact and priority EMS dispatch are recommended (Class II, Level B).
- Priority transport with advance notification to the receiving hospital (outside and inside hospital) is recommended (Class III, Level B).
- It is recommended that suspected stroke victims should be transported without delay to the nearest medical centre with a stroke unit that can provide ultra-early treatment (Class III, Level B).
- It is recommended that dispatchers and ambulance personnel be trained to recognize stroke using simple instruments such as the Face–Arm–Speech–Test (Class IV, GCP).
- Immediate emergency room triage, clinical, laboratory and imaging evaluation, accurate diagnosis, therapeutic decision, and administration of appropriate treatments at the receiving hospital are recommended (Class III, Level B).
- It is recommended that in remote or rural areas helicopter transfer should be considered in order to improve access to treatment (Class III, Level C).
- It is recommended that in remote or rural areas telemedicine should be considered in order to improve access to treatment (Class II, Level B).
- It is recommended that patients with suspected TIA be referred without delay to a TIA clinic or to a medical centre with a stroke unit that can provide expert evaluation and immediate treatment (Class III, Level B).

Successful care of the acute stroke victim begins with the recognition by both the public and health professionals [56] that stroke is an emergency, like acute myocardial infarction or trauma. However, in practice the majority of ischaemic stroke patients do not receive recombinant tissue plasminogen activator (rtPA) because they do not

reach the hospital soon enough [22, 36, 57, 58]. Emergency care of the acute stroke victim depends on a four-step chain:

- rapid recognition of, and reaction to, stroke signs and TIAs
- immediate EMS contact and priority EMS dispatch
- priority transport with notification of the receiving hospital
- immediate emergency room triage, clinical, laboratory and imaging evaluation, accurate diagnosis, and administration of appropriate treatments at the receiving hospital.

Once stroke symptoms are suspected, patients or their proxies should call EMS. The EMS system should have an electronic validated algorithm of questions to diagnose stroke during the phone interview [33, 59]. The ambulance dispatchers and paramedics should be able to diagnose stroke using simple instruments such as the Face–Arm–Speech–Test [60]. They should also be able to identify and provide appropriate help for patients who need urgent care because of early complications or comorbidities of stroke, such as impaired consciousness, seizures, vomiting, or haemodynamic instability.

Suspected stroke victims should be transported without delay to the nearest medical centre with a stroke unit that can provide ultra-early treatment. Patients with onset of stroke symptoms within 3 h should be given priority in evaluation and transportation [20]. In each community, a network of stroke units or, if stroke units are not yet available, a network of medical centres providing organized acute stroke care should be implemented and publicized to the general population, health professionals, and the emergency transport systems [61, 62].

If a doctor receives a call or consultation from a patient with suspected stroke, they should recommend or arrange transportation, preferably through the EMS system, to the nearest hospital with a stroke unit providing organized acute stroke care and ultra-early treatment. Ambulance dispatchers should inform the stroke unit and describe the patient's clinical status. Proxies who can describe symptom onset or the patient's medical history should accompany the patient.

Few intervention studies have examined the impact of decreasing the delay from symptom onset to arrival at the hospital and making ultra-early treatment accessible for a larger proportion of patients. Most such studies have

used a before-and-after intervention design, were neither randomized nor masked with respect to intervention or evaluation of outcome, and lacked concurrent controls [23, 53]. The types of intervention included education and training programmes, helicopter transfer, telemedicine, and reorganization of pre-hospital and in-hospital protocols for acute stroke patients.

Direct presentation to the ED via ambulance or EMS transportation is the fastest way of referral [28, 53, 63–65]. Helicopter transport can reduce the time between referral and hospital arrival [66, 67], and also promotes access to thrombolytic therapy in remote and rural areas [68]. In mixed rural and urban areas, air and ground distances can be compared using simple rules [69]. No studies have compared air and ground transport specifically in stroke patients. In one study, predominantly in trauma patients, ground ambulances provided shorter arrival times at distances less than 10 miles (≈ 16 km) from the hospital; even with only short delays in despatching air transport, air was faster only for distances longer than 45 miles (≈ 72 km) [70]. One economic study showed that helicopter transfer of patients with suspected acute ischaemic stroke for potential thrombolysis is cost-effective [71].

Telemedicine using bidirectional video-conferencing equipment to provide health services or assist health care personnel at distant sites is a feasible, valid, and reliable means of facilitating thrombolysis delivery to patients in distant or rural hospitals, where timely air or ground transportation is not feasible. The quality of treatment, complication rates, and short- and long-term outcomes are similar for acute stroke patients treated with rtPA via a telemedicine consultation at local hospitals and those treated in academic centres [72–81].

Activation of the stroke code as a special infrastructure with immediate calling of a stroke neurologist at a stroke unit and priority transfer of the patients to this centre is effective in increasing the percentage of patients treated with thrombolysis, and also in shortening pre-hospital delays [82, 83].

Recent community and hospital-based studies demonstrated a high risk of stroke immediately after a TIA [6, 84]. Observational studies showed that urgent evaluation at a TIA clinic and immediate initiation of treatment reduces stroke risk after TIA [85, 86]. This underlines the need for urgent referral of TIA for expert evaluation and immediate treatment.

Emergency management

Recommendations

- Organization of pre-hospital and in-hospital pathways and systems for acute stroke patients is recommended (Class III, Level C).
- Ancillary tests, as outlined in table 9.3, are recommended (Class IV, GCP).

In-hospital delay may account for 16% of total time lost between stroke onset and computed tomography (CT) [22]. Reasons for in-hospital delays are:

- a failure to identify stroke as an emergency
 - inefficient in-hospital transport
 - delayed medical assessment
 - delay in imaging
 - uncertainty in administering thrombolysis [20, 21, 24].
- Stroke care pathways may allow care to be organized more effectively, although a meta-analysis [87] did not support their routine implementation. Such pathways may reduce delays in door-to-medical department time, door-to-imaging time [88, 89], door-to-needle time [89] and, where appropriate, door-to-arteriography time.

Acute stroke care has to integrate EMS, ED staff, and stroke care specialists. Communication and collabora-

tion between EMS, ED staff, radiologists, clinical laboratories, and neurologists are important for rapid delivery of treatment [11, 90, 91]. Integrating EMS and ED staff was found to increase the use of thrombolysis [92]. Hospitals where patients are not delivered directly to a stroke unit should implement a system allowing the ED to pre-notify the acute stroke team as soon as possible. Routinely informing ED physicians or stroke physicians during transport has been shown to be associated with reduced in-hospital delay [82, 93-95], increased use of thrombolysis [92, 93], decreased length of hospital stay [95], and decreased in-hospital mortality [92].

A stroke recognition instrument with high diagnostic accuracy is necessary for rapid triage [96]; stroke mimics such as migraine and seizure might be a problem [97, 98]. Stroke recognition instruments such as Face-Arm-Speech-Test and Recognition of Stroke in the Emergency Room (ROSIER) can assist the correct recognition of stroke by ED personnel [60, 97, 99].

A neurologist or stroke physician should be involved in the acute care of stroke patients and available in the ED [98]. Comparing neurologist care to non-neurologist care, two studies in the USA found that neurologists perform more extensive and costly testing, but that their patients had lower in-hospital and 90-day mortality rates, and were less dependent on discharge [100, 101]. However, this might not be true for other countries such as the UK, where most stroke physicians are not neurologists, but are still highly skilled in management of patients with TIA and stroke.

Reorganization of stroke wards can help to avoid bottlenecks and unnecessary in-hospital transport. Brain imaging facilities should be relocated in or next to the stroke unit or the ED, and stroke patients should have priority access [90]. Neuroradiologists should be notified as early as possible [90]. In a Finnish study, in-hospital delays were decreased considerably by moving the CT scanner close to the ED and by implementing a pre-notifying system [94]. Thrombolysis should be started in the CT room or in the vicinity of the scanner. Finally, an arteriography suite should be readily accessible if endovascular treatment is required.

Written care protocols for acute stroke patients should be available; centres using such protocols were found to have higher thrombolysis rates [92]. Implementing a continuous quality improvement scheme can also diminish in-hospital delays [81, 102]. Benchmarks should be

Table 9.3 Emergency diagnostic tests in acute stroke patients.

In all patients

- 1 Brain imaging: CT or MRI
- 2 ECG
- 3 *Laboratory tests*
Complete blood count and platelet count, prothrombin time or INR, partial thrombin time (PTT)
Serum electrolytes, blood glucose
C-reactive protein (CRP) or sedimentation rate
Hepatic and renal chemical analysis

When indicated

- 4 Extracranial and transcranial Duplex/Doppler ultrasound
- 5 MRA or CTA
- 6 Diffusion and perfusion MR or perfusion CT
- 7 Echocardiography (transthoracic and/or transoesophageal)
- 8 Chest X-ray
- 9 Pulse oximetry and arterial blood gas analysis
- 10 Lumbar puncture
- 11 EEG
- 12 Toxicology screen

defined and measured for individual institutions, and have recently been developed for regional networks and countries. As a minimum requirement, door-to-imaging and door-to-treatment times should be monitored.

While only a minority of stroke patients present in an immediately life-threatening condition, many have significant physiological abnormalities or comorbidities. Symptoms and signs that may predict later complications such as space-occupying infarction, bleeding, or recurrent stroke, and medical conditions such as hypertensive crisis, co-existing myocardial infarction, aspiration pneumonia, or cardiac and renal failure, must be recognized early. Stroke severity should be assessed by trained staff using the National Institutes of Health Stroke Scale (NIHSS) [103].

Initial examination should include:

- observation of breathing and pulmonary function
- early signs of dysphagia, preferably with a validated assessment form [104]
- evaluation of concomitant heart disease
- assessment of blood pressure (BP) and heart rate
- determination of arterial oxygen saturation using infrared pulse oximetry if available.

Simultaneously, blood samples for clinical chemistry, glucose, coagulation, and haematology studies should be drawn, and a venous line inserted. The examination should be supplemented by a medical history that includes risk factors for stroke and cardiac disease, medications, conditions that may predispose to bleeding complications, and markers for stroke mimics. A history of drug abuse, oral contraceptive use, infection, trauma, or migraine may give important clues, particularly in young patients.

Stroke services and stroke units

Recommendations

- It is recommended that all stroke patients should be treated in a stroke unit (Class I, Level A).
- It is recommended that healthcare systems ensure that acute stroke patients have access to high technology medical and surgical stroke care when required (Class III, Level B).
- The development of clinical networks, including telemedicine, is recommended to expand access to high-technology specialist stroke care (Class II, Level B).

Providing stroke services

All acute stroke patients require specialist multidisciplinary care delivered in a stroke unit, and selected patients will require additional high-technology interventions. Health services need to establish the infrastructure to deliver these interventions to all patients who require them: the only reason for excluding patients from stroke units is if their condition does not warrant active management. Recent consensus documents [11, 105] have defined the roles of primary and comprehensive stroke centres (table 9.4).

Primary stroke centres are defined as centres with the necessary staffing, infrastructure, expertise, and programmes to provide appropriate diagnosis and treatment for most stroke patients. Some patients with rare disorders, complex stroke, or multi-organ disease may need more specialized care and resources that are not available in primary stroke centres.

Comprehensive stroke centres are defined as centres that provide both appropriate diagnosis and treatment for most stroke patients, and also high-technology medical and surgical care (new diagnostic and rehabilitation methods, specialized tests, automatic monitoring of multiple physiological parameters, interventional radiology, vascular surgery, neurosurgery).

The organization of clinical networks using telemedicine is recommended to facilitate treatment options not previously available at remote hospitals. Administration of rtPA during telemedicine consultations is feasible and safe [106]. Clinical networks using telemedicine systems achieve increased use of rtPA [80, 107] and better stroke care and clinical outcomes [80].

Stroke unit care

An updated systematic review has confirmed significant reductions in death (3% absolute reduction), dependency (5% increase in independent survivors), and the need for institutional care (2% reduction) for patients treated in a stroke unit, compared with those treated in general wards. All types of patients, irrespective of gender, age, stroke subtype, and stroke severity, appear to benefit from treatment in stroke units [61, 108]. These results have been confirmed in large observational studies of routine practice [109–111]. Although stroke unit care is more costly than treatment on general neurological or medical wards, it reduces post-acute inpatient care costs [112, 113] and is cost-effective [114–117].

Table 9.4 Recommended requirements for centres managing acute stroke patients.

Primary stroke centre	Comprehensive stroke centre
Availability of 24-h CT scanning	MRI/MRA/CTA
Established stroke treatment guidelines and operational procedures, including i.v. rTPA protocols 24/7	Transoesophageal echocardiography
Close co-operation of neurologists, internists and rehabilitation experts	Cerebral angiography
Specially trained nursing personnel	Transcranial Doppler sonography
Early multidisciplinary stroke unit rehabilitation including speech therapy, occupational therapy, and physical therapy	Extracranial and intracranial colour-coded duplex sonography
Neurosonological investigations within 24 h (extracranial doppler sonography)	Specialized neuroradiological, neurosurgical and vascular surgical consultation (including telemedicine networks)
Transthoracic echocardiography	Carotid surgery
Laboratory examinations (including coagulation parameters)	Angioplasty and stenting
Monitoring of blood pressure, ECG, oxygen saturation, blood glucose, body temperature	Automated monitoring of pulse oximetry, blood pressure
Automated ECG monitoring at bedside	Established network of rehabilitation facilities to provide a continuous process of care, including collaboration with outside rehabilitation centre

A stroke unit consists of a discrete area of a hospital ward that exclusively or nearly exclusively takes care of stroke patients and is staffed by a specialist multidisciplinary team [61]. The core disciplines of the team are medicine, nursing, physiotherapy, occupational therapy, speech and language therapy, and social work [118]. The multidisciplinary team should work in a co-ordinated way through regular meetings to plan patient care. Programmes of regular staff education and training should be provided [118]. The typical components of stroke unit care in stroke unit trials [118] were:

- medical assessment and diagnosis, including imaging (CT, magnetic resonance imaging [MRI]), and early assessment of nursing and therapy needs
- early management, consisting of early mobilization, prevention of complications, and treatment of hypoxia, hyperglycaemia, pyrexia, and dehydration
- ongoing rehabilitation, involving co-ordinated multidisciplinary team care, and early assessment of needs after discharge.

Both acute and comprehensive stroke units admit patients acutely and continue treatment for several days. Rehabilitation stroke units admit patients after 1–2 weeks and continue treatment and rehabilitation for several weeks if necessary. Most of the evidence for effectiveness comes from trials of comprehensive stroke units and rehabilitation stroke units [61, 119]. Mobile stroke

teams, which offer stroke care and treatment in a number of wards, probably do not influence important outcomes and cannot be recommended [120]. Such teams have usually been established in hospitals where stroke units were not available.

The stroke unit should be of sufficient size to provide specialist multidisciplinary care for the whole duration of hospital admission. Smaller hospitals may achieve this with a single comprehensive unit, but larger hospitals may require a pathway of care incorporating separate acute and rehabilitation units.

Diagnosics

Diagnostic imaging

Recommendations

- In patients with suspected TIA or stroke, urgent cranial CT (Class I), or alternatively MRI (Class II), is recommended (Level A).
- If MRI is used, the inclusion of diffusion-weighted imaging (DWI) and T2*-weighted gradient echo sequences is recommended (Class II, Level A).
- In patients with TIA, minor stroke, or early spontaneous recovery immediate diagnostic work-up, including urgent vascular imaging (ultrasound, CT-angiography, or MR angiography) is recommended (Class I, Level A).

Imaging of the brain and supplying vessels is crucial in the assessment of patients with stroke and TIA. Brain imaging distinguishes ischaemic stroke from intracranial haemorrhage and stroke mimics, and identifies the type and often also the cause of stroke; it may also help to differentiate irreversibly damaged tissue from areas that may recover, thus guiding emergency and subsequent treatment, and may help to predict outcome. Vascular imaging may identify the site and cause of arterial obstruction, and identifies patients at high risk of stroke recurrence.

General principles

Stroke victims should have clear priority over other patients for brain imaging, because time is crucial. In patients with suspected TIA or stroke, general and neurological examination followed by diagnostic brain imaging must be performed immediately on arrival at the hospital so that treatment can be started promptly. Investigation of TIA is equally urgent, because up to 10% of these patients will suffer stroke within the next 48 h. Immediate access to imaging is facilitated by pre-hospital notification and good communication with the imaging facility: stroke services should work closely with the imaging department to plan the best use of resources.

Diagnostic imaging must be sensitive and specific in detecting stroke pathology, particularly in the early phase of stroke. It should provide reliable images, and should be technically feasible in acute stroke patients. Rapid, focused neurological assessment is helpful to determine which imaging technique should be used. Imaging tests should take into account the patient's condition [121]; for example, up to 45% of patients with severe stroke may not tolerate MR examination because of their medical condition and contraindications [122–124].

Imaging in patients with acute stroke

Patients admitted within 3 h of stroke onset may be candidates for intravenous (i.v.) thrombolysis [125]; CT is usually sufficient to guide routine thrombolysis. Patients arriving later may be candidates for trials testing extended time windows for thrombolysis or other experimental reperfusion strategies.

Plain CT is widely available, reliably identifies most stroke mimics, and distinguishes acute ischaemic from

haemorrhagic stroke within the first 5–7 days [126–128]. Immediate CT scanning is the most cost-effective strategy for imaging acute stroke patients [129], but is not sensitive for old haemorrhage. Overall, CT is less sensitive than MRI, but equally specific, for early ischaemic changes [130]. Two-thirds of patients with moderate to severe stroke have visible ischaemic changes within the first few hours [130–134], but no more than 50% of patients with minor stroke have a visible relevant ischaemic lesion on CT, especially within the first few hours of stroke [135]. Training in identification of early ischaemic changes on CT [134, 136, 137], and the use of scoring systems [133], improve detection of early ischaemic changes.

Early CT changes in ischaemic stroke include decreases in tissue X-ray attenuation, tissue swelling with effacement of cerebrospinal fluid spaces, and arterial hyperattenuation, which indicates the presence of intraluminal thrombus with high specificity [138]. CT is highly specific for the early identification of ischaemic brain damage [131, 139, 140]. The presence of early signs of ischaemia on CT should not exclude patients from thrombolysis within the first 3 h, though patients with a hypoattenuating ischaemic lesion which exceeds one-third of the middle cerebral artery (MCA) territory may benefit less from thrombolysis [125, 133, 134, 141, 142].

Some centres prefer to use MRI as first-line routine investigation for acute stroke. MRI with diffusion-weighted imaging (DWI) has the advantage of higher sensitivity for early ischaemic changes than CT [130]. This higher sensitivity is particularly useful in the diagnosis of posterior circulation stroke and lacunar or small cortical infarctions. MRI can also detect small and old haemorrhages for a prolonged period with T2* (gradient echo) sequences [143]. However, DWI can be negative in patients with definite stroke [144].

Restricted diffusion on DWI, measured by the apparent diffusion coefficient (ADC), is not 100% specific for ischaemic brain damage. Although abnormal tissue on DWI often proceeds to infarction it can recover, which indicates that DWI does not show only permanently damaged tissue [145, 146]. Tissue with only modestly reduced ADC values may be permanently damaged; there is as yet no reliable ADC threshold to differentiate dead from still viable tissue [147, 148]. Other MRI sequences (T2, FLAIR, T1) are less sensitive in the early detection of ischaemic brain damage.

MRI is particularly important in acute stroke patients with unusual presentations, stroke varieties, and uncommon aetiologies, or in whom a stroke mimic is suspected but not clarified on CT. If arterial dissection is suspected, MRI of the neck with fat-suppressed T1-weighted sequences is required to detect intramural haematoma.

MRI is less suited for agitated patients or for those who may vomit and aspirate. If necessary, emergency life support should be continued while the patient is being imaged, as patients (especially those with severe stroke) may become hypoxic while supine during imaging [124]. The risk of aspiration is increased in the substantial proportion of patients who are unable to protect their airway.

Perfusion imaging with CT or MRI and angiography may be used in selected patients with ischaemic stroke (e.g. unclear time window, late admission) to aid the decision on whether to use thrombolysis, although there is no clear evidence that patients with particular perfusion patterns are more or less likely to benefit from thrombolysis [149–152]. Selected patients with intracranial arterial occlusion may be candidates for intra-arterial thrombolysis, although there is only limited evidence to support this [153, 154]. Patients with combined obstructions of the internal carotid artery (ICA) and MCA have less chance of recovering with i.v. thrombolysis than patients with isolated MCA obstructions [155]. In patients with MCA trunk occlusions, the frequency of severe extracranial occlusive disease in the carotid distribution is high [156, 157].

Mismatch between the volume of brain tissue with critical hypoperfusion (which can recover after reperfusion) and the volume of infarcted tissue (which does not recover even with reperfusion) can be detected with MR diffusion/perfusion imaging with moderate reliability [158], but this is not yet a proven strategy for improving the response to thrombolysis up to 9h [159]. There is disagreement on how to best identify irreversible ischaemic brain injury and to define critically impaired blood flow [149, 152, 160]. Quantification of MR perfusion is problematic [161], and there are widely differing associations between perfusion parameters and clinical and radiological outcomes [149]. Decreases in cerebral blood flow on CT are associated with subsequent tissue damage [150, 151], but the therapeutic value of CT perfusion imaging is not yet established. Although infarct expansion may occur in a high proportion of patients with

mismatch, up to 50% of patients without mismatch may also have infarct growth and so might benefit from tissue salvage [152, 162]. The ‘imaging/clinical’ mismatch, i.e. the mismatch between the extent of the lesion seen on DWI or CT and the extent of the lesion as expected from the severity of the neurological deficit, has produced mixed results [163, 164]. Hence, neither perfusion imaging with CT or MRI nor the mismatch concept can be recommended for routine treatment decisions.

Microhaemorrhages are present on T2* MRI in up to 60% of patients with haemorrhagic stroke, and are associated with older age, hypertension, diabetes, leukoariosis, lacunar stroke, and amyloid angiopathy [165]. The incidence of symptomatic intracranial haemorrhage following thrombolysis in ischaemic stroke patients was not increased in those having cerebral microbleeds on pre-treatment T2*-weighted MRI [166].

Vascular imaging should be performed rapidly to identify patients with tight symptomatic arterial stenosis who could benefit from endarterectomy or angioplasty. Non-invasive imaging with colour-coded duplex imaging of the extracranial and intracranial arteries, CT angiography (CTA), or contrast-enhanced MR angiography (CE-MRA) is widely available. These approaches are relatively risk-free, whereas intra-arterial angiography has a 1–3% risk of causing stroke in patients with symptomatic carotid lesions [167, 168]. Digital subtraction angiography (DSA) may be needed in some circumstances, for example when other tests have been inconclusive.

Carotid ultrasound, MRA, and CTA visualise carotid stenosis. Systematic reviews and individual patient data meta-analysis indicate that CE-MRA is the most sensitive and specific non-invasive imaging modality for carotid artery stenosis, closely followed by Doppler ultrasound and CTA, with non-contrast MRA being the least reliable [169, 170].

Some data suggest that vertebrobasilar TIA and minor stroke is associated with a high risk of recurrent stroke [171]. Extracranial vertebral ultrasound diagnosis is useful, but intracranial ultrasound of the vertebrobasilar system can be misleading due to low specificity. Limited data suggest that CE-MRA and CTA offer better non-invasive imaging of the intracranial vertebral and basilar arteries [172].

Unlike other imaging modalities ultrasound is fast, non-invasive, and can be administered using portable

machines. It is therefore applicable to patients unable to co-operate with MRA or CTA [157]. However, Doppler studies alone often provide only limited information, are investigator-dependent and require skilled operators, although they allow repeated measurements at the bedside.

Transcranial Doppler ultrasound (TCD) is useful for the diagnosis of abnormalities in the large cerebral arteries at the base of the skull. However, between 7 and 20% of acute stroke patients, particularly elderly individuals and those from certain ethnic groups do not have an adequate acoustic window [173, 174]. This problem can be considerably reduced by using ultrasound contrast agents, which also allow perfusion studies in the acute phase [175–177] and continuous monitoring of cerebral haemodynamic responses [178]. The combination of ultrasound imaging techniques and MRA reveals excellent results equal to DSA [179]. Cerebral reactivity and cerebral autoregulation are impaired in patients with occlusive extracerebral arterial disease (particularly carotid stenosis and occlusion) and inadequate collateral supply, who are at increased risk of recurrent stroke [180, 181]. TCD is the only technique that detects circulating intracranial emboli [182], which are particularly common in patients with large artery disease. In patients with symptomatic carotid artery stenoses, they are a strong independent predictor of early recurrent stroke and TIA [183], and have been used as a surrogate marker to evaluate antiplatelet agents [184]. TCD microbubble detection can be used to identify a right-to-left shunt, which mainly results from a patent foramen ovale (PFO) [185].

Imaging in patients with TIA, minor non-disabling stroke, and stroke with spontaneous recovery

Patients presenting with TIA are at high risk of early recurrent stroke (up to 10% in the first 48 h) [186]. They therefore need urgent clinical diagnosis to treat associated general abnormalities, modify active risk factors, and identify specific treatable causes, particularly arterial stenosis and other embolic sources. Vascular imaging is a priority in those patients with TIA or minor stroke, more than in those with major stroke in whom surgery is not going to be of benefit in the short term. Immediate preventive treatment will reduce stroke, disability, and death [86, 187]. Simple clinical scoring systems can be

used to identify patients at particularly high risk [186]. Patients with minor non-disabling stroke and rapid spontaneous clinical recovery are also at high risk of recurrent stroke [58].

Patients with widely varying brain pathology may present with transient neurological deficits indistinguishable from TIA. CT reliably detects some of these pathologies (e.g. intracerebral haemorrhage, subdural haematoma, tumours) [129], but others (e.g. multiple sclerosis, encephalitis, hypoxic brain damage, etc.) are better identified on MRI, while others (e.g. acute metabolic disturbances) are not visible at all. Intracranial haemorrhage is a rare cause of TIA.

Between 20 and 50% of patients with TIAs may have acute ischaemic lesions on DWI [144, 188, 189]. These patients are at increased risk of early recurrent disabling stroke [189]. However, there is currently no evidence that DWI provides better stroke prediction than clinical risk scores [190]. The risk of recurrent disabling stroke is also increased in patients with TIA and an infarct on CT [191].

The ability of DWI to identify very small ischaemic lesions may be particularly helpful in patients presenting late or in patients with mild non-disabling stroke, in whom the diagnosis may be difficult to establish on clinical grounds [130]. T2*-MRI is the only reliable method to identify haemorrhages after the acute phase, when blood is no longer visible on CT [143].

Other diagnostic tests

Recommendations

- In patients with acute stroke and TIA, early clinical evaluation, including physiological parameters and routine blood tests, is recommended (Class I, Level A).
- For all stroke and TIA patients, a sequence of blood tests is recommended (table 9.3, table 9.5).
- It is recommended that all acute stroke and TIA patients should have a 12-lead ECG. In addition continuous ECG recording is recommended for ischaemic stroke and TIA patients (Class I, Level A).
- It is recommended that for stroke and TIA patients seen after the acute phase, 24-h Holter ECG monitoring should be performed when arrhythmias are suspected and no other causes of stroke are found (Class I, Level A).
- Echocardiography is recommended in selected patients (Class III, Level B).

Table 9.5 Subsequent laboratory tests, according to the type of stroke and suspected aetiology.

All patients	Full blood count, electrolytes, glucose, lipids, creatinine, CRP or ESR
Cerebral venous thrombosis, hypercoagulopathy	Thrombophilia screen, AT3, Factor 2, 5, mutations, factor 8, protein C, protein S, Antiphospholipid-antibodies, d-dimer, homocysteine
Bleeding disorder	INR, aPTT, fibrinogen, etc.
Vasculitis or systemic disorder	Cerebrospinal fluid, autoantibody screen, specific antibodies or PCR for HIV, syphilis, borreliosis, tuberculosis, fungi, illicit drug- screening, blood culture
Suspected genetic disorders, e. g. mitochondrial disorders (MELAS), CADASIL, sickle cell disease, Fabry disease, multiple cavernoma, etc.	Genetic testing

Cardiac evaluation

Cardiac and ECG abnormalities are common in acute stroke patients [192]. In particular, prolonged QTc, ST depression, and T wave inversion are prevalent in acute ischaemic stroke, especially if the insular cortex is involved [193, 194]. Hence, all acute stroke and TIA patients should have a 12-channel ECG.

Cardiac monitoring should be conducted routinely after an acute cerebrovascular event to screen for serious cardiac arrhythmias. It is unclear whether continuous ECG recording at the bedside is equivalent to Holter monitoring for the detection of atrial fibrillation (AF) in acute stroke patients. Holter monitoring is superior to routine ECG for the detection of AF in patients anticipated to have thromboembolic stroke with sinus rhythm [195]; however, serial 12-channel ECG might be sufficient to detect new AF in a stroke unit setting [196]. A recent systematic review found that new AF was detected by Holter ECG in 4.6% of patients with recent ischaemic stroke or TIA, irrespective of baseline ECG and clinical examination [197]. Extended duration of monitoring, prolonged event loop recording, and confining Holter monitoring to patients with non-lacunar stroke, may improve detection rates [198].

Echocardiography can detect many potential causes of stroke [199], but there is controversy about the indications for, and type of, echocardiography in stroke and TIA patients. Transoesophageal echocardiography (TOE) has been claimed to be superior to transthoracic echocardiography (TTE) for the detection of potential cardiac sources of embolism [200], independent of age [201].

Echocardiography is particularly required in patients with:

- evidence of cardiac disease on history, examination, or ECG
- suspected cardiac source of embolism (e.g. infarctions in multiple cerebral or systemic arterial territories)
- suspected aortic disease
- suspected paradoxical embolism
- no other identifiable causes of stroke.

TTE is sufficient for evaluation of mural thrombi, particularly in the apex of the left ventricle; this technique has >90% sensitivity and specificity for ventricular thrombi after myocardial infarction [202]. TOE is superior for evaluation of the aortic arch, left atrium, and atrial septum [199]. It also allows risk stratification for further thromboembolic events in patients with AF [203].

The role of cardiac CT and cardiac MRI in the detection of embolic sources in stroke patients has not been evaluated systematically.

Blood tests

Blood tests required on emergency admission are listed in table 9.3. Subsequent tests depend on the type of stroke and suspected aetiology (table 9.5).

Primary prevention

The aim of primary prevention is to reduce the risk of stroke in asymptomatic people. Relative risk (RR), absolute risk (AR), odds ratio (OR), numbers needed to treat (NNT) to avoid one major vascular event per year, and numbers needed to harm (NNH) to cause one major

complication per year are provided for each intervention in tables 9.6–9.8.

Management of vascular risk factors

Recommendations

- Blood pressure should be checked regularly. It is recommended that high blood pressure should be managed with lifestyle modification and individualized pharmacological therapy (Class I, Level A) aiming at normal levels of 120/80 mmHg (Class IV, GCP). For prehypertensive (120–139/80–90 mmHg) with congestive heart failure, MI, diabetes, or chronic renal failure, antihypertensive medication is indicated (Class I, Level A).
- Blood glucose should be checked regularly. It is recommended that diabetes should be managed with lifestyle modification and individualized pharmacological therapy (Class IV, Level C). In diabetic patients, high blood pressure should be managed intensively (Class I, Level A) aiming for levels below 130/80 mmHg (Class IV, Level C). Where possible, treatment should include an angiotensin converting enzyme inhibitor or angiotensin receptor antagonist (Class I, Level A).
- Blood cholesterol should be checked regularly. It is recommended that high blood cholesterol (e.g. LDL > 150 mg/dl [3.9 mmol/l]) should be managed with lifestyle modification (Class IV, Level C) and a statin (Class I, Level A).
- It is recommended that cigarette smoking be discouraged (Class III, Level B).
- It is recommended that heavy use of alcohol be discouraged (Class III, Level B).
- Regular physical activity is recommended (Class III, Level B).
- A diet low in salt and saturated fat, high in fruit and vegetables and rich in fibre is recommended (Class III, Level B).
- Subjects with an elevated body mass index are recommended to take a weight-reducing diet (Class III, Level B).
- Antioxidant vitamin supplements are not recommended (Class I, Level A).
- Hormone replacement therapy is not recommended for the primary prevention of stroke (Class I, Level A).

A healthy lifestyle, consisting of abstinence from smoking, low–normal body mass index, moderate alcohol consumption, regular exercise and healthy diet, is associated with a reduction in ischaemic stroke (RR 0.29; 95% CI 0.14–0.63) [204].

Table 9.6 Number need to treat (NNT) to prevent one stroke per year in patients who undergo surgery for ICA stenosis; all percentages reflect to the NASCET method (modified from [584] and [338]).

Disease	NNT to avoid one stroke/year
Asymptomatic (60–99%)	85
Symptomatic (70–99%)	27
Symptomatic (50–69%)	75
Symptomatic (>50%) in men	45
Symptomatic (>50%) in women	180
Symptomatic (>50%) >75 years	25
Symptomatic (>50%) <65 years	90
Symptomatic (>50%) <2 weeks after the event	25
Symptomatic (>50%) >12 weeks after the event	625
Symptomatic (≤50%)	No benefit

High blood pressure

A high (>120/80 mmHg) blood pressure (BP) is strongly and directly related to vascular and overall mortality without evidence of any threshold [205]. Lowering BP substantially reduces stroke and coronary risks, depending on the magnitude of the reduction [206–208]. BP should be lowered to 140/85 mmHg or below [209]; anti-hypertensive treatment should be more aggressive in diabetic patients (see below) [210]. A combination of two or more antihypertensive agents is often necessary to achieve these targets.

Most studies comparing different drugs do not suggest that any class is superior [206, 207, 211]. However, the LIFE (Losartan Intervention for Endpoint reduction in hypertension) trial found that losartan was superior to atenolol in hypertensive patients with left ventricular hypertrophy (NNT to prevent stroke 270) [212, 213]. Similarly, the ALLHAT (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack) trial found that chlorthalidone was more effective than amlodipine and lisinopril [214]. Beta-blockers may still be considered an option for initial and subsequent antihypertensive treatment [209]. In elderly subjects, controlling isolated systolic hypertension (systolic blood pressure >140 mmHg and diastolic blood pressure <90 mmHg) is beneficial [207, 215].

Table 9.7 Relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to treat (NNT) to avoid one major vascular event per year in patients with antithrombotic therapy (modified from [318, 321, 584]).

Disease	Treatment	RRR %	ARR % per year	NNT to avoid one event per year
Non-cardioembolic ischaemic stroke or TIA	aspirin/PCB	13	1.0	100
	aspirin + DIP/PCB	28	1.9	53
	aspirin + DIP/aspirin	18	1.0	104
	Clopidogrel/PCB	23	1.6	62
	Clopidogrel/aspirin	10	0.6	166
Atrial fibrillation (primary prevention)	warfarin/PCB	62	2.7	37
	aspirin/PCB	22	1.5	67
Atrial fibrillation (secondary prevention)	warfarin/PCB	67	8	13
	aspirin/PCB	21	2.5	40

PCB: placebo; Clopidogrel; DIP: dipyridamole.

Table 9.8 Relative risk reduction (RRR), absolute risk reduction (ARR), and number needed to treat (NNT) to avoid one major vascular event per year in patients with risk factor modifications (modified from [287, 289, 293, 584]).

Clinical condition	Treatment	RRR %	ARR % per year	NNT to avoid one event per year
General population with increased blood pressure	Antihypertensive	42	0.4	250
General population with increased vascular risk	ACE inhibitor	22	0.65	154
Post-stroke/TIA with increased blood pressure	Antihypertensive	31	2.2	45
Post-stroke/TIA with normal blood pressure	ACE inhibitor ± diuretic	24	0.85	118
Post-stroke/TIA	Statins	16	0.44	230
	Smoking cessation	33	2.3	43

Diabetes mellitus

There is no evidence that improving glucose control reduces stroke [216]. In diabetic patients, blood pressure should be lowered to below 130/80 mmHg [210]. Treatment with a statin reduces the risk of major cardiovascular events, including stroke [217–219].

Hyperlipidaemia

In a review of 26 statin trials (95 000, patients), the incidence of stroke was reduced from 3.4% to 2.7% [220]. This was due mainly to a reduction in non-fatal stroke, from 2.7% to 2.1%. The review included the Heart Protection Study, which was, in part, a secondary prevention trial [221]; this trial found an excess of myopathy of one per 10 000 patients treated per annum [221]. There are

no data to suggest that statins prevent stroke in patients with low-density lipoprotein (LDL) cholesterol below 150 mg/dl (3.9 mmol/l).

Cigarette smoking

Observational studies have shown cigarette smoking to be an independent risk factor for ischaemic stroke [222] in both men and women [223–227]. Spousal cigarette smoking may be associated with an increased stroke risk [228]. A meta-analysis of 22 studies indicates that smoking doubles the risk of ischaemic stroke [229]. Subjects who stop smoking reduce this risk by 50% [224]. Making workplaces smoke-free would result in considerable health and economic benefits [230].

Alcohol consumption

Heavy alcohol drinking (>60 g/day) increases the risk of ischaemic stroke (RR 1.69; 95% CI 1.34–2.15) and haemorrhagic stroke (RR 2.18; 95% CI 1.48–3.20). In contrast, light consumption (<12 g/day) is associated with a reduction in all stroke (RR 0.83; 95% CI 0.75–0.91) and ischaemic stroke (RR 0.80; 95% CI 0.67–0.96), and moderate consumption (12–24 g/day) with a reduction in ischaemic stroke (RR 0.72; 95% CI 0.57–0.91) [231]. Red wine consumption is associated with the lowest risk in comparison with other beverages [232]. Blood pressure elevation appears to be an important intermediary in the relation between alcohol consumption and stroke [233].

Physical activity

In a meta-analysis of cohort and case-control studies, physically active individuals had a lower risk of stroke or death than those with low activity (RR 0.73; 95% CI 0.67–0.79). Similarly, moderately active individuals had a lower risk of stroke, compared with those who were inactive (RR 0.80; 95% CI 0.74–0.86) [234]. This association is mediated, in part, through beneficial effects on body weight, blood pressure, serum cholesterol, and glucose tolerance. Leisure-based physical activity (2 to 5 hours per week) has been independently associated with a reduced severity of ischaemic stroke at admission and better short-term outcome [235].

Diet

Fruit, vegetable, and fish intake

In observational studies, high fruit and vegetable intake was associated with a decreased risk of stroke, compared with lower intake (RR 0.96 for each increment of two servings/day; 95% CI 0.93–1.00) [236]. The risk of ischaemic stroke was lower in people who consumed fish at least once per month (RR 0.69; 95% CI 0.48–0.99) [237]. Whole grain intake was associated with a reduction in cardiovascular disease (OR 0.79; 95% CI 0.73–0.85) but not stroke [238]. Dietary calcium intake from dairy products was associated with lower mortality from stroke in a Japanese population [239]. However, in a further study there was no interaction between the intake of total fat or cholesterol, and stroke risk in men [240].

In a randomized controlled trial in women, dietary interventions did not reduce the incidence of coronary events and stroke despite there being an 8.2% reduction

of total fat intake and an increased consumption of vegetables, fruits and grains [241].

Body weight

A high body mass index (BMI ≥ 25) is associated with an increased risk of stroke in men [242] and women [243], mainly mediated by concomitant arterial hypertension and diabetes. Abdominal adiposity is a risk factor for stroke in men but not women [244]. Although weight loss reduces blood pressure [245], it does not lower stroke risk [246].

Vitamins

A low intake of vitamin D is associated with an increased risk of stroke [247], but supplements of calcium plus vitamin D do not reduce the risk of stroke [248]. Supplements of tocopherol and beta carotene do not reduce stroke [249]. A meta-analysis of trials with vitamin E supplementation found that it might increase mortality when used at high doses (≥ 400 IU/d) [250].

High homocysteine levels are associated with increased stroke risk (OR 1.19; 95% CI 1.05–1.31) [251]. Since folic acid fortification of enriched grain products was mandated by the US Food and Drug Administration there has been a reduction in stroke mortality rates, in contrast to countries without fortification [252]. A meta-analysis concluded that folic acid supplementation can reduce the risk of stroke (RR 0.82; 95% CI 0.68–1.00) [253]; the benefit was greatest in trials with long treatment durations or larger homocysteine-lowering effects, and in countries where grain was not fortified.

Postmenopausal oestrogen replacement therapy

Stroke rates rise rapidly in women after the menopause. However, in an analysis based on a 16-year follow-up of 59,337 postmenopausal women participating in the Nurses' Health Study, there was only a weak association between stroke and oestrogen replacement [254]. According to the HERS II trial, hormone replacement in healthy women is associated with an increased risk of ischaemic stroke [255]. A Cochrane systematic review [256] found hormone replacement therapy to be associated with an increased risk of stroke (RR 1.44; 95% CI 1.10–1.89). A secondary analysis of the Women's Health Initiative randomized controlled trial suggests that the risk of stroke is increased with hormone replacement therapy only in women with prolonged hormone use (> 5 years; RR 1.32; 95% CI 1.12–1.56) [257, 258].

Antithrombotic therapy

Recommendations

- Low-dose aspirin is recommended in women aged 45 years or more who are not at increased risk for intracerebral haemorrhage and who have good gastrointestinal tolerance; however, its effect is very small (Class I, Level A).
- It is recommended that low-dose aspirin may be considered in men for the primary prevention of myocardial infarction; however, it does not reduce the risk of ischaemic stroke (Class I, Level A).
- Antiplatelet agents other than aspirin are not recommended for primary stroke prevention (Class IV, GCP).
- Aspirin may be recommended for patients with non-valvular AF who are younger than 65 years and free of vascular risk factors (Class I, Level A).
- Unless contraindicated, either aspirin or an oral anticoagulant (international normalized ratio [INR] 2.0–3.0) is recommended for patients with non-valvular AF who are aged 65–75 years and free of vascular risk factors (Class I, Level A).
- Unless contraindicated, an oral anticoagulant (INR 2.0–3.0) is recommended for patients with non-valvular AF who are aged >75, or who are younger but have risk factors such as high blood pressure, left ventricular dysfunction, or diabetes mellitus (Class I, Level A).
- It is recommended that patients with AF who are unable to receive oral anticoagulants should be offered aspirin (Class I, Level A).
- It is recommended that patients with AF who have mechanical prosthetic heart valves should receive long-term anticoagulation with a target INR based on the prosthesis type, but not less than INR 2–3 (Class II, Level B).
- Low-dose aspirin is recommended for patients with asymptomatic internal carotid artery (ICA) stenosis >50% to reduce their risk of vascular events (Class II, Level B).

Low-risk subjects

Six large randomized trials have evaluated the benefits of aspirin for the primary prevention of cardiovascular (CV) events in men and women (47,293 on aspirin, 45,580 controls) with a mean age of 64.4 years [259–264]. Aspirin reduced coronary events and CV events, but not stroke, CV mortality, or all-cause mortality [265]. In women, aspirin reduced stroke (OR 0.83; 95% CI 0.70–0.97) and ischaemic stroke (OR 0.76; 95% CI 0.63–0.93) [266]. In a separate study in 39,876 healthy women aged 45 years or more, aspirin reduced stroke (RR 0.83; 95% CI 0.69–0.99) and ischaemic stroke (RR 0.76; 95% CI

0.63–0.93), and caused a non-significant increase in haemorrhagic stroke, over 10 years; it did not reduce the risk of fatal or nonfatal myocardial infarction, or cardiovascular death [267].

No data are currently available on the use of other antiplatelet agents in primary prevention in low-risk subjects.

Subjects with vascular risk factors

A systematic review of randomized studies comparing antithrombotic agents with placebo in patients with elevated BP and no prior cardiovascular disease showed that aspirin did not reduce stroke or total cardiovascular events [266]. In the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, the combination of aspirin and clopidogrel was less effective than aspirin alone in the subgroup of patients with multiple vascular risk factors but no ischaemic event [268].

Large artery atheroma

Patients with atherosclerotic arterial disease have an increased risk of myocardial infarction, stroke, and cardiovascular death. Aspirin reduces MI in patients with asymptomatic carotid artery disease [269], and reduces stroke after carotid artery surgery [270].

Atrial fibrillation

AF is a strong independent risk factor for stroke. A meta-analysis of randomized trials with at least 3 months' follow-up showed that antiplatelet agents reduced stroke (RR 0.78; 95% CI 0.65–0.94) in patients with non-valvular AF [271]. Warfarin (target INR 2.0–3.0) is more effective than aspirin at reducing stroke (RR 0.36; 95% CI 0.26–0.51) [271]. As the risk of stroke in people with AF varies considerably, risk stratification should be used to determine whether patients should be given oral anticoagulation, aspirin, or nothing [14]. Oral anticoagulation is more effective in patients with AF who have one or more risk factors, such as previous systemic embolism, age over 75 years, high blood pressure, or poor left ventricular function [14]. In the meta-analysis described above, absolute increases in major extracranial haemorrhage were less than the absolute reductions in stroke [271]. The WASPO (Warfarin versus Aspirin for Stroke Prevention in Octogenarians) [272] and BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged)

[273] trials showed that warfarin was safe and effective in older individuals. The ACTIVE W (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events) study found that the combination of aspirin and clopidogrel was less effective than warfarin and had a similar bleeding rate [274].

Patients with a prosthetic heart valve, with or without AF, should receive long-term anticoagulation with a target INR based on the prosthesis type (bio-prosthetic valves: INR 2.0–3.0; mechanical valves: INR 3.0–4.0 [275]).

Carotid surgery and angioplasty

Recommendations

- Carotid surgery is not recommended for asymptomatic individuals with significant carotid stenosis (NASCET 60–99%), except in those at high risk of stroke (Class I, Level C).
- Carotid angioplasty, with or without stenting, is not recommended for patients with asymptomatic carotid stenosis (Class IV, GCP).
- It is recommended that patients should take aspirin before and after surgery (Class I, Level A).

Trials of carotid surgery for asymptomatic carotid stenosis have concluded that although surgery reduces the incidence of ipsilateral stroke (RR 0.47–0.54) and any stroke, the absolute benefit is small (approximately 1% per annum) [276–278], whereas the perioperative stroke or death rate is 3%. Medical management is the most appropriate option for most asymptomatic subjects; only centres with a perioperative complication rate of 3% or less should contemplate surgery. Patients with a high risk of stroke (men with stenosis of more than 80% and a life expectancy of more than 5 years) may derive some benefit from surgery in appropriate centres [276, 278]. All stenosis are graded following the NASCET-method (distal stenosis)[279].

Carotid endarterectomy (CEA) is effective in younger patients, and possibly also in older individuals, but does not appear to benefit women [276]. Patients with occlusion of the internal carotid artery contralateral to the operated carotid artery do not benefit from CEA [280, 281]. The risk of ipsilateral stroke increases with the degree of stenosis [280, 282]; CEA appears to be effective irrespective of the degree of ipsilateral stenosis over the range of 60–99% [276]. CEA is not beneficial for asymp-

tomatic patients who have a life expectancy of less than 5 years. Aspirin should not be stopped in patients undergoing carotid surgery [283]. Patients should be followed up by the referring physician after surgery. There are no data from randomized trials about the benefits and risks of carotid angioplasty, compared with CEA, in asymptomatic patients [284].

Secondary prevention

Optimal management of vascular risk factors

Recommendations

- It is recommended that blood pressure be checked regularly. Blood pressure lowering is recommended after the acute phase, including in patients with normal blood pressure (Class I, Level A).
- It is recommended that blood glucose should be checked regularly. It is recommended that diabetes should be managed with lifestyle modification and individualized pharmacological therapy (Class IV, GCP).
- In patients with type 2 diabetes who do not need insulin, treatment with pioglitazone is recommended after stroke (Class III, Level B).
- Statin therapy is recommended in subjects with non-cardioembolic stroke (Class I, Level A).
- It is recommended that cigarette smoking be discouraged (Class III, Level C).
- It is recommended that heavy use of alcohol be discouraged (Class IV, GCP).
- Regular physical activity is recommended (Class IV, GCP).
- A diet low in salt and saturated fat, high in fruit and vegetables, and rich in fibre is recommended (Class IV, GCP).
- Subjects with an elevated body mass index are recommended to adopt a weight-reducing diet (Class IV, Level C).
- Antioxidant vitamin supplements are not recommended (Class I, Level A).
- Hormone replacement therapy is not recommended for the secondary prevention of stroke (Class I, Level A).
- It is recommended that sleep-disordered breathing such as obstructive sleep apnoea be treated with continuous positive airway pressure breathing (Class III, Level GCP).
- It is recommended that endovascular closure of PFO be considered in patients with cryptogenic stroke and high risk PFO (Class IV, GCP).

High blood pressure

A meta-analysis of seven randomized controlled trials showed that antihypertensive drugs reduced stroke recurrence after stroke or TIA (RR 0.76; 95% CI 0.63–0.92) [285]. This analysis included the PATS (indapamide, a diuretic), HOPE (ramipril) and PROGRESS (perindopril, with or without indapamide) studies [286–289]. The reduction in stroke occurs regardless of BP and type of stroke [289]. Hence, BP should be lowered and monitored indefinitely after stroke or TIA. The absolute target BP level and reduction are uncertain and should be individualized, but benefit has been associated with an average reduction of about 10/5 mmHg, and normal BP levels have been defined as <120/80 mmHg [290]. However, blood pressure should not be lowered intensively in patients with suspected haemodynamic stroke or in those with bilateral carotid stenosis. The angiotensin receptor antagonist eprosartan may be more effective than the calcium channel blocker nitrendipine [291].

Diabetes mellitus

The prospective, double-blind PROactive trial randomized 5238 patients with type 2 diabetes and a history of macrovascular disease to pioglitazone or placebo. In patients with previous stroke ($n = 486$ in the pioglitazone group, $n = 498$ in the placebo group), there was a trend towards benefit with pioglitazone for the combined endpoint of death and major vascular events (HR 0.78; 95% CI 0.60–1.02; $p = 0.067$). In a secondary analysis, pioglitazone reduced fatal or non-fatal stroke (HR 0.53; 95% CI 0.34–0.85; $p = 0.0085$) and cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (HR 0.72; 95% CI 0.52–1.00; $p = 0.0467$) [292].

Hyperlipidaemia

In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, statin therapy with atorvastatin reduced stroke recurrence (HR 0.84; 95% CI 0.71–0.99) [293], while in the Heart Protection Study, simvastatin reduced vascular events in patients with prior stroke, and reduced stroke in patients with other vascular disease (RR 0.76) [221]. Neither trial assessed efficacy by stroke subtype, and SPARCL did not include patients with presumed cardioembolic stroke [221, 293]. The risk of haemorrhagic stroke was slightly increased in both trials [221, 293]. The absolute risk reduction achieved with statin therapy is low (NNT 112–143 for 1 year). Statin

withdrawal at the acute stage of stroke may be associated with an increased risk of death or dependency [294].

Cigarette smoking

There are no specific data in secondary prevention. See primary prevention.

Diet

Overweight

There are no specific data in secondary prevention. See primary prevention. Weight loss may be beneficial after stroke as it lowers blood pressure [245].

Vitamins

Beta carotene increased the risk of cardiovascular death in a meta-analysis of primary and secondary prevention trials (RR 1.10; 95% CI 1.03–1.17) [295]. Vitamin E supplementation does not prevent vascular events [296]. Fat-soluble antioxidant supplements may increase mortality [297].

Vitamins that lower homocysteine (folate, B12, B6) do not appear to reduce stroke recurrence and may increase vascular events [298–301], but further trials are ongoing [302].

Sleep-disordered breathing

Sleep-disordered breathing represents both a risk factor and a consequence of stroke and is linked with poorer long-term outcome and increased long-term stroke mortality [303]. More than 50% of stroke patients have sleep-disordered breathing, mostly in the form of obstructive sleep apnoea (OSA). This can improve spontaneously after stroke, but may need treatment. Continuous positive airway pressure is the treatment of choice for OSA. Oxygen and other forms of ventilation may be helpful in other (e.g. central) forms of SDB.

Patent foramen ovale

Case reports and case control studies indicate an association between the presence of PFO and cryptogenic stroke in both younger and older stroke patients [304, 305]. Two population-based studies pointed in the same direction but did not confirm a significant association [306, 307]. In patients with PFO alone, the overall risk of recurrence is low. However, when the PFO is combined with an atrial septal aneurysm, a Eustachian valve, a Chiari network, or in patients who have suffered more

than one stroke, the risk of recurrence can be substantial [308]. Endovascular closure of PFOs with or without septal aneurysms is feasible in such patients [309] and may lower the risk of recurrent stroke compared to medical treatment [310]; however, RCTs are still lacking.

Postmenopausal oestrogen replacement therapy

Hormone replacement therapy does not protect against vascular events and may increase stroke severity [311].

Antithrombotic therapy

Recommendations

- It is recommended that patients receive antithrombotic therapy (Class I, Level A).
- It is recommended that patients not requiring anticoagulation should receive antiplatelet therapy (Class I, Level A). Where possible, combined aspirin and dipyridamole, or clopidogrel alone, should be given. Alternatively, aspirin alone or triflusal alone may be used (Class I, Level A).
- The combination of aspirin and clopidogrel is not recommended in patients with recent ischaemic stroke, except in patients with specific indications (e.g. unstable angina or non-Q-wave MI, or recent stenting); treatment should be given for up to 9 months after the event (Class I, Level A).
- It is recommended that patients who have a stroke on antiplatelet therapy should be re-evaluated for pathophysiology and risk factors (Class IV, GCP).
- Oral anticoagulation (INR 2.0–3.0) is recommended after ischaemic stroke associated with AF (Class I, Level A). Oral anticoagulation is not recommended in patients with comorbid conditions such as falls, poor compliance, uncontrolled epilepsy, or gastrointestinal bleeding (Class III, Level C). Increasing age alone is not a contraindication to oral anticoagulation (Class I, Level A).
- It is recommended that patients with cardioembolic stroke unrelated to AF should receive anticoagulants (INR 2.0–3.0) if the risk of recurrence is high (Class III, Level C).
- It is recommended that anticoagulation should not be used after non-cardioembolic ischaemic stroke, except in some specific situations, such as aortic atheromas, fusiform aneurysms of the basilar artery, cervical artery dissection, or patent foramen ovale in the presence of proven deep vein thrombosis (DVT) or atrial septal aneurysm (Class IV, GCP).
- It is recommended that combined low dose aspirin and dipyridamole should be given if oral anticoagulation is contraindicated (Class IV, GCP).

Antiplatelet therapy

Antiplatelet therapy reduces vascular events, including non-fatal myocardial infarction, nonfatal stroke and vascular death in patients with previous stroke or TIA (RR 0.78; 95% CI 0.76–0.80) [312].

Aspirin

Aspirin reduces recurrence irrespective of dose (50 to 1300 mg/d) [313–316], although high doses (>150 mg/day) increase adverse events. In patients with symptomatic intracranial atherosclerosis, aspirin is as effective as oral anticoagulation and has fewer complications [317].

Clopidogrel

Clopidogrel is slightly more effective than aspirin in preventing vascular events (RR 0.91; 95% CI 0.84–0.97) [318]. It may be more effective in high-risk patients (i.e. those with previous stroke, peripheral artery disease, symptomatic coronary disease, or diabetes) [268].

Dipyridamole

Dipyridamole reduces stroke recurrence with similar efficacy to aspirin [319].

Triflusal

Triflusal reduces stroke recurrence with similar efficacy to aspirin but with fewer adverse events [320].

Dipyridamole plus aspirin

The combination of aspirin (38–300 mg/d) and dipyridamole (200 mg extended release twice daily) reduces the risk of vascular death, stroke or MI, compared with aspirin alone (RR 0.82; 95% CI 0.74–0.91) [319, 321]. Dipyridamole may cause headache; the incidence of this may be reduced by increasing the dose gradually [322, 323].

Clopidogrel plus aspirin

Compared with clopidogrel alone, the combination of aspirin and clopidogrel did not reduce the risk of ischaemic stroke, myocardial infarction, vascular death, or re-hospitalization [324]; however, life-threatening or

major bleeding were increased with the combination. Similarly, in the CHARISMA study, the combination of aspirin and clopidogrel did not reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, compared with aspirin alone [268]. In patients who have had an acute coronary event within 12 months, or coronary stenting, the combination of clopidogrel and aspirin reduces the risk of new vascular events [325].

Oral anticoagulation

Oral anticoagulation after non-cardiac ischaemic stroke is not superior to aspirin, but causes more bleeding [326–328]. Oral anticoagulation (INR 2.0–3.0) reduces the risk of recurrent stroke in patients with non-valvular AF (whether of permanent, chronic, or paroxysmal type) [329] and most other cardiac sources of emboli. Anticoagulation should be taken long term, or for at least 3 months after cardioembolic stroke due to MI [330]. There is a controversial discussion about the optimal time point to start oral anticoagulation. After TIA or minor stroke one could start immediately, but after major stroke with significant infarction on neuroimaging (e.g. above a third of the MCA territory) one should wait for some (e.g. 4) weeks. However, this decision has to be individualized.

In patients with AF and stable coronary disease, aspirin should not be added to oral anticoagulation [331]. Anticoagulation may be beneficial in patients with aortic atheroma [332], fusiform aneurysms of the basilar artery [333], or cervical dissection [334]. The ongoing ARCH trial is comparing the combination of clopidogrel plus aspirin with oral anticoagulation in secondary prevention of patients with atherosclerotic plaques in the aortic arch.

Recurrent vascular event on antiplatelet therapy

The treatment of patients who have a recurrent vascular event on antiplatelet therapy remains unclear. Alternative causes of stroke should be sought and consistent risk-factor management is mandatory especially in those patients. Alternative treatment strategies may be considered: leave unchanged, change to another antiplatelet agent, add another antiplatelet agent, or use oral anticoagulation.

Surgery and angioplasty

Recommendations

- CEA is recommended for patients with 70–99% stenosis (Class I, Level A). CEA should only be performed in centres with a perioperative complication rate (all strokes and death) of less than 6% (Class I, Level A).
- It is recommended that CEA be performed as soon as possible after the last ischaemic event, ideally within 2 weeks (Class II, Level B).
- It is recommended that CEA may be indicated for certain patients with stenosis of 50–69%; males with very recent hemispheric symptoms are most likely to benefit (Class III, Level C). CEA for stenosis of 50–69% should only be performed in centres with a perioperative complication rate (all stroke and death) of less than 3% (Class I, Level A).
- CEA is not recommended for patients with stenosis of less than 50% (Class I, Level A).
- It is recommended that patients remain on antiplatelet therapy both before and after surgery (Class I, Level A).
- Carotid percutaneous transluminal angioplasty and/or stenting (CAS) is only recommended in selected patients (Class I, Level A). It should be restricted to the following subgroups of patients with severe symptomatic carotid artery stenosis: those with contraindications to CEA, stenosis at a surgically inaccessible site, re-stenosis after earlier CEA, and post-radiation stenosis (Class IV, GCP). Patients should receive a combination of clopidogrel and aspirin immediately before and for at least 1 month after stenting (Class IV, GCP).
- It is recommended that endovascular treatment may be considered in patients with symptomatic intracranial stenosis (Class IV, GPC).

Carotid endarterectomy

The grading of stenosis should be performed according to the NASCET criteria. Although ECST (European Carotid Surgery Trialists) and NASCET use different methods of measurement, it is possible to convert the percentage stenosis derived by one method to the other [335]. CEA reduces the risk of recurrent disabling stroke or death (RR 0.52) in patients with severe (70–99%) ipsilateral internal carotid artery stenosis [279, 336, 337]. Patients with less severe ipsilateral carotid stenosis (50–69%) may also benefit [337]. Surgery is potentially harmful in patients with mild or moderate degrees of stenosis (<50%) [337].

CEA should be performed as soon as possible (ideally within 2 weeks) after the last cerebrovascular event [338].

Surgical procedure is important in preventing stroke; carotid patch angioplasty may reduce the risk of perioperative arterial occlusion and restenosis [339].

Older patients (>75 years) without organ failure or serious cardiac dysfunction benefit from CEA [338]. Women with severe (>70%) symptomatic stenosis should undergo CEA, whereas women with more moderate stenosis should be treated medically [340]. Patients with amaurosis fugax, severe stenosis, and a high-risk profile should be considered for CEA; those with amaurosis fugax and few risk factors do better with medical treatment. Patients with mild-to-moderate intracranial stenosis and severe extracranial stenosis should be considered for CEA.

The benefit from CEA is less in patients with lacunar stroke [341]. Patients with leukoaraiosis carry an increased perioperative risk [342]. Occlusion of the contralateral ICA is not a contraindication to CEA but carries a higher perioperative risk. The benefit from endarterectomy is marginal in patients with carotid near-occlusion.

Carotid angioplasty and stenting

Several trials have compared CAS and CEA in secondary stroke prevention (table 9.9) [343–346]. However, the SAPPHERE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial included more than 70% asymptomatic patients, and therefore should not be used for decisions about secondary prevention [345]. In CAVATAS (Carotid and Vertebral Artery Transluminal Angioplasty Study) the majority of the

patients in the endovascular group underwent angioplasty, and only 26% were treated with a stent [346]. The two most recent studies revealed different results. SPACE (Stent-protected Angioplasty versus Carotid Endarterectomy in symptomatic patients) marginally failed to prove the non-inferiority of CAS compared to CEA; for the endpoint ipsilateral stroke or death up to day 30, the event rates after 1,200 patients were 6.8% for CAS and 6.3% for CEA-patients (absolute difference 0.5%; 95% CI –1.9% to +2.9%; $p = 0.09$) [344]. The French EVA3S (Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis) trial was stopped prematurely after the inclusion of 527 patients because of safety concerns and lack of efficacy. The RR of any stroke or death after CAS, compared with CEA, was 2.5 (95% CI 1.2–5.1) [343]. An updated meta-analysis of these studies revealed a significantly higher risk of any stroke and death within 30 days after CAS, compared with CEA (OR 1.41; 95% CI 1.07–1.87; $p = 0.016$). However, significant heterogeneity was found in this analysis ($p = 0.035$) [347]. After the periprocedural period, few ipsilateral strokes occurred with either procedure (table 9.9).

Intracranial and vertebral artery occlusive disease

Extracranial-intracranial anastomosis

Anastomosis between the superficial temporal and middle cerebral arteries is not beneficial in preventing stroke in patients with MCA or ICA stenosis or occlusion [348].

Table 9.9 Risk of stroke or death from large-scale randomized trials comparing endovascular and surgical treatment in patients with severe carotid artery stenosis.

Outcome	Any stroke or death at 30 days		Disabling stroke or death at 30 days		Ipsilateral stroke after 30 days	
	CAS <i>n</i> (%)	CEA <i>n</i> (%)	CAS <i>n</i> (%)	CEA <i>n</i> (%)	CAS <i>n</i> (%)	CEA <i>n</i> (%)
CAVATAS [346]	25 (10.0)	25 (9.9)	16 (6.4)	15 (5.9)	6*	10*
SAPPHERE [345]	8 (4.8)	9 (5.4)	unk	unk	unk	unk
SPACE [344, 585]	46 (7.7)	38 (6.5)	29 (4.8)	23 (3.9)	4 (0.7)*	1 (0.2)*
EVA3S [343]	25 (9.6)	10 (3.9)	9 (3.4)	4 (1.5)	2 (0.6)*	1 (0.3)*

Intention-to-treat data; unk: unknown.

*Follow-up duration 1.95 years in mean;

*up to 6 months.

Stenting of intracranial or vertebral artery stenoses

Patients with symptomatic intracranial stenoses of $\geq 50\%$ are at high risk of recurrent strokes, both in the anterior and posterior circulation (12% after 1 year and 15% after 2 years in the territory of the stenosed artery) [317, 349]. Severe stenoses ($\geq 70\%$) carry a higher risk than moderate stenoses (50% to $<70\%$) [349]. After stenting, recurrent strokes are reported in about 5–7% of patients with moderate or severe stenoses after 1 year, and in around 8% after 2 years [350, 351]. However, the incidence of complications after either angioplasty or stenting may be up to 6% [352–354]. No randomized controlled trials have evaluated angioplasty, stenting, or both for intracranial stenosis. Several non-randomized trials have shown feasibility and acceptable safety of intracranial stenting, but the risk of restenosis remains high [354, 355]. Also stenting of the extracranial segments of the vertebral artery is technical feasible with a moderate periprocedural risk as demonstrated in the SSVLIVA trial for example; but especially at the origin there is a particular high rate of restenoses [355].

General stroke treatment

Recommendations

- Intermittent monitoring of neurological status, pulse, blood pressure, temperature, and oxygen saturation is recommended for 72 h in patients with significant persisting neurological deficits (Class IV, GCP).
- It is recommended that oxygen should be administered if the oxygen saturation falls below 95% (Class IV, GCP).
- Regular monitoring of fluid balance and electrolytes is recommended in patients with severe stroke or swallowing problems (Class IV, GCP).
- Normal saline (0.9%) is recommended for fluid replacement during the first 24 h after stroke (Class IV, GCP).
- Routine blood pressure lowering is not recommended following acute stroke (Class IV, GCP).
- Cautious blood pressure lowering is recommended in patients with extremely high blood pressures ($>220/120$ mmHg) on repeated measurements, or with severe cardiac failure, aortic dissection, or hypertensive encephalopathy (Class IV, GCP).
- It is recommended that abrupt blood pressure lowering be avoided (Class II, Level C).

- It is recommended that low blood pressure secondary to hypovolaemia or associated with neurological deterioration in acute stroke should be treated with volume expanders (Class IV, GCP).
- Monitoring serum glucose levels is recommended (Class IV, GCP).
- Treatment of serum glucose levels >180 mg/dl (>10 mmol/l) with insulin titration is recommended (Class IV, GCP).
- It is recommended that severe hypoglycaemia (<50 mg/dl [<2.8 mmol/l]) should be treated with i.v. dextrose or infusion of 10–20% glucose (Class IV, GCP points).
- It is recommended that the presence of pyrexia (temperature $>37.5^\circ\text{C}$) should prompt a search for concurrent infection (Class IV, GCP).
- Treatment of pyrexia (temperature $>37.5^\circ\text{C}$) with paracetamol and fanning is recommended (Class III, Level C).
- Antibiotic prophylaxis is not recommended in immunocompetent patients (Class II, Level B).

The term ‘general treatment’ refers to treatment strategies aimed at stabilizing the critically ill patient in order to control systemic problems that may impair stroke recovery; the management of such problems is a central part of stroke treatment [2, 105]. General treatment includes respiratory and cardiac care, fluid and metabolic management, blood pressure control, the prevention and treatment of conditions such as seizures, venous thromboembolism, dysphagia, aspiration pneumonia, other infections, or pressure ulceration, and occasionally management of elevated intracranial pressure. However, many aspects of general stroke treatment have not been adequately assessed in randomized clinical trials.

It is common practice to actively manage neurological status and vital physiological functions such as blood pressure, pulse, oxygen saturation, blood glucose, and temperature. Neurological status can be monitored using validated neurological scales such as the NIH Stroke Scale [103] or the Scandinavian Stroke Scale [356]. There is little direct evidence from randomized clinical trials to indicate how intensively monitoring should be carried out, but in stroke unit trials [118] it was common practice to have a minimum of 4-hourly observations for the first 72 h after stroke. Clinical trials using continuous telemetry [357, 358] suggest there may be some benefit from more intensive continuous monitoring in terms of improved detection of complications and reduced length

of stay, but clinical outcomes are inconclusive. In practice, more intensive monitoring is often provided for subgroups of patients, such as those with reduced consciousness, progressing neurological deficits, or a history of cardiorespiratory disease. Close monitoring is also required for the first 24 h after thrombolysis. More invasive monitoring procedures, such as central venous catheters or intracranial pressure monitoring, are used only in highly selected patient groups.

Pulmonary function and airway protection

Normal respiratory function with adequate blood oxygenation is believed to be important in the acute stroke period to preserve ischaemic brain tissue. However, there is no convincing evidence that routine provision of oxygen at low flow rates to all acute stroke patients is effective [359]. Identification and treatment of hypoxia is believed to be important in individuals with extensive brainstem or hemispheric stroke, seizure activity, or complications such as pneumonia, cardiac failure, pulmonary embolism, or exacerbation of chronic obstructive pulmonary disease (COPD). Blood oxygenation is usually improved by the administration of 2–4 litres of oxygen via a nasal tube. Ventilation may be necessary in patients with severely compromised respiratory function. However, before ventilation is performed the general prognosis, coexisting medical conditions, and the presumed wishes of the patient need to be considered.

Cardiac care

Cardiac arrhythmias, particularly AF, are relatively common after stroke, and heart failure, myocardial infarction, and sudden death are also recognized complications [360, 361]. A significant minority of stroke patients show raised blood troponin levels indicative of cardiac damage [362]. Every stroke patient should have an initial ECG. Cardiac monitoring should be conducted to screen for AF. Optimizing cardiac output with maintenance of high normal blood pressure and a normal heart rate is a standard component of stroke management. The use of inotropic agents is not routine practice, but fluid replacement therapy is commonly used to correct hypovolaemia. Increases in cardiac output may increase cerebral perfusion. Restoration of normal cardiac rhythm using drugs, cardioversion, or pacemaker support may occasionally be required.

Fluid replacement therapy

Many stroke patients are dehydrated on admission to hospital, and this is associated with a poor outcome [363]. Although clinical trial evidence is limited, delivery of i.v. fluids is commonly considered part of general management of acute stroke, particularly in patients at risk of dehydration due to reduced consciousness or impaired swallowing. Experience in the management of hyperglycaemia supports the avoidance of dextrose in the early post-stroke phase [364]. More specialist fluid replacement therapy with haemodilution has not been shown to improve stroke outcomes [365].

Blood pressure management

Blood pressure monitoring and treatment is a controversial area in stroke management. Patients with the highest and lowest levels of blood pressure in the first 24 h after stroke are more likely to have early neurological decline and poorer outcomes [366]. A low or low-normal blood pressure at stroke onset is unusual [367], and may be the result of a large cerebral infarct, cardiac failure, ischaemia, hypovolaemia, or sepsis. Blood pressure can usually be raised by adequate rehydration with crystalloid (saline) solutions; patients with low cardiac output may occasionally need inotropic support. However, clinical trials of actively elevating a low blood pressure in acute stroke have yielded inconclusive results.

A systematic review covering a variety of blood pressure altering agents has not provided any convincing evidence that active management of blood pressure after acute stroke influences patient outcomes [368]. Small studies looking at surrogate markers of cerebral blood flow such as SPECT have indicated that neither perindopril nor losartan lower cerebral blood flow when given within 2–7 days of stroke onset [369]. Several ongoing trials are examining whether blood pressure should be lowered after acute stroke, and whether antihypertensive therapy should be continued or stopped in the first few days after stroke [370, 371]. In the absence of reliable evidence from clinical trials, many clinicians have developed protocols for the management of extremely high blood pressure. In some centres it is common practice to begin cautious blood pressure reduction when levels exceed 220 mmHg systolic and 120 mmHg diastolic. However, in many centres blood pressure reduction is only considered in the presence of severe cardiac insufficiency, acute renal failure, aortic arch dissection, or

malignant hypertension. In patients undergoing thrombolysis it is common practice to avoid systolic blood pressures above 185 mmHg.

The use of sublingual nifedipine should be avoided because of the risk of an abrupt decrease in blood pressure [372]. Intravenous labetalol or urapidil are frequently used in North America. Sodium nitroprusside is sometimes recommended.

Blood glucose management

Hyperglycaemia occurs in up to 60% of stroke patients without known diabetes [373, 374]. Hyperglycaemia after acute stroke is associated with larger infarct volumes and cortical involvement, and with poor functional outcome [375-377]. There is limited evidence as to whether active reduction of glucose in acute ischaemic stroke improves patient outcomes. The largest randomized trial of blood glucose lowering by glucose potassium insulin infusion [364], compared with standard i.v. saline infusion, found no difference in mortality or functional outcomes in patients with mild-to-moderate blood glucose elevations (median 137 mg/dl [7.6 mmol/l]). This regime was labour-intensive and associated with episodes of hypoglycaemia. At present the routine use of insulin infusion regimes in patients with moderate hyperglycaemia cannot be recommended. However, it is common practice in stroke units to reduce blood glucose levels exceeding 180 mg/dl (10 mmol/l) [118]. The use of i.v. saline and avoidance of glucose solutions in the first 24 h after stroke is common practice, and appears to reduce blood glucose levels [364].

Hypoglycaemia (<50 mg/dl [2.8 mmol/l]) may mimic an acute ischaemic infarction, and should be treated by i.v. dextrose bolus or infusion of 10–20% glucose [378].

Body temperature management

In experimental stroke, hyperthermia is associated with increased infarct size and poor outcome [379]. Raised temperature can be centrally driven or a result of concurrent infection, and is associated with poorer clinical outcomes [380-382]. A raised body temperature should prompt a search for infection and treatment where appropriate. Studies with antipyretic medication have been inconclusive, but treatment of raised body temperature (>37.5°C) with paracetamol is common practice in stroke patients.

Specific treatment

Recommendations

- Intravenous rtPA (0.9 mg/kg body weight, maximum 90 mg), with 10% of the dose given as a bolus followed by a 60-min infusion, is recommended within 4.5 h of onset of ischaemic stroke (Class I, Level A), although treatment between 3 and 4.5 h is currently not included in the European labelling (modified January 2009).
- The use of multimodal imaging criteria may be useful for patient selection for thrombolysis but is not recommended for routine clinical practice (Class III, Level C).
- It is recommended that blood pressures of 185/110 mmHg or higher is lowered before thrombolysis (Class IV, GCP).
- It is recommended that i.v. rtPA may be used in patients with seizures at stroke onset, if the neurological deficit is related to acute cerebral ischaemia (Class IV, GCP).
- It is recommended that i.v. rtPA may also be administered in selected patients under 18 years and over 80 years of age, although this is outside the current European labelling (Class III, Level C).
- Intra-arterial treatment of acute MCA occlusion within a 6-h time window is recommended as an option (Class II, Level B).
- Intra-arterial thrombolysis is recommended for acute basilar occlusion in selected patients (Class III, Level B). Intravenous thrombolysis for basilar occlusion is an acceptable alternative even after 3 h (Class III, Level B).
- It is recommended that aspirin (160–325 mg loading dose) be given within 48 h after ischaemic stroke (Class I, Level A).
- It is recommended that if thrombolytic therapy is planned or given, aspirin or other antithrombotic therapy should not be initiated within 24 h (Class IV, GCP).
- The use of other antiplatelet agents (single or combined) is not recommended in the setting of acute ischaemic stroke.
- The administration of glycoprotein-IIb/IIIa inhibitors is not recommended (Class I, Level A).
- Early administration of unfractionated heparin, low molecular weight heparin, or heparinoids is not recommended for the treatment of patients with acute ischaemic stroke (Class I, Level A).
- Currently, there is no recommendation to treat ischaemic stroke patients with neuroprotective substances (Class I, Level A).

Thrombolytic therapy

Intravenous tissue plasminogen activator

Thrombolytic therapy with rtPA (0.9 mg/kg body weight, maximum dose 90 mg) given within 3 h after stroke onset

significantly improves outcome in patients with acute ischaemic stroke [125]: the NNT to achieve a favourable clinical outcome after 3 months is 7. By contrast, the ECASS (European Cooperative Acute Stroke Study) and ECASS II studies did not show statistically significant superiority of rtPA for the primary endpoints when treatment was given within 6 h [383, 384]. Trials with rtPA, involving a total of 2,889 patients, have shown a significant reduction in the number of patients with death or dependency (OR 0.83; 95% CI 0.73–0.94) [385]. A pooled analysis of individual data of rtPA trials showed that, even within a 3-h window, earlier treatment results in a better outcome (0–90 min: OR 2.11; 95% CI 1.33 to 3.55; 90–180 min: OR 1.69; 95% CI 1.09 to 2.62) [386]. This analysis suggested a benefit up to 4.5 h.

The recently published trial European Cooperative Acute Stroke Study III (ECASS III) has shown that i.v. alteplase administered between 3 and 4.5 h (median 3 h 59 min) after the onset of symptoms significantly improves clinical outcomes in patients with acute ischaemic stroke compared to placebo [387, 388]; the absolute improvement was 7.2% and the adjusted OR of favourable outcome (mRS 0–1) was 1.42, 1.02–1.98. Mortality did not differ significantly (7.7% versus 8.4%), but alteplase increased the risk of SICH (2.4% versus 0.2%). Treatment benefit is time-dependent. The number needed to treat to get one more favourable outcome drops from 2 during the first 90 min through 7 within 3 h and towards 14 between 3 and 4.5 h [387, 388].

The SITS investigators compared 664 patients with ischaemic stroke treated between 3 and 4.5 h otherwise compliant with the European summary of the product characteristics criteria with 11,865 patients treated within 3 h [389].

In the 3–4.5-h cohort, treatment was started on average 55 min later after symptom onset. There were no significant differences between the 3–4.5-h cohort and the 3-h cohort for any outcome measures, confirming that alteplase remains safe when given between 3 and 4.5 h after the onset of symptoms in ischaemic stroke patients who otherwise fulfil the European summary of product characteristics criteria [389] (modified January 2009).

The NINDS (National Institute of Neurological Disorders and Stroke) Study showed that the extent of early ischaemic changes (using the ASPECT score) had no effect on treatment response within the 3-h time window [387]. However, European regulatory agencies do not

advocate rtPA treatment in patients with severe stroke (NIHSS ≥ 25), extended early ischaemic changes on CT scan, or age above 80 years (unlike the US labelling). Nevertheless, observational studies suggest that rtPA given within 3 h of stroke onset is safe and effective in patients over 80 years of age [390–392], but more randomized data are pending. The effect of gender on the response to rtPA is uncertain [393].

Thrombolytic therapy appears to be safe and effective across various types of hospitals, if the diagnosis is established by a physician with stroke expertise and brain CT is assessed by an experienced physician [394–396]. Whenever possible, the risks and benefits of rtPA should be discussed with the patient and family before treatment is initiated.

Blood pressure must be below 185/110 mmHg before, and for the first 24 h after, thrombolysis. Management of high blood pressure is required [125]. Protocol violations are associated with higher mortality rates [397, 398].

Continuous transcranial ultrasound was associated with an increased rate of early recanalization after rtPA in a small randomized trial [399]; this effect may be facilitated by the administration of microbubbles [400]. However, a randomized clinical trial has recently been stopped for undisclosed reasons.

Intravenous rtPA may be of benefit also for acute ischaemic stroke beyond 3 h after onset, but is not recommended in clinical routine. The use of multimodal imaging criteria may be useful for patient selection. Several large observational studies suggest improved safety and possibly improved efficacy in patients treated with i.v. rtPA beyond 3 h based on advanced imaging findings [130, 159, 401, 402]. However, available data on mismatch, as defined by multimodal MRI or CT, are too limited to guide thrombolysis in routine practice (see also the section on imaging) [152].

Patients with seizures at stroke onset have been excluded from thrombolytic trials because of potential confusion with post-ictal Todd's phenomena. Case series have suggested that thrombolysis may be used in such patients when there is evidence for new ischaemic stroke [390].

Post hoc analyses have identified the following potential factors associated with increased risk of intracerebral bleeding complications after rtPA use [403]:

- elevated serum glucose
- history of diabetes

- baseline symptom severity
- advanced age
- increased time to treatment
- previous aspirin use
- history of congestive heart failure
- low plasminogen activator inhibitor activity
- NINDS protocol violations.

However, none of these factors reversed the overall benefit of rtPA.

Other intravenous thrombolytics

Intravenous streptokinase was associated with an unacceptable risk of haemorrhage and death [404, 405]. Intravenous desmoteplase administered 3 to 9 h after acute ischaemic stroke in patients selected on the basis of perfusion/diffusion mismatch was associated with a higher rate of reperfusion and better clinical outcome, compared with placebo, in two small randomized clinical trials (RCTs) [406, 407]. These findings were not confirmed in the phase III DIAS (Desmoteplase in Acute Ischemic Stroke)-II study, but this agent will be evaluated further.

Intra-arterial and combined (IV + IA) thrombolysis

Intra-arterial thrombolytic treatment of proximal MCA occlusion using pro-urokinase (PUK) within 6 h was significantly associated with better outcome in the PROACT II (Pro-urokinase for Acute Ischemic Stroke) trial [153]. Additional smaller RCTs with PUK (PROACT I) or urokinase (MELT) and a meta-analysis of PROACT I, PROACT II, and MELT indicate a benefit of intra-arterial thrombolytic therapy in patients with proximal MCA occlusions [408]. Pro-urokinase is not available and intra-arterial thrombolysis with tPA is not substantiated by RCTs, but observational data and non-randomised comparisons are available [154, 409].

A randomized trial comparing standard i.v. rtPA with a combined intravenous and intra-arterial approach (IMS3) has started [410].

Intra-arterial treatment of acute basilar occlusion with urokinase or rtPA has been available for more than 20 years, but has not been tested in an adequately powered RCT [411], although encouraging results have been obtained in observational studies [412, 413]. A systematic analysis found no significant differences between

intravenous or intra-arterial thrombolysis for basilar occlusion [414].

Intra-arterial recanalization devices

The MERCI (Mechanical Embolus Removal in Cerebral Embolism) trial evaluated a device that removed the thrombus from an intracranial artery. Recanalization was achieved in 48% (68/141) of patients in whom the device was deployed within 8 h of the onset of stroke symptoms [415]. No RCTs with outcome data are available for any recanalization devices.

Antiplatelet therapy

The results of two large randomized, non-blinded, intervention studies indicate that aspirin is safe and effective when started within 48 h after stroke [416, 417]. In absolute terms, 13 more patients were alive and independent at the end of follow-up for every 1000 patients treated. Furthermore, treatment increased the odds of making a complete recovery from the stroke (OR 1.06; 95% CI 1.01–1.11): 10 more patients made a complete recovery for every 1000 patients treated. Antiplatelet therapy was associated with a small but definite excess of two symptomatic intracranial haemorrhages for every 1000 patients treated, but this was more than offset by a reduction of seven recurrent ischaemic strokes and about one pulmonary embolism for every 1000 patients treated.

A randomized, double-blind, placebo-controlled trial showed that aspirin (325 mg), given once daily for 5 consecutive days and starting within 48 h of stroke onset, did not significantly reduce stroke progression, compared with placebo (RR 0.95; 95% CI 0.62–1.45) in patients with incomplete paresis [418].

The use of clopidogrel, dipyridamole, or combinations of oral antiplatelet agents in acute ischaemic stroke has not been evaluated.

In a double-blind phase II, the glycoprotein-IIb/IIIa inhibitor abciximab produced a non-significant shift in favourable outcomes, as measured by modified Rankin scores (mRS) at 3 months, compared with placebo (OR 1.20; 95% CI 0.84–1.70) [419]. A phase III study evaluating the safety and efficacy of abciximab was terminated prematurely after 808 patients had been enrolled because of an increased rate of symptomatic or fatal intracranial bleeding with abciximab compared to placebo (5.5% versus 0.5%; $p = 0.002$). This trial also did not demon-

strate an improvement in outcomes with abciximab [420].

Early anticoagulation

Subcutaneous unfractionated heparin (UFH) at low or moderate doses [415], nadroparin [421, 422], certoparin [423], tinzaparin [424], dalteparin [425], and i.v. danaparoid [426] have failed to show an overall benefit of anticoagulation when initiated within 24 to 48 h from stroke onset. Improvements in outcome or reductions in stroke recurrence rates were mostly counterbalanced by an increased number of haemorrhagic complications. In a meta-analysis of 22 trials, anticoagulant therapy was associated with about nine fewer recurrent ischaemic strokes per 1000 patients treated (OR 0.76; 95% CI 0.65–0.88), and with about nine more symptomatic intracranial haemorrhages per 1,000 (OR 2.52; 95% CI 1.92–3.30) [427]. However, the quality of the trials varied considerably. The anticoagulants tested were standard UFH, low molecular weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors.

Few clinical trials have assessed the risk-benefit ratio of very early administration of UFH in acute ischaemic stroke. In one study, patients with nonlacunar stroke anticoagulated within 3 h had more self-independence (38.9% versus 28.6%; $p = 0.025$), fewer deaths (16.8% versus 21.9%; $p = 0.189$), and more symptomatic brain haemorrhages (6.2% versus 1.4%; $p = 0.008$) [428]. In the RAPID (Rapid Anticoagulation Prevents Ischemic Damage) trial, patients allocated UFH had fewer early recurrent strokes and a similar incidence of serious haemorrhagic events, compared with those receiving aspirin [429]. In the UFH group, ischaemic or haemorrhagic worsening was associated with inadequate plasma levels of UFH. In view of these findings, the value of UFH administered shortly after symptom onset is still debated [430, 431].

RCTs have not identified a net benefit of heparin for any stroke subtype. A meta-analysis restricted to patients with acute cardioembolic stroke showed that anticoagulants given within 48 h of clinical onset were associated with a non-significant reduction in recurrence of ischaemic stroke, but no substantial reduction in death or disability [432]. Despite this lack of evidence, some experts recommend full-dose heparin in selected patients, such as those with cardiac sources of embolism with high risk of re-embolism, arterial dissection, or high-grade

arterial stenosis prior to surgery. Contraindications for heparin treatment include large infarcts (e.g. more than 50% of MCA territory), uncontrollable arterial hypertension and advanced microvascular changes in the brain.

Neuroprotection

No neuroprotection programme has shown improved outcome on its predefined primary endpoint. Recent RCTs with the free radical trapping agent NXY-059 [433] and magnesium sulphate [434] were negative. A randomized, placebo-controlled, phase III trial of i.v. rtPA followed by antioxidant therapy with uric acid is ongoing, following a safe phase II study [435]. A meta-analysis has suggested a mild benefit with citocoline [436]; a clinical trial with this agent is in progress.

Brain oedema and elevated intracranial pressure

Recommendations

- Surgical decompressive therapy within 48 h after symptom onset is recommended in patients up to 60 years of age with evolving malignant MCA infarcts (Class I, Level A).
- It is recommended that osmotherapy can be used to treat elevated intracranial pressure prior to surgery if this is considered (Class III, Level C).
- No recommendation can be given regarding hypothermic therapy in patients with space-occupying infarctions (Class IV, GCP).
- It is recommended that ventriculostomy or surgical decompression be considered for treatment of large cerebellar infarctions that compress the brainstem (Class III, Level C).

Space-occupying brain oedema is a main cause of early deterioration and death in patients with large supratentorial infarcts. Life-threatening brain oedema usually develops between the second and fifth day after stroke onset, but up to a third of patients can have neurological deterioration within 24 h after symptom onset [437, 438].

Medical therapy

Medical therapy in patients with large space-occupying infarctions and brain oedema is based mostly on observational data. Basic management includes head positioning at an elevation of up to 30°, avoidance of noxious stimuli, pain relief, appropriate oxygenation, and normalizing body temperature. If intracranial pressure (ICP)

monitoring is available, cerebral perfusion pressure should be kept above 70 mmHg [439]. Intravenous glycerol (4×250 ml of 10% glycerol over 30–60 minutes) or mannitol (25–50 g every 3–6 h) is first-line medical treatment if clinical or radiological signs of space-occupying oedema occur [440, 441]. Intravenous hypertonic saline solutions are probably similarly effective [442]. Hypotonic and glucose-containing solutions should be avoided as replacement fluids. Dexamethasone and corticosteroids are not useful [443]. Thiopental given as a bolus can quickly and significantly reduce ICP, and can be used to treat acute crises. Barbiturate treatment requires ICP and electroencephalography (EEG) monitoring and careful haemodynamic monitoring, as a significant blood pressure drop may occur.

Hypothermia

Mild hypothermia (i.e. brain temperature between 32 and 33°C) reduces mortality in patients with severe MCA infarcts, but may cause severe side effects, including recurrent ICP crisis during re-warming [444, 445]. In a small RCT, mild hypothermia (35°C) in addition to decompressive surgery produced a trend towards a better clinical outcome than decompressive surgery alone ($p = 0.08$) [446].

Decompressive surgery

Malignant MCA infarction

A pooled analysis of 93 patients included in the DECIMAL (decompressive craniectomy in malignant middle cerebral artery infarcts), DESTINY (decompressive surgery for the treatment of malignant infarction of the middle cerebral artery), and HAMLET (hemispheric craniectomy after middle cerebral artery infarction with life-threatening edema trial) trials showed that, compared with the control group, at 1 year more patients in the decompressive surgery group had a mRS ≤ 4 or mRS ≤ 3 , and more survived (NNTs 2, 4 and 2 respectively) [447, 448]. There was no increase in the proportion of patients who survived surgery in a vegetative stage (mRS 5). Inclusion criteria for this combined analysis were age 18–60 years, NIHSS >15 , decrease in level of consciousness to a score of 1 or greater on item 1a of the NIHSS, infarct signs on CT of 50% or more of the MCA territory or >145 cm³ on DWI, and inclusion <45 h after onset (surgery <48 h). Follow-up of survival and functional status beyond 1 year

is currently ongoing in the DECIMAL and DESTINY studies [448].

A systematic review of 12 observational retrospective studies found age above 50 years to be a predictor of poor outcome. The timing of surgery, side of infarction, clinical signs of herniation before surgery, and involvement of other vascular territories did not significantly affect outcome [449].

Cerebellar infarction

Ventriculostomy and decompressive surgery are considered treatments of choice for space-occupying cerebellar infarctions, although RCTs are lacking. As in space-occupying supratentorial infarction, the operation should be performed before signs of herniation are present. The prognosis among survivors can be very good, even in patients who are comatose before surgery.

Prevention and management of complications

Recommendations

- It is recommended that infections after stroke should be treated with appropriate antibiotics (Class IV, GCP).
- Prophylactic administration of antibiotics is not recommended, and levofloxacin can be detrimental in acute stroke patients (Class II, Level B).
- Early rehydration and graded compression stockings are recommended to reduce the incidence of venous thromboembolism (Class IV, GCP).
- Early mobilization is recommended to prevent complications such as aspiration pneumonia, DVT, and pressure ulcers (Class IV, GCP).
- It is recommended that low-dose subcutaneous heparin or low molecular weight heparins should be considered for patients at high risk of DVT or pulmonary embolism (Class I, Level A).
- Administration of anticonvulsants is recommended to prevent recurrent post-stroke seizures (Class I, Level A). Prophylactic administration of anticonvulsants to patients with recent stroke who have not had seizures is not recommended (Class IV, GCP).
- An assessment of falls risk is recommended for every stroke patient (Class IV, GCP).
- Calcium/vitamin D supplements are recommended in stroke patients at risk of falls (Class II, Level B).
- Bisphosphonates (alendronate, etidronate, and risedronate) are recommended in women with previous fractures (Class II, Level B).

- In stroke patients with urinary incontinence, specialist assessment and management is recommended (Class III, Level C).
- Swallowing assessment is recommended but there are insufficient data to recommend a specific approach for treatment (Class III, GCP).
- Oral dietary supplements are only recommended for non-dysphagic stroke patients who are malnourished (Class II, Level B).
- Early commencement of nasogastric (NG) feeding (within 48 h) is recommended in stroke patients with impaired swallowing (Class II, Level B).
- It is recommended that percutaneous enteral gastrostomy (PEG) feeding should not be considered in stroke patients in the first 2 weeks (Class II, Level B).

Aspiration and pneumonia

Bacterial pneumonia is one of the most important complications in stroke patients [450], and is mainly caused by aspiration [451]. Aspiration is frequently found in patients with reduced consciousness and in those with swallowing disturbances. Oral feeding should be withheld until the patient has demonstrated intact swallowing with small amounts of water and intact coughing on command. Nasogastric (NG) or percutaneous enteral gastrostomy (PEG) feeding may prevent aspiration pneumonia, although reflux of liquid feed, hypostasis, diminished cough, and immobilization increase the risk. Frequent changes of the patient's position in bed and pulmonary physical therapy may prevent aspiration pneumonia. A brain-mediated immunodepressive state contributes to post-stroke infection [452, 453]. Prophylactic administration of levofloxacin (500 mg/100 ml/day for 3 days) is not better than optimal care for the prevention of infection in patients with nonseptic acute stroke and was inversely associated with outcome at day 90 (OR 0.19; 95% CI 0.04 to 0.87; $p = 0.03$) [454].

Deep vein thrombosis and pulmonary embolism

It is generally accepted that the risk of DVT and pulmonary embolism (PE) can be reduced by early hydration and early mobilization. Although graded compression stockings are effective in preventing venous thromboembolism in surgical patients, their efficacy after stroke is unproven [455]. In stroke patients low-dose LMWH reduced the incidence of both DVT (OR 0.34; 95% CI

0.19–0.59) and pulmonary embolism (OR 0.36; 95% CI 0.15–0.87), without an increased risk of intracerebral (OR 1.39; 95% CI 0.53–3.67) or extracerebral haemorrhage (OR 1.44; 95% CI 0.13–16), NNT: 7 and 38 for DVT and pulmonary embolism respectively, while low-dose UFH decreased the thrombosis risk (OR 0.17; 95% CI 0.11–0.26), but had no influence on pulmonary embolism (OR 0.83, 95% CI 0.53–1.31); the risk of ICH was not statistically significantly increased (OR 1.67; 95% CI 0.97–2.87) [456]. Nevertheless, prophylaxis with subcutaneous low-dose heparin (5000 IU twice daily) or low molecular weight heparins is indicated in patients at high risk of DVT or PE (e.g. due to immobilization, obesity, diabetes, previous stroke) [457, 458].

Pressure ulcer

In patients at high risk of developing pressure ulcers, use of support surfaces, frequent repositioning, optimizing nutritional status, and moisturizing sacral skin are appropriate preventive strategies [459]. The skin of the incontinent patient must be kept dry. For patients at particularly high risk, an air-filled or fluid-filled mattress system should be used.

Seizures

Partial or secondary generalized seizures may occur in the acute phase of ischaemic stroke. Standard anti-epileptic drugs should be used based on general principles of seizure management. There is no evidence that primary prophylactic anticonvulsive treatment is beneficial.

Agitation

Agitation and confusion may be a consequence of acute stroke, but may also be due to complications such as fever, volume depletion, or infection. Adequate treatment of the underlying cause must precede any type of sedation or antipsychotic treatment.

Falls

Falls are common (up to 25%) after stroke in the acute setting [460], during inpatient rehabilitation [461], and in the long term [462]. Likely risk factors for falls in stroke survivors [463] include cognitive impairment, depression, polypharmacy, and sensory impairment [464, 465]. A multidisciplinary prevention package that focuses on personal and environmental factors has been found to be successful in general rehabilitation settings

[466, 467]. There is a 5% incidence of serious injury [460], including hip fractures (which are four-fold more common than in age-matched controls [468]), which is associated with poor outcome [469]. Exercise [470], calcium supplements [471], and bisphosphonates [472] improve bone strength and decrease fracture rates in stroke patients. Hip protectors can reduce the incidence of fracture for high-risk groups in institutional care, but evidence is less convincing for their use in a community setting [473].

Urinary tract infections and incontinence

Intermittent catheterization has not been shown to reduce the risk of infection. Once urinary infection is diagnosed, appropriate antibiotics should be chosen; to avoid bacterial resistance developing, prophylactic antibiotics are best avoided.

Urinary incontinence is common after stroke, particularly in older, more disabled, and cognitively impaired patients [476]. Recent estimates suggest a prevalence of 40–60% in an acute stroke population, of whom 25% are still incontinent at discharge and 15% remain incontinent at one year [477]. Urinary incontinence is a strong predictor of poor functional outcome, even after correcting for age and functional status [478]. However, data from the available trials are insufficient to guide continence care of adults after stroke [475, 479]. However, there is suggestive evidence that professional input through structured assessment and management of care and specialist continence nursing may reduce urinary incontinence and related symptoms after stroke. Structured assessment and physical management have been shown to improve continence rates in both inpatients and outpatients [475, 477]. However, trials of interventions are insufficient in number and quality to make any recommendations [479].

Dysphagia and feeding

Oropharyngeal dysphagia occurs in up to 50% of patients with unilateral hemiplegic stroke [480]. The prevalence of dysphagia is highest in the acute stages of stroke, and declines to around 15% at 3 months [481]. Dysphagia is associated with a higher incidence of medical complications and increased overall mortality [480].

Withholding or limiting oral intake can worsen the catabolic state that may be associated with an acute illness

such as stroke. Estimates of the incidence of malnutrition vary from 7 to 15% at admission [482, 483] and 22 to 35% at 2 weeks [484]. Among patients requiring prolonged rehabilitation, the prevalence of malnutrition may reach 50% [485]. Malnutrition predicts a poor functional outcome [486] and increased mortality [487, 488]. However, routine supplementation for all acute stroke patients did not improve outcomes or reduce complications [489]. There are no adequately powered trials of targeting supplementation to stroke patients at high risk of malnutrition.

For patients with continuing dysphagia, options for enteral nutrition include NG or PEG feeding. A trial of early (median 48 h post-stroke) versus delayed (1 week) NG feeding found no significant benefit of early feeding, although there was a trend to fewer deaths in the early NG group [489]. In a related trial examining PEG and NG feeding within 30 days, PEG feeding was no better than NG and in fact was potentially harmful [489]. PEG feeding has also been studied in longer-term dysphagia. Two trials comparing PEG and NG feeding found a trend towards improved nutrition with PEG feeding that did not reach statistical significance [490, 491]. Studies that have addressed quality of life found it was not improved by PEG feeding [492, 493].

Rehabilitation

Even with optimal stroke unit care including thrombolysis, fewer than one-third of patients recover fully from stroke [388]. Rehabilitation aims to enable people with disabilities to reach and maintain optimal physical, intellectual, psychological, and/or social function [494]. Goals of rehabilitation can shift from initial input to minimize impairment to more complex interventions designed to encourage active participation.

Setting for rehabilitation

Recommendations

- Admission to a stroke unit is recommended for acute stroke patients to receive co-ordinated multidisciplinary rehabilitation (Class I, Level A).
- Early initiation of rehabilitation is recommended (Class III, Level C).

- It is recommended that early discharge from stroke unit care is possible in medically stable patients with mild or moderate impairment providing that rehabilitation is delivered in the community by a multidisciplinary team with stroke expertise (Class I, Level A).
- It is recommended to continue rehabilitation after discharge during the first year after stroke (Class II, Level A).
- It is recommended to increase the duration and intensity of rehabilitation (Class II, Level B).

A key characteristic of stroke units is rehabilitation delivered by a specialized multidisciplinary team [495]. The Stroke Unit Trialists' Collaboration [61] has shown improved survival and functional outcomes for patients treated in a dedicated stroke ward, and there are also long-term functional benefits of dedicated stroke unit care; follow-up at 5 and 10 years has revealed persisting efficacy compared with controls [496, 497]. The financial and social implications of prolonged hospitalization have prompted increasing interest in services to facilitate early return to the community. A multidisciplinary early supported discharge team with stroke expertise, comprising (at least) nursing, physiotherapy, and occupational therapy, can significantly reduce bed days for selected stroke patients [498] who have mild or moderate impairment at baseline [499]. However, specialist discharge services are required; mortality was substantially increased when patients were discharged early with only generic community support [500].

A meta-analysis showed that continued rehabilitation after discharge during the first year after stroke reduces the risk of deterioration in function and improves activities of daily living [501]. The interventions included occupational therapy, physiotherapy, and multidisciplinary teams, and therefore no definitive statement can be made concerning the optimal mode of service delivery.

Timing, duration and intensity of rehabilitation

The optimal timing of rehabilitation is unclear. Proponents of early therapy cite evidence from functional neuroimaging [502] and animal studies [503, 504] that define the peri-infarct period as the crucial time to begin rehabilitation. Early initiation of rehabilitation is a key component of stroke unit care [61] but there is a lack of

consensus on the definition of 'early therapy'. Trials comparing 'early' and 'late' initiation of rehabilitation have reported improved prognosis if therapy is started within 20–30 days [505, 506]. Many of the immediate complications of stroke (DVT, skin breakdown, contracture formation, constipation, and hypostatic pneumonia) are related to immobility [507], and hence mobilization is a fundamental component of early rehabilitation. The optimal timing of first mobilization is unclear, but mobilization within the first few days appears to be well tolerated [508]. Preliminary results from the ongoing AVERT study of rehabilitation within 24 h suggest that immediate physical therapy is well tolerated with no increase in adverse events [509].

There are few studies of rehabilitation beyond a year after the acute event, and data are inconclusive to make a recommendation on rehabilitation in this phase [510].

Greater intensity of rehabilitation, especially time spent working on activities of daily living (ADL), is associated with improved functional outcomes [511, 512]. A systematic review of rehabilitation therapies for improving arm function also suggests a dose–response relationship, although heterogeneity of included studies precluded a formal measure of effect size [513]. Greatest benefits were observed in studies of lower limb exercises and general ADL training.

Organisation and 'quality' of care may be more important than absolute hours of therapy [514]. In a comparison between a dedicated stroke multidisciplinary team and usual ward-based rehabilitation, the dedicated team achieved better outcomes with significantly fewer hours of therapy [515].

Elements of rehabilitation

Recommendations

- Physiotherapy is recommended, but the optimal mode of delivery is unclear (Class I, Level A).
- Occupational therapy is recommended, but the optimal mode of delivery is unclear (Class I, Level A).
- While assessment for communication deficits is recommended, there are insufficient data to recommend specific treatments (Class III, GCP).
- It is recommended that information is provided to patient and carers but evidence does not support use of a dedicated stroke liaison service for all patients (Class II, Level B).

- It is recommended that rehabilitation be considered for all stroke patients, but there is limited evidence to guide appropriate treatment for the most severely disabled (Class II, Level B).
- While assessment for cognitive deficits appears desirable, there are insufficient data to recommend specific treatments (Class I, Level A).
- It is recommended that patients be monitored for depression during hospital stay and throughout follow-up (Class IV, Level B).
- Drug therapy and non-drug interventions are recommended to improve mood (Class I, Level A).
- Drug therapy should be considered to treat post-stroke emotionalism (Class II, Level B).
- Tricyclic or anticonvulsant therapy are recommended to treat post-stroke neuropathic pain in selected patients (Class III, Level B).
- It is recommended that botulinum toxin be considered to treat post-stroke spasticity, but functional benefits are uncertain (Class III, Level B).

The results from stroke unit trials favour co-ordinated multidisciplinary teams of staff with expertise in stroke care [516]. The composition of these teams is not formally prescribed, but usually includes stroke physicians, nursing staff, physiotherapists, occupational therapists, and speech and language therapists.

Physiotherapy

There is no clearly superior model of physiotherapy for stroke rehabilitation [517, 518], but some evidence exists to support specific interventions. Several groups have shown that strength can be improved in a dose-dependent manner, without increasing spasticity [513]. Functional electrical stimulation may increase strength, but the effect on clinically relevant outcomes is uncertain [519].

A systematic review did not demonstrate efficacy of treadmill training to improve walking [520]. Electromechanical gait training in combination with physical therapy may be more effective than physiotherapy alone [521]. There are limited data to support the widespread use of orthoses and assistive devices [522].

Cardiovascular fitness can deteriorate during the recovery phase of a stroke. This physical deconditioning impairs active rehabilitation and is a risk marker for further events [523]. Meta-analysis has shown that

aerobic training can improve exercise capacity in individuals with mild to moderate motor deficit post-stroke [470].

Constraint-induced movement therapy involves intensive task-orientated exercise of the paretic limb, with restraint of the non-paretic limb. The EXCITE study reported positive results for this method 3–9 months after stroke in a group of medically stable stroke survivors, with some arm movement benefit persisting at 1 year [524].

Occupational therapy

A systematic review of nine trials comparing occupational therapy (OT)-based ADL therapy with usual care reported improved functional outcomes in the active intervention group [525]. The data do not justify conclusions on the optimal mode of OT delivery.

A meta-analysis of community-based OT trials found improved performance on ADL measures. The greatest effects were seen in older patients and with the use of targeted interventions [526]. Specific leisure-based OT therapies did not translate into improved ADL. A trial of providing OT intervention to care home residents post-stroke found less functional deterioration in the active intervention group [527]. No controlled trial data describe the effectiveness of occupational therapy beyond 1 year after stroke.

Speech and language therapy

Speech and language therapy (SLT) may optimize safe swallowing, and may assist communication. Two trials of formal SLT input for dysphagia found no significant difference to usual care [528]. A study comparing simple written instruction to graded levels of speech and language intervention for dysphagia found no difference in outcomes between the groups [529].

Aphasia and dysarthria are common symptoms after stroke, and impact on quality of life [530]. A systematic review of SLT for dysarthria in non-progressive brain damage (stroke and head injury) found no good-quality evidence for benefit [531]. Similarly, a systematic review of SLT for aphasia [532] reported insufficient good-quality evidence to recommend formal or informal interventions. The studies included in this review were community-based and had an average time to therapy of 3 months; they offer little to inform acute ward-based rehabilitation. Two related meta-analyses of studies with

weaker design concluded that improvement in speech is greater if SLT is initiated early [533, 534]. Limited evidence supports the possible use of modified constraint-induced therapy for patients with aphasia [535, 536].

Stroke liaison and information provision

A recent systematic review comparing dedicated stroke liaison to usual care found no evidence of improvement in ADL, subjective health status, or carers' health [537]. On subgroup analysis, success of a stroke liaison service was predicted by younger age, less severe deficit, and an emphasis on education within the service.

Inadequate provision of information is predictive of poor quality of life in stroke patients and their families [538]. There is some evidence that combining information with educational sessions improves knowledge and is more effective than providing information alone [539]. As the patient progresses from hospital-based rehabilitation to the community, involvement of carers in rehabilitation becomes increasingly important. Formal training of caregivers in delivery of care reduces personal costs and improves quality of life [540].

Other groups

Depending on patient-specific goals, input from various other therapists may be appropriate. Such groups include dietitians, orthoptists, and social workers. Although there has been limited formal research in this area, some authors have argued that dedicated staffing creates an 'enriched environment' that encourages practice in rehabilitation activities outside periods of formal therapy [541].

Cognitive deficits

Cognitive deficits are common following stroke and impact on quality of life. At present, there is no evidence for the efficacy of specific memory rehabilitation [542]. Cognitive training for attention deficit has not resulted in meaningful clinical improvement in ADL measures [543]. Training for spatial neglect has improved impairment measures, but an effect on ADL performance has not been demonstrated [544]. A few studies have assessed rehabilitation training strategies in visual inattention and apraxia; no specific conclusions can be drawn [545].

Sexuality

Sexuality can suffer after a stroke. Underlying physical limitations and comorbid vascular disease may be com-

pounded by side effects of medications [546]. It may be desirable to discuss issues of sexuality and intimacy with patients [547]. Provision of support and information is important; many patients wrongly fear that resuming an active sex life may result in further stroke [548].

Complications affecting rehabilitation

Rehabilitation can be compromised by complications, which may be strong predictors of poor functional outcome and mortality. Common complications during inpatient rehabilitation include depression, shoulder pain, falls, urinary disturbances, and aspiration pneumonia [549]. Some of these are discussed under 'Prevention of complications'.

Post-stroke depression

Post-stroke depression is associated with poor rehabilitation results and ultimately poor outcome [550, 551]. In clinical practice, only a minority of depressed patients are diagnosed and even fewer are treated [552]. Depression has been reported in up to 33% of stroke survivors, compared with 13% of age- and sex-matched controls [553], but reliable estimates of the incidence and prevalence of depression in a stroke cohort are limited [551]. Predictors of post-stroke depression in the rehabilitation setting include increasing physical disability, cognitive impairment, and stroke severity [551]. There is no consensus on the optimal method for screening or diagnosis of post-stroke depression. Standard depression screening tools may be inappropriate for patients with aphasia or cognitive impairment [554, 555].

Antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs) and heterocyclics can improve mood after stroke [556, 557], but there is less evidence that these agents can effect full remission of a major depressive episode or prevent depression. SSRIs are better tolerated than heterocyclics [558]. There is no good evidence to recommend psychotherapy for treatment or prevention of post-stroke depression [559], although such therapy can elevate mood. There is a lack of robust evidence regarding the effect of treating post-stroke depression on rehabilitation or functional outcomes.

Emotionalism is a distressing symptom for patients and carers. SSRIs may reduce emotional outbursts but effects on quality of life are not clear [560].

Pain and spasticity

Post-stroke shoulder pain (PSSP) is common [561], especially in patients with impaired arm function and poor functional status, and is associated with poorer outcome. Passive movement of a paretic limb may be preventive [562]. Electrical stimulation is commonly used for treatment, but its efficacy is unproven [563]. A Cochrane systematic review found insufficient data to recommend the use of orthotic devices for shoulder subluxation, despite a trend towards efficacy for arm strapping of the affected limb [564].

Lamotrigine and gabapentin may be considered for neuropathic pain [565]. They appear to be well tolerated, but cognitive side effects should be considered.

Spasticity in the chronic phase may adversely affect ADL and quality of life [566]. Posture and movement therapy, relaxing therapy, splints and supports are all commonly employed, but a sound evidence base is lacking [567]. Pharmacotherapy with botulinum toxin has proven effects on muscle tone in arms and legs, but functional benefits are less well studied [568-570]. Oral agents are limited in their use because of side effects [571].

Eligibility for rehabilitation

An important predictor of rehabilitation outcome is initial stroke severity [550]. Pre-stroke disability is clearly also a strong determinant of outcome [572]. Other factors, such as sex [573], stroke aetiology [574], age [575], and topography of lesion [576], have all been studied as potential predictors of rehabilitation outcome; however, there is no evidence that these non-modifiable factors should influence decisions on rehabilitation [577]. Admission to a dedicated stroke unit improves outcomes for all strokes irrespective of age, sex, and severity [61].

Exclusion from rehabilitation on the basis of pre-stroke dependence remains a contentious issue [578, 579]. Patients with the most severe cognitive or physical impairments have been excluded from most rehabilitation trials, and therefore caution is required in extrapolating results to this group [580]. Limited data suggest that active rehabilitation allows severely disabled patients to return home [581, 582]. For those unable to participate actively, passive movements to prevent contractures or pressure sores have been recommended [2].

Appendix

ESO (EUSI) Recommendation Writing Committee

Chair: Werner Hacke, Heidelberg, Germany

Co-chairs: Marie-Germaine Boussier, Paris, France; Gary Ford, Newcastle, UK

Education, referral and emergency room

Co-chairs: Michael Brainin, Krems, Austria; José Ferro, Lisbon, Portugal

Members: Charlotte Cordonnier, Lille, France; Heinrich P. Mattle, Bern, Switzerland; Keith Muir, Glasgow, UK; Peter D. Schellinger, Erlangen, Germany

Substantial assistance received from: Isabel Henriques, Lisbon, Portugal

Stroke units

Co-chairs: Hans-Christoph Diener, Essen, Germany; Peter Langhorne, Glasgow, UK

Members: Antony Davalos, Barcelona, Spain; Gary Ford, Newcastle, UK; Veronika Skvortsova, Moscow, Russia

Imaging and diagnostics

Co-chairs: Michael Hennerici, Mannheim, Germany; Markku Kaste, Helsinki, Finland

Members: Hugh S. Markus, London, UK; E. Bernd Ringelstein, Münster, Germany; Rüdiger von Kummer, Dresden, Germany; Joanna Wardlaw, Edinburgh, UK

Substantial assistance received from: Oliver Müller, Heidelberg, Germany

Prevention

Co-chairs: Philip Bath, Nottingham, UK; Didier Leys, Lille, France

Members: Álvaro Cervera, Barcelona, Spain; László Csiba, Debrecen, Hungary; Jan Lodder, Maastricht, The Netherlands; Nils Gunnar Wahlgren, Stockholm, Sweden

General treatment

Co-chairs: Christoph Diener, Essen, Germany; Peter Langhorne, Glasgow, UK

Members: Antony Davalos, Barcelona, Spain; Gary Ford, Newcastle, UK; Veronika Skvortsova, Moscow, Russia

Acute treatment and treatment of complications

Co-chairs: Angel Chamorro, Barcelona, Spain; Bo Norrving, Lund, Sweden

Members: Valerica Caso, Perugia, Italy; Jean-Louis Mas, Paris, France; Victor Obach, Barcelona, Spain; Peter A. Ringleb, Heidelberg, Germany; Lars Thomasen, Bergen, Norway

Rehabilitation

Co-chairs: Kennedy Lees, Glasgow, UK; Danilo Toni, Rome, Italy

Members: Stefano Paolucci, Rome, Italy; Juhani Sivenius, Kuopio, Finland; Katharina Stibrant Sunnerhagen, Göteborg, Sweden; Marion F. Walker, Nottingham, UK

Substantial assistance received from: Yvonne Teuschl, Isabel Henriques, Terence Quinn

We want to thank Dr Michael Shaw for his assistance during the preparation of this manuscript.

Glossary

ADC	apparent diffusion coefficient
ADL	activities of daily living
AF	atrial fibrillation
AR	absolute risk
BP	blood pressure
CAS	carotid artery stenting
CEA	carotid endarterectomy
CE-MRA	contrast-enhanced MR angiography
CI	confidence interval
CSF	cerebral spinal fluid
CT	computed tomography
CTA	computed tomography angiography
CV	cardiovascular
DSA	digital subtraction angiograph
DVT	deep vein thrombosis
DWI	diffusion-weighted imaging
ECG	electrocardiography
ED	emergency department
EEG	electroencephalography

EFNS	European Federation of Neurological Societies
EMS	emergency medical service
ESO	European Stroke Organisation
EUSI	European Stroke Initiative
FLAIR	fluid attenuated inversion recovery
GCP	good clinical practice
HR	hazard ratio
ICA	internal carotid artery
ICP	intracranial pressure
INR	international normalized ratio
i.v.	intravenous
LDL	low density lipoprotein
MCA	middle cerebral artery
MI	myocardial infarction
MRA	magnetic resonance angiography
MRI	magnetic resonance imaging
mRS	modified Rankin score
NASCET	North American Symptomatic Carotid Endarterectomy Trial
NG	nasogastric
NIHSS	National Institutes of Health Stroke Scale
NINDS	National Institute of Neurological Disorders and Stroke
NNH	numbers needed to harm
NNT	numbers needed to treat
OSA	obstructive sleep apnoea
OR	odds ratio
OT	occupational therapy
PE	pulmonary embolism
PEG	percutaneous enteral gastrostomy
PFO	patent foramen ovale
pUK	pro-urokinase
QTc	heart rate corrected QT interval
RCT	randomized clinical trial
RR	relative risk
rtPA	recombinant tissue plasminogen activator
SLT	speech and language therapy
SSRI	selective serotonin reuptake inhibitor
TCD	transcranial Doppler
TOE	transoesophageal echocardiography
TIA	transient ischaemic attack
TTE	transthoracic echocardiography
UFH	unfractionated heparin

Conflicts of interest

P. Bath: Research support from Boehringer-Ingelheim; speakers honoraria from AZ, Boehringer-Ingelheim; consultancy/advisory board AZ, BI, Lundbeck, ReNeurone, Servier.

M. G. Bousser: Research grants and support from SANOFI Servier; research support from Novo-Nordisk, Paion; consultancy/advisory board Servier, Sanofi.

M. Brainin: Research grant from Ebewe, Novo Nordisk; research support from Boehringer-Ingelheim, Sanofi-Aventis, Solvaypharma; speakers' honoraria, Novartis, Boehringer-Ingelheim, Sanofi-Aventis, Ebewe, Solvaypharma; consultancy/advisory board, Boehringer-Ingelheim, Ebewe.

A. Chamorro: Speaker's honoraria from BMS, Sanofi, Boehringer; consultancy/advisory board Servier, Sanofi.

L. Csiba: Research grant from UCB EGIS Zrt, Gedeon Richter, Aventis; speakers' honoraria from Boehringer-Ingelheim, PAION, Lundbeck A/S, Pfizer, EGIS Zrt, Sanofi-Aventis, Novo-Nordisk A/S, Astra-Zeneca, Johnson & Johnson, Gedeon Richter, MSD, UCB, Convex; consultancy/advisory board, Pfizer Hungary, Johnson & Johnson, Paion, Gedeon Richter, Boehringer-Ingelheim.

A. Davalos: Speakers' honoraria from Ferrer, PAION, Lundbeck, Pfizer, Astra-Zeneca, BMS, Thrombogenics, Boehringer-Ingelheim; consultancy/advisory board, Ferrer, PAION, Lundbeck, Pfizer, Astra-Zeneca, BMS, Thrombogenics, Boehringer-Ingelheim.

H. C. Diener: Research grant from AstraZeneca, GSK, Boehringer-Ingelheim, Novartis, Janssen-Cilag, Sanofi-Aventis; research support from German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, Bertelsmann Foundation, Heinz-Nixdorf Foundation; speakers' honoraria from Abbott, AstraZeneca, Bayer Vital, Boehringer-Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Servier, Solvay, Wyeth, Yamaguchi; consultancy/advisory board, Abbott, AstraZeneca, Bayer Vital, Boehringer-Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Servier, Solvay, Wyeth, Yamaguchi.

J. M. Ferro: Research grant from Tecnifar, Boehringer-Ingelheim; research support from Bayer, Sanofi-Aventis; speaker's honoraria from Tecnifar, Ferrer; consultancy/advisory board, Sanofi-Aventis, Uriach, Servier, Ferrer.

G. Ford: Research grant from Boehringer-Ingelheim, Servier, NTI, Lundbeck, Paion; speakers' honoraria from Boehringer-Ingelheim, AstraZeneca; consultancy/advisory board, Boehringer-Ingelheim.

W. Hacke: Research grant from DFG, BMBF; speakers' honoraria from Sanofi Aventis, Novo-Nordisk, Ferrer, Boehringer-Ingelheim; consultancy/advisory board, Sanofi Aventis, BMS, Novo-Nordisk, Boehringer-Ingelheim, Nuvelo, Novothera, Bayer, J&J, Brainsgate, Paion, Ferrer, Lilly, Centocor, ImarX.

M. G. Hennerici: Research grants from DFG, BMBF, EU specific foundations; research support from RCTs grants; speaker's honoraria, several studies from Pfizer, Boehringer, Sanofi, Bayer, Knoll, Janssen, etc; consultancy/advisory board, SPARCL, ESTAT, ECASSII, etc.

M. Kaste: Speakers' honoraria from Boehringer-Ingelheim, Sanofi-Aventis, Pfizer, Ferro; consultancy/advisory board, Bayer, BMS, Boehringer-Ingelheim, Mitsubishi, PAION, Brainsgate, Ferrer, Neurobiological Technologies, Lundbeck A/S, Orion Oy, Pfizer, Astellas, Glaxo-Wellcome, Servier, Encorium, Forest Laboratories, Concentric Medical, Sanofi-Aventis, Novo-Nordisk A/S, Astra-Zeneca, Centocor, Johnson & Johnson.

P. Langhorne: Speakers' honoraria, Previous Boehringer, Pfizer, Sanofi.

K. Lees: Research grant from MRC, Stroke Association, Lundbeck, AstraZeneca, Boehringer-Ingelheim, Servier, NTI, Brainsgate; speakers' honoraria, AstraZeneca, BMS, NTI, Sanofi, Paion, Forest, Lundbeck, Boehringer-Ingelheim, GlaxoSmithKline, Mitsubishi, Bayer, Ferrer, Novonordisk, DPharm, Brainsgate, Thrombogenics, Servier; ownership interest, NTI; consultancy/advisory board, see honoraria.

D. Leys: Research grants from BMS, Astra Zeneca, Boehringer-Ingelheim, NovoNordisk, Servier; consultancy/advisory board, Paion.

J. Lodder: Research support and speakers' honoraria from Boehringer-Ingelheim; consultancy/advisory board, Boehringer-Ingelheim.

H. Markus: Speakers' honoraria from Sanofi; consultancy/advisory board, Sanofi, GE, Boehringer.

J. L. Mas: Research grant from Sanofi, BMS; speakers' honoraria, Sanofi, BMS, Servier, Boehringer, Johnson & Johnson; consultancy/advisory board, Sanofi, BMS, Servier.

H. Mattle: Research grant from AGA Medical, Bayer-Schering; research support from Biogen-Idec, Merck-

Serono, Sanofi-Aventis; speakers' honoraria, Servier, Pfizer, Sanofi-Aventis, Bristol Myers Squibb, Boehringer-Ingelheim; ownership interest, Novartis, Roche; consultancy/advisory board, Pfizer, Merck Sharp & Dohme.

K. W. Muir: Research grants from Shire Pharmaceuticals, BMS, Sanofi; speakers' honoraria from Novo Nordisk, Sanofi; consultancy advisory board, GSK, Paion, Lilly, Novo Nordisk, ThromboGenics.

B. Norrving: Speakers' honoraria from MSD, SHIRE; consultancy/advisory board, Boehringer, Pfizer, Servier.

S. S. Paolucci: Speakers' honoraria from Boehringer-Ingelheim, Eli Lilly.

B. Ringelstein: Research grants from Novartis, NTI (Ancrod) and INC Research; speakers' honoraria, Boehringer-Ingelheim, Sanofi-Aventis, Altana, UCB, BMS; consultancy/advisory board, INC Research, AstraZeneca, Bayer-Schering Health Care.

P. A. Ringleb: Speakers' honoraria from Paion, Sanofi, Boehringer; consultancy/advisory board, Paion.

P. D. Schellinger: Speaker's honoraria from Boehringer-Ingelheim, Paion, Sanofi-Aventis, Ferrer, ImarX, Solvay, Altana; consultancy/advisory board, Boehringer-Ingelheim, Ferrer, ImarX.

J. Sivenius: Speakers' honoraria from Boehringer-Ingelheim, Pfizer; consultancy/advisory board, Boehringer-Ingelheim, Pfizer.

V. Skvortsova: Speakers' honoraria from Boehringer-Ingelheim, Ebewe, Sanofi Aventis; consultancy/advisory board, Boehringer-Ingelheim.

L. Thomassen: Restricted research funding from Boehringer-Ingelheim; Speakers' honoraria, Pfizer, Boehringer-Ingelheim, Sanofi, Astra Zeneca, MSD, etc.; consultancy/advisory board, Sanofi, Boehringer, Gore reduce trial.

D. Toni: Research grants from Boehringer-Ingelheim, SHIRE; speaker's honoraria from Boehringer-Ingelheim, Novo Nordisk, Sanofi-Aventis, Astra-Zeneca; consultancy/advisory board, Boehringer-Ingelheim.

R. von Kummer: Speakers' honoraria from Boehringer-Ingelheim, Bayer Schering; consultancy/advisory board, Boehringer-Ingelheim, Paion, Bayer Schering, Novo Nordisk, Nuvelo, Astellas.

N. Wahlgren: Research grant from Boehringer-Ingelheim; research support from Boehringer-Ingelheim, Bayer, AstraZeneca, Sanofi-Aventis, Novo-Nordisk, Thrombogenics, Servier; speakers' honoraria, Boehringer-Ingelheim, Bayer, Astra-Zeneca, Sanofi-Aventis, Novo-

Nordisk; consultancy/advisory board, Boehringer-Ingelheim, Bayer, AstraZeneca, Sanofi-Aventis, Novo-Nordisk.

These statements were valid at the time of the publication of this guideline in the journal *Cerebrovascular Diseases* in 2008.

References

Important references for special topics are marked with asterisks.

1. European Stroke Initiative. European Stroke Initiative recommendations for stroke management. European Stroke Council, European Neurological Society and European Federation of Neurological Societies. *Cerebrovasc Dis* 2000;**10**:335–51.
2. The European Stroke Initiative Executive Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management – update 2003. *Cerebrovasc Dis* 2003;**16**:311–37.
3. Steiner T, Kaste M, Forsting M, *et al.* Recommendations for the management of intracranial haemorrhage – part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. *Cerebrovasc Dis* 2006;**22**:294–316.
4. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet* 2006;**367**:1747–57.
5. Brainin M, Bornstein N, Boysen G, Demarin V. Acute neurological stroke care in Europe: results of the European Stroke Care Inventory. *Eur J Neurol* 2000;**7**:5–10.
6. Rothwell PM, Coull AJ, Silver LE, *et al.* Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet* 2005;**366**:1773–83.
7. O'Brien JT, Erkinjuntti T, Reisberg B, *et al.* Vascular cognitive impairment. *Lancet Neurol* 2003;**2**:89–98.
8. *Adams HP Jr, del Zoppo G, Alberts MJ, *et al.* Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. *Stroke* 2007;**38**:1655–711.

9. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. *Stroke* 1999;**30**:2502–11.
10. Albers MJ, Hademenos G, Latchaw RE, *et al.* Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. *JAMA* 2000;**283**:3102–9.
11. Albers MJ, Latchaw RE, Selman WR, *et al.* Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. *Stroke* 2005;**36**:1597–616.
12. Biller J, Feinberg WM, Castaldo JE, *et al.* Guidelines for carotid endarterectomy: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1998;**29**:554–62.
13. Diener HC, Allenberg JR, Bode C, *et al.* Primär- und Sekundärprävention der zerebralen Ischämie. In: Diener HC (ed.) *Leitlinien Für Diagnostik Und Therapie in Der Neurologie*. Stuttgart, New York: Thieme, 2005.
14. Fuster V, Ryden LE, Asinger RW, *et al.* ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. *Circulation* 2001;**104**:2118–50.
15. Goldstein LB, Adams R, Albers MJ, *et al.* Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. *Stroke* 2006;**37**:1583–633.
16. Hacke W, Kaste M, Skyhoj Olsen T, Orgogozo JM, Bogousslavsky J. European Stroke Initiative (EUSI) recommendations for stroke management. The European Stroke Initiative Writing Committee. *Eur J Neurol* 2000;**7**:607–23.
17. Sacco RL, Adams R, Albers G, *et al.* Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Stroke* 2006;**37**:577–617.
18. The National Board of Health and Welfare. Swedish National Guidelines for the Management of Stroke, Version for Health and Medical Personnel 2000. Available at: www.sosse/sosmenyeh.htm 2000:Article number: 2002-2102-2001.
19. Kjellstrom T, Norrving B, Shatchkute A. Helsingborg Declaration 2006 on European stroke strategies. *Cerebrovasc Dis* 2007;**23**:231–41.
20. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. *Age Ageing* 2004;**33**:116–21.
21. Evenson KR, Rosamond WD, Morris DL. Prehospital and in-hospital delays in acute stroke care. *Neuroepidemiology* 2001;**20**:65–76.
22. Ferro J, Melo T, Oliveira V, Crespo M, Canhão P, Pinto A. An analysis of the admission delay of acute stroke. *Cerebrovasc Dis* 1994;**4**:72–5.
23. Moser DK, Kimble LP, Albers MJ, *et al.* Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. *Circulation* 2006;**114**:168–82.
24. Gil Nunez AC, Vivancos Mora J. Organization of medical care in acute stroke: importance of a good network. *Cerebrovasc Dis* 2004;**17**(Suppl. 1):113–23.
25. Keskin O, Kalemoglu M, Ulusoy RE. A clinic investigation into prehospital and emergency department delays in acute stroke care. *Med Princ Pract* 2005;**14**:408–12.
26. Chang K, Tseng M, Tan T. Prehospital delay after acute stroke in Kaohsiung, Taiwan. *Stroke* 2004;**35**:700–4.
27. Yu RF, San Jose MC, Manzanilla BM, Oris MY, Gan R. Sources and reasons for delays in the care of acute stroke patients. *J Neurol Sci* 2002;**199**:49–54.
28. Mosley I, Nicol M, Donnan G, Patrick I, Kerr F, Dewey H. The impact of ambulance practice on acute stroke care. *Stroke* 2007;**38**:2765–70.
29. Wein TH, Staub L, Felberg R, *et al.* Activation of emergency medical services for acute stroke in a nonurban population: the T.L.L. Temple Foundation Stroke Project. *Stroke* 2000;**31**:1925–8.
30. Rosamond WD, Evenson KR, Schroeder EB, Morris DL, Johnson AM, Brice JH. Calling emergency medical services for acute stroke: a study of 9-1-1 tapes. *Prehosp Emerg Care* 2005;**9**:19–23.
31. Mandelzweig L, Goldbourt U, Boyko V, Tanne D. Perceptual, social, and behavioral factors associated with delays

- in seeking medical care in patients with symptoms of acute stroke. *Stroke* 2006;**37**:1248–53.
32. Montaner J, Vidal C, Molina C, Alvarez-Sabin J. Selecting the target and the message for a stroke public education campaign: a local survey conducted by neurologists. *Eur J Epidemiol* 2001;**17**:581–6.
 33. Porteous GH, Corry MD, Smith WS. Emergency medical services dispatcher identification of stroke and transient ischemic attack. *Prehosp Emerg Care* 1999;**3**:211–6.
 34. DeLemos CD, Atkinson RP, Croopnick SL, Wentworth DA, Akins PT. How effective are 'community' stroke screening programs at improving stroke knowledge and prevention practices? Results of a 3-month follow-up study. *Stroke* 2003;**34**:e247–9.
 35. Agyeman O, Nedeltchev K, Arnold M, *et al.* Time to admission in acute ischemic stroke and transient ischemic attack. *Stroke* 2006;**37**:963–6.
 36. Harraf F, Sharma AK, Brown MM, Lees KR, Vass RL, Kalra L. A multicentre observational study of presentation and early assessment of acute stroke. *BMJ* 2002;**325**:17–21.
 37. Schneider AT, Pancioli AM, Khoury JC, *et al.* Trends in community knowledge of the warning signs and risk factors for stroke. *JAMA* 2003;**289**:343–6.
 38. Nedeltchev K, Fischer U, Arnold M, Kappeler L, Mattle HP. Low awareness of transient ischemic attacks and risk factors of stroke in a Swiss urban community. *J Neurol* 2007;**254**:179–84.
 39. Müller-Nordhorn J, Nolte C, Rossnagel K, *et al.* Knowledge about risk factors for stroke. A population-base survey with 28 090 participants. *Stroke* 2006;**37**:946–50.
 40. Parahoo K, Thompson K, Cooper M, Stringer M, Ennis E, McCollam P. Stroke: awareness of the signs, symptoms and risk factors – a population-based survey. *Cerebrovasc Dis* 2003;**16**:134–40.
 41. Evci ED, Memis S, Ergin F, Beser E. A population-based study on awareness of stroke in Turkey. *Eur J Neurol* 2007;**14**:517–22.
 42. Sug Yoon S, Heller RF, Levi C, Wiggers J, Fitzgerald PE. Knowledge of stroke risk factors, warning symptoms, and treatment among an Australian urban population. *Stroke* 2001;**32**:1926–30.
 43. Pandian JD, Jaison A, Deepak SS, *et al.* Public awareness of warning symptoms, risk factors, and treatment of stroke in northwest India. *Stroke* 2005;**36**:644–8.
 44. DuBard CA, Garrett J, Gizlice Z. Effect of language on heart attack and stroke awareness among US Hispanics. *Am J Prev Med* 2006;**30**:189–96.
 45. Luiz T, Moosmann A, Koch C, Behrens S, Daffertshofer M, Ellinger K. [Optimized logistics in the prehospital management of acute stroke]. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2001;**36**:735–41.
 46. Schmidt NK, Huwel J, Weisner B. Causes of a prolonged prehospital phase in patients admitted to a stroke unit. Can it be influenced by campaigns to educate the public? *Nervenarzt* 2005;**76**:181–5.
 47. Alberts MJ, Perry A, Dawson DV, Bertels C. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. *Stroke* 1992;**23**:352–6.
 48. Barsan W, Brott T, Broderick J, Haley ECJ, Levy D, Marler J. Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients. *Stroke* 1994;**25**:2132–7.
 49. Hodgson C, Lindsay P, Rubini F. Can mass media influence emergency department visits for stroke? *Stroke* 2007;**38**:2115–22.
 50. Morgenstern L, Staub L, Chan W, *et al.* Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. *Stroke* 2002;**33**:160–6.
 51. Morgenstern L, Bartholomew L, Grotta J, Staub L, King M, Chan W. Sustained benefit of a community and professional intervention to increase acute stroke therapy. *Arch Intern Med* 2003;**163**:2198–202.
 52. Wojner-Alexandrov AW, Alexandrov AV, Rodriguez D, Persse D, Grotta JC. Houston paramedic and emergency stroke treatment and outcomes study (HoPSTO). *Stroke* 2005;**36**:1512–8.
 53. Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. *QJM* 2004;**97**:273–9.
 54. Behrens S, Daffertshofer M, Interthal C, Ellinger K, van Ackern K, Hennerici M. Improvement in stroke quality management by an educational programme. *Cerebrovasc Dis* 2002;**13**:262–6.
 55. Billings-Gagliardi S, Fontneau NM, Wolf MK, Barrett SV, Hademenos G, Mazor KM. Educating the next generation of physicians about stroke: incorporating stroke prevention into the medical school curriculum. *Stroke* 2001;**32**:2854–9.
 56. Wang MY, Lavine SD, Soukiasian H, Tabrizi R, Levy ML, Giannotta SL. Treating stroke as a medical emergency: a survey of resident physicians' attitudes toward 'brain attack' and carotid endarterectomy. *Neurosurgery* 2001;**48**:1109–15, discussion 1115–1107.
 57. Derex L, Adeleine P, Nighoghossian N, Honnorat J, Trouillas P. Factors influencing early admission in a French stroke unit. *Stroke* 2002;**33**:153–9.
 58. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. *Neurology* 2001;**56**:1015–20.
 59. Camerlingo M, Casto L, Censori B, *et al.* Experience with a questionnaire administered by emergency medical

- service for pre-hospital identification of patients with acute stroke. *Neurol Sci* 2001;**22**:357–61.
60. Nor AM, McAllister C, Louw SJ, *et al*. Agreement between ambulance paramedic- and physician-recorded neurological signs with Face Arm Speech Test (FAST) in acute stroke patients. *Stroke* 2004;**35**:1355–9.
 61. *Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. *Cochrane Database Syst Rev* 2007;(4):CD000197.
 62. Stroke Unit Trialists' Collaboration. A systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. *BMJ* 1997;**314**:1151–9.
 63. Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marler JR. Time of hospital presentation in patients with acute stroke. *Arch Intern Med* 1993;**153**:2558–61.
 64. Harbison J, Massey A, Barnett L, Hodge D, Ford GA. Rapid ambulance protocol for acute stroke. *Lancet* 1999;**353**:1935.
 65. Sobesky J, Frackowiak M, Zaro Weber O, *et al*. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. *Cerebrovasc Dis* 2007;**24**:56–65.
 66. Thomas SH, Kociszewski C, Schwamm LH, Wedel SK. The evolving role of helicopter emergency medical services in the transfer of stroke patients to specialized centers. *Prehosp Emerg Care* 2002;**6**:210–4.
 67. Svenson JE, O'Connor JE, Lindsay MB. Is air transport faster? A comparison of air versus ground transport times for interfacility transfers in a regional referral system. *Air Med J* 2006;**25**:170–2.
 68. Silliman SL, Quinn B, Huggett V, Merino JG. Use of a field-to-stroke center helicopter transport program to extend thrombolytic therapy to rural residents. *Stroke* 2003;**34**:729–33.
 69. Diaz M, Hendey G, Winters R. How far is by air? The derivation of an air: ground coefficient. *J Emerg Med* 2003;**24**:199–202.
 70. Diaz M, Hendey G, Bivins H. When is helicopter faster? A comparison of helicopter and ground ambulance transport times. *J Trauma* 2005;**58**:148–53.
 71. Silbergleit R, Scott PA, Lowell MJ. Cost-effectiveness of helicopter transport of stroke patients for thrombolysis. *Acad Emerg Med* 2003;**10**:966–72.
 72. Shafqat S, Kvedar JC, Guanci MM, Chang Y, Schwamm LH. Role for telemedicine in acute stroke. Feasibility and reliability of remote administration of the NIH stroke scale. *Stroke* 1999;**30**:2141–5.
 73. Wiborg A, Widder B. Telemedicine to improve stroke care in rural areas: the Telemedicine in Stroke in Swabia (TESS) Project. *Stroke* 2003;**34**:2951–6.
 74. Handschu R, Littmann R, Reulbach U, *et al*. Telemedicine in emergency evaluation of acute stroke: interrater agreement in remote video examination with a novel multimedia system. *Stroke* 2003;**34**:2842–6.
 75. Wang S, Lee SB, Pardue C, *et al*. Remote evaluation of acute ischemic stroke: reliability of National Institutes of Health Stroke Scale via telestroke. *Stroke* 2003;**34**:188–91.
 76. Audebert HJ, Kukla C, Clarmann von Clarana S, *et al*. Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedical Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. *Stroke* 2005;**36**:287–91.
 77. Audebert HJ, Kukla C, Vatankhah B, *et al*. Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany. *Stroke* 2006;**37**:1822–7.
 78. Hess DC, Wang S, Hamilton W, *et al*. REACH: clinical feasibility of a rural telestroke network. *Stroke* 2005;**36**:2018–20.
 79. Schwab S, Vatankhah B, Kukla C, *et al*. Long-term outcome after thrombolysis in telemedical stroke care. *Neurology* 2007;**69**:898–903.
 80. Audebert HJ, Schenkel J, Heuschmann PU, Bogdahn U, Haberl RL. Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. *Lancet Neurol* 2006;**5**:742–8.
 81. Schwamm LH, Rosenthal ES, Hirshberg A, *et al*. Virtual TeleStroke support for the emergency department evaluation of acute stroke. *Acad Emerg Med* 2004;**11**:1193–7.
 82. Bélvis R, Cocho D, Martí-Fàbregas J, *et al*. Benefits of a prehospital stroke code system. Feasibility and efficacy in the first year of clinical practice in Barcelona//Spain. *Cerebrovasc Dis* 2005;**19**:96–101.
 83. de la Ossa NP, Sanchez-Ojanguren J, Palomeras E, *et al*. Influence of the stroke code activation source on the outcome of acute ischemic stroke patients. *Neurology* 2008;**70**:1238–43.
 84. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol* 2007;**6**:1063–72.
 85. Lavalley PC, Meseguer E, Abboud H, *et al*. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. *Lancet Neurol* 2007;**6**:953–60.
 86. *Rothwell PM, Giles MF, Chandratheva A, *et al*. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. *Lancet* 2007;**370**:1432–42.
 87. Kwan J, Sandercock P. In-hospital care pathways for stroke: a Cochrane systematic review. *Stroke* 2003;**34**:587–8.
 88. Suzuki M, Imai A, Honda M, Kobayashi K, Ohtsuka S. Role of a critical pathway for door-to-CT-completion

- interval in the management of acute ischemic stroke patients in the emergency room. *Keio J Med* 2004;**53**:247–50.
89. Mehdiratta M, Woolfenden AR, Chapman KM, *et al*. Reduction in IV t-PA door to needle times using an Acute Stroke Triage Pathway. *Can J Neurol Sci* 2006;**33**:214–6.
 90. NINDS rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. *Stroke* 1997;**28**:1530–40.
 91. Acker JE 3rd, Pancioli AM, Crocco TJ, *et al*. Implementation strategies for emergency medical services within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council. *Stroke* 2007;**38**:3097–115.
 92. Douglas VC, Tong DC, Gillum LA, *et al*. Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke? *Neurology* 2005;**64**:422–7.
 93. Alvarez Sabin J, Molina C, Abilleira S, Montaner J, García F, Alijotas J. 'Stroke code'. Shortening the delay in reperfusion treatment of acute ischemic stroke. *Med Clin (Barc)* 1999;**113**:481–3.
 94. Lindsberg PJ, Happola O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. *Neurology* 2006;**67**:334–6.
 95. Hamidon BB, Dewey HM. Impact of acute stroke team emergency calls on in-hospital delays in acute stroke care. *J Clin Neurosci* 2007;**14**:831–4.
 96. Goldstein LB, Simel DL. Is this patient having a stroke? *JAMA* 2005;**293**:2391–402.
 97. Harbison J, Hossain O, Jenkinson D, Davis J, Louw SJ, Ford GA. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians and ambulance staff using the face arm speech test. *Stroke* 2003;**34**:71–6.
 98. Hand PJ, Kwan J, Lindley RI, Dennis MS, Wardlaw JM. Distinguishing between stroke and mimic at the bedside: the brain attack study. *Stroke* 2006;**37**:769–75.
 99. Nor AM, Davis J, Sen B, *et al*. The Recognition of Stroke in the Emergency Room (ROSIER) scale: development and validation of a stroke recognition instrument. *Lancet Neurol* 2005;**4**:727–34.
 100. Mitchell JB, Ballard DJ, Whisnant JP, Ammering CJ, Samsa GP, Matchar DB. What role do neurologists play in determining the costs and outcomes of stroke patients? *Stroke* 1996;**27**:1937–43.
 101. Goldstein LB, Matchar DB, Hoff-Lindquist J, Samsa GP, Horner RD. VA Stroke Study: neurologist care is associated with increased testing but improved outcomes. *Neurology* 2003;**61**:792–6.
 102. Tilley B, Lyden P, Brott T, Lu M, Levine S, Welch K. Total Quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *Arch Neurol* 2007;**64**:1466–74.
 103. Lyden P, Brott T, Tilley B, *et al*. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. *Stroke* 1994;**25**:2220–6.
 104. Trapl M, Enderle P, Nowotny M, *et al*. Dysphagia bedside screening for acute-stroke patients: the Gugging Swallowing Screen. *Stroke* 2007;**38**:2948–52.
 105. Leys D, Ringelstein EB, Kaste M, Hacke W. The main components of stroke unit care: results of a European expert survey. *Cerebrovasc Dis* 2007;**23**:344–52.
 106. LaMonte MP, Bahouth MN, Hu P, *et al*. Telemedicine for acute stroke: triumphs and pitfalls. *Stroke* 2003;**34**:725–8.
 107. Wu O, Langhorne P. The challenge of acute-stroke management: does telemedicine offer a solution? *Int J Stroke* 2006;**1**:201–7.
 108. Ronning OM, Guldvog B, Stavem K. The benefit of an acute stroke unit in patients with intracranial haemorrhage: a controlled trial. *J Neurol Neurosurg Psychiatry* 2001;**70**:631–4.
 109. Seenan P, Long M, Langhorne P. Stroke units in their natural habitat: systematic review of observational studies. *Stroke* 2007;**38**:1886–92.
 110. Candelise L, Gattinoni M, Bersano A, Micieli G, Sterzi R, Morabito A. Stroke-unit care for acute stroke patients: an observational follow-up study. *Lancet* 2007;**369**:299–305.
 111. Walsh T, Cotter S, Boland M, Grealley T, O'Riordan R, Lyons D. Stroke unit care is superior to general rehabilitation unit care. *Ir Med J* 2006;**99**:300–2.
 112. Launois R, Giroud M, Megnigbeto AC, *et al*. Estimating the cost-effectiveness of stroke units in France compared with conventional care. *Stroke* 2004;**35**:770–5.
 113. Epifanov Y, Dodel R, Haacke C, *et al*. Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting. *Health Policy* 2007;**81**:339–49.
 114. Patel A, Knapp M, Perez I, Evans A, Kalra L. Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. *Stroke* 2004;**35**:196–203.
 115. *Brady BK, McGahan L, Skidmore B. Systematic review of economic evidence on stroke rehabilitation services. *Int J Technol Assess Health Care* 2005;**21**:15–21.
 116. Moodie M, Cadilhac D, Pearce D, *et al*. Economic evaluation of Australian stroke services: a prospective, multi-

- center study comparing dedicated stroke units with other care modalities. *Stroke* 2006;**37**:2790–5.
117. Dewey HM, Sherry LJ, Collier JM. Stroke rehabilitation 2007: what should it be? *Int J Stroke* 2007;**2**:191–200.
 118. Langhorne P, Pollock A. What are the components of effective stroke unit care? *Age Ageing* 2002;**31**:365–71.
 119. Teasell R, Foley N, Bhogal S, Bagg S, Jutai J. Evidence-based practice and setting basic standards for stroke rehabilitation in Canada. *Top Stroke Rehabil* 2006;**13**:59–65.
 120. Langhorne P, Dey P, Woodman M, *et al.* Is stroke unit care portable? A systematic review of the clinical trials. *Age Ageing* 2005;**34**:324–30.
 121. Fryback D, Thornbury J. The efficacy of diagnostic imaging. *Med Decis Making* 1991;**11**:88–94.
 122. Schramm P, Schellinger PD, Klotz E, *et al.* Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration. *Stroke* 2004;**35**:1562–8.
 123. Barber PA, Hill MD, Eliasziw M, *et al.* Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. *J Neurol Neurosurg Psychiatry* 2005;**76**:1528–33.
 124. Hand PJ, Wardlaw JM, Rowat AM, Haisma JA, Lindley RI, Dennis MS. Magnetic resonance brain imaging in patients with acute stroke: feasibility and patient related difficulties. *J Neurol Neurosurg Psychiatry* 2005;**76**:1525–7.
 125. *The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995;**333**:1581–7.
 126. *Wardlaw JM, Keir SL, Dennis MS. The impact of delays in computed tomography of the brain on the accuracy of diagnosis and subsequent management in patients with minor stroke. *J Neurol Neurosurg Psychiatry* 2003;**74**:77–81.
 127. *Kidwell CS, Chalela JA, Saver JL, *et al.* Comparison of MRI and CT for detection of acute intracerebral hemorrhage. *JAMA* 2004;**292**:1823–30.
 128. *Schellinger PD, Fiebich JB. Intracranial hemorrhage: the role of magnetic resonance imaging. *Neurocrit Care* 2004;**1**:31–45.
 129. Wardlaw JM, Keir SL, Seymour J, *et al.* What is the best imaging strategy for acute stroke? *Health Technol Assess* 2004;**8**(iii, ix–x):1–180.
 130. *Chalela JA, Kidwell CS, Nentwich LM, *et al.* Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. *Lancet* 2007;**369**:293–8.
 131. von Kummer R, Bourquain H, Bastianello S, *et al.* Early prediction of irreversible brain damage after ischemic stroke at CT. *Radiology* 2001;**219**:95–100.
 132. von Kummer R, Allen KL, Holle R, *et al.* Acute stroke: usefulness of early CT findings before thrombolytic therapy. *Radiology* 1997;**205**:327–33.
 133. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. *Lancet* 2000;**355**:1670–4.
 134. Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment – systematic review. *Radiology* 2005;**235**:444–53.
 135. Wardlaw JM, West TM, Sandercock PA, Lewis SC, Mielke O. Visible infarction on computed tomography is an independent predictor of poor functional outcome after stroke, and not of haemorrhagic transformation. *J Neurol Neurosurg Psychiatry* 2003;**74**:452–8.
 136. von Kummer R. Effect of training in reading CT scans on patient selection for ECASS II. *Neurology* 1998;**51**:S50–2.
 137. Wardlaw JM, Farrall AJ, Perry D, *et al.* Factors influencing the detection of early CT signs of cerebral ischemia: an internet-based, international multiobserver study. *Stroke* 2007;**38**:1250–6.
 138. von Kummer R, Meyding-Lamade U, Forsting M, *et al.* Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. *AJNR Am J Neuroradiol* 1994;**15**:9–15, discussion 16–18.
 139. Dzialowski I, Weber J, Doerfler A, Forsting M, von Kummer R. Brain tissue water uptake after middle cerebral artery occlusion assessed with CT. *J Neuroimaging* 2004;**14**:42–8.
 140. Dzialowski I, Klotz E, Goericke S, Doerfler A, Forsting M, von Kummer R. Ischemic brain tissue water content: CT monitoring during middle cerebral artery occlusion and reperfusion in rats. *Radiology* 2007;**243**:720–6.
 141. Hill MD, Rowley HA, Adler F, *et al.* Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. *Stroke* 2003;**34**:1925–31.
 142. Patel SC, Levine SR, Tilley BC, *et al.* Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. *JAMA* 2001;**286**:2830–8.
 143. *Dimigen M, Keir S, Dennis M, Wardlaw J. Long-term visibility of primary intracerebral hemorrhage on magnetic resonance imaging. *J Stroke Cerebrovasc Dis* 2004;**13**:104–8.

144. Ay H, Oliveira-Filho J, Buonanno FS, *et al.* 'Footprints' of transient ischemic attacks: a diffusion-weighted MRI study. *Cerebrovasc Dis* 2002;**14**:177–86.
145. Fiehler J, Knudsen K, Kucinski T, *et al.* Predictors of apparent diffusion coefficient normalization in stroke patients. *Stroke* 2004;**35**:514–9.
146. *Oppenheim C, Lamy C, Touze E, *et al.* Do transient ischemic attacks with diffusion-weighted imaging abnormalities correspond to brain infarctions? *AJNR Am J Neuroradiol* 2006;**27**:1782–7.
147. Wardlaw JM, Keir SL, Bastin ME, Armitage PA, Rana AK. Is diffusion imaging appearance an independent predictor of outcome after ischemic stroke? *Neurology* 2002;**59**:1381–7.
148. Hand PJ, Wardlaw JM, Rivers CS, *et al.* MR diffusion-weighted imaging and outcome prediction after ischemic stroke. *Neurology* 2006;**66**:1159–63.
149. Kane I, Carpenter T, Chappell F, *et al.* Comparison of 10 different magnetic resonance perfusion imaging processing methods in acute ischemic stroke: effect on lesion size, proportion of patients with diffusion/perfusion mismatch, clinical scores, and radiologic outcomes. *Stroke* 2007;**38**:3158–64.
150. Wintermark M, Reichhart M, Thiran JP, *et al.* Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. *Ann Neurol* 2002;**51**:417–32.
151. Lev MH, Gonzalez RG, Schaefer PW, Koroshetz WJ, Dillon WP, Wintermark M. Cerebral blood flow thresholds in acute stroke triage. *Stroke* 2006;**37**:1334–9.
152. *Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. *J Neurol Neurosurg Psychiatry* 2007;**78**:485–90.
153. *Furlan A, Higashida R, Wechsler L, *et al.* Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. *JAMA* 1999;**282**:2003–11.
154. Mattle HP, Arnold M, Georgiadis D, *et al.* Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. *Stroke* 2008;**39**:379–83.
155. Rubiera M, Ribo M, Delgado-Mederos R, *et al.* Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. *Stroke* 2006;**37**:2301–5.
156. Fischer U, Arnold M, Nedeltchev K, *et al.* NIHSS score and arteriographic findings in acute ischemic stroke. *Stroke* 2005;**36**:2121–5.
157. Allendoerfer J, Goertler M, von Reutern G. Prognostic relevance of ultra-early doppler sonography in acute ischaemic stroke: a prospective multicentre study. *Lancet Neurol* 2005;**5**:835–40.
158. Coutts SB, Simon JE, Tomanek AI, *et al.* Reliability of assessing percentage of diffusion-perfusion mismatch. *Stroke* 2003;**34**:1681–3.
159. *Albers GW, Thijs VN, Wechsler L, *et al.* Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. *Ann Neurol* 2006;**60**:508–17.
160. *Bandera E, Botteri M, Minelli C, Sutton A, Abrams KR, Latronico N. Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. *Stroke* 2006;**37**:1334–9.
161. Carpenter TK, Armitage PA, Bastin ME, Wardlaw JM. DSC perfusion MRI-Quantification and reduction of systematic errors arising in areas of reduced cerebral blood flow. *Magn Reson Med* 2006;**55**:1342–9.
162. Rivers CS, Wardlaw JM, Armitage PA, *et al.* Do acute diffusion- and perfusion-weighted MRI lesions identify final infarct volume in ischaemic stroke? *Stroke* 2006;**37**:98–104.
163. Dávalos A, Blanco M, Pedraza S, *et al.* The clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarction. *Neurology* 2004;**62**:2187–92.
164. Kent DM, Hill MD, Ruthazer R, *et al.* 'Clinical-CT mismatch' and the response to systemic thrombolytic therapy in acute ischemic stroke. *Stroke* 2005;**36**:1695–9.
165. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. *Brain* 2007;**130**:1988–2003.
166. Fiehler J, Albers GW, Boulanger JM, *et al.* Bleeding risk analysis in stroke imaging before thrombolysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. *Stroke* 2007;**38**:2738–44.
167. Forsting M, Wanke I. Funeral for a friend. *Stroke* 2003;**34**:1324–32.
168. Willinsky RA, Taylor SM, TerBrugge K, Farb RI, Tomlinson G, Montanera W. Neurologic complications of cerebral angiography: prospective analysis of 2,899 procedures and review of the literature. *Radiology* 2003;**227**:522–8.
169. *Wardlaw JM, Chappell FM, Best JJ, Wartolowska K, Berry E. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. *Lancet* 2006;**367**:1503–12.
170. Wardlaw JM, Chappell FM, Stevenson M, *et al.* Accurate, practical and cost-effective assessment of carotid stenosis in the UK. *Health Technol Assess* 2006;**10**(iii–iv, ix–x):1–182.

171. Flossmann E, Rothwell PM. Prognosis of vertebrobasilar transient ischaemic attack and minor stroke. *Brain* 2003;**126**:1940–54.
172. Khan S, Cloud GC, Kerry S, Markus HS. Imaging of vertebral artery stenosis: a systematic review. *J Neurol Neurosurg Psychiatry* 2007;**78**:1218–25.
173. Postert T, Federlein J, Przutek H, Buttner T. Insufficient and absent acoustic temporal bone window: potential and limitations of transcranial contrast-enhanced color-coded sonography and contrast-enhanced power-based sonography. *Ultrasound Med Biol* 1997;**23**:857–62.
174. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. *Circulation* 2001;**103**:2897–902.
175. Droste DW, Jurgens R, Nabavi DG, Schuierer G, Weber S, Ringelstein EB. Echocontrast-enhanced ultrasound of extracranial internal carotid artery high-grade stenosis and occlusion. *Stroke* 1999;**30**:2302–6.
176. Droste DW, Jurgens R, Weber S, Tietje R, Ringelstein EB. Benefit of echocontrast-enhanced transcranial color-coded duplex ultrasound in the assessment of intracranial collateral pathways. *Stroke* 2000;**31**:920–3.
177. Droste DW, Nabavi DG, Kemeny V, *et al.* Echocontrast enhanced transcranial colour-coded duplex offers improved visualization of the vertebrobasilar system. *Acta Neurol Scand* 1998;**98**:193–9.
178. Ringelstein E, van Eyck S, Mertens I. Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli: comparison of CO₂ to acetazolamide. *Cereb Blood Flow Metab* 1992;**12**:162–8.
179. *Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. *Stroke* 2003;**34**:1324–32.
180. Markus H, Cullinane M. Severely impaired cerebrovascular reactivity predicts stroke and TIA risk in patients with carotid artery stenosis and occlusion. *Brain* 2001;**124**:457–67.
181. Blaser T, Hofmann K, Buerger T, Effenberger O, Wallesch CW, Goertler M. Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe carotid stenosis. *Stroke* 2002;**33**:1057–62.
182. Ringelstein EB, Droste DW, Babikian VL, *et al.* Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection. *Stroke* 1998;**29**:725–9.
183. Markus HS, MacKinnon A. Asymptomatic embolization detected by Doppler ultrasound predicts stroke risk in symptomatic carotid artery stenosis. *Stroke* 2005;**36**:971–5.
184. Markus HS, Droste DW, Kaps M, *et al.* Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. *Circulation* 2005;**111**:2233–40.
185. Klötzsch C, Janssen G, Berlit P. Transesophageal echocardiography and contrast-TCD in the detection of a patent foramen ovale: experiences with 111 patients. *Neurology* 1994;**44**:1603–6.
186. Rothwell P, Buchan A, Johnston S. Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. *Lancet Neurol* 2005;**5**:323–31.
187. Daffertshofer M, Mielke O, Pullwitt A, Felsenstein M, Hennerici M. Transient ischemic attacks are more than ‘ministrokes’. *Stroke* 2004;**35**:2453–8.
188. Crisostomo RA, Garcia MM, Tong DC. Detection of diffusion-weighted MRI abnormalities in patients with transient ischemic attack: correlation with clinical characteristics. *Stroke* 2003;**34**:932–7.
189. Coutts SB, Simon JE, Eliasziw M, *et al.* Triaging transient ischemic attack and minor stroke patients using acute magnetic resonance imaging. *Ann Neurol* 2005;**57**:848–54.
190. Redgrave JN, Coutts SB, Schulz UG, Briley D, Rothwell PM. Systematic review of associations between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical predictors of early stroke risk after transient ischemic attack. *Stroke* 2007;**38**:1482–8.
191. Douglas VC, Johnston CM, Elkins J, Sidney S, Gress DR, Johnston SC. Head computed tomography findings predict short-term stroke risk after transient ischemic attack. *Stroke* 2003;**34**:2894–8.
192. Christensen H, Fogh Christensen A, Boysen GG. Abnormalities on ECG and telemetry predict stroke outcome at 3 months. *J Neurol Sci* 2005;**234**:99–103.
193. Fure B, Bruun Wyller T, Thommessen B. Electrocardiographic and troponin T changes in acute ischaemic stroke. *J Intern Med* 2006;**259**:592–7.
194. Tatschl C, Stollberger C, Matz K, *et al.* Insular involvement is associated with QT prolongation: ECG abnormalities in patients with acute stroke. *Cerebrovasc Dis* 2006;**21**:47–53.
195. Gunalp M, Atalar E, Coskun F, *et al.* Holter monitoring for 24 hours in patients with thromboembolic stroke and sinus rhythm diagnosed in the emergency department. *Adv Ther* 2006;**23**:854–60.
196. Douen AG, Pageau N, Medic S. Serial electrocardiographic assessments significantly improve detection of atrial fibril-

- lation 2.6-fold in patients with acute stroke. *Stroke* 2008;**39**:480–2.
197. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Non-invasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. *Stroke* 2007;**38**:2935–40.
198. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. *Stroke* 2004;**35**:1647–51.
199. Lerakis S, Nicholson WJ. Part I: use of echocardiography in the evaluation of patients with suspected cardioembolic stroke. *Am J Med Sci* 2005;**329**:310–6.
200. Kapral MK, Silver FL. Preventive health care, 1999 update: 2. Echocardiography for the detection of a cardiac source of embolus in patients with stroke. Canadian Task Force on Preventive Health Care. *CMAJ* 1999;**161**:989–96.
201. de Bruijn SF, Agema WR, Lammers GJ, *et al*. Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. *Stroke* 2006;**37**:2531–4.
202. Chiarella F, Santoro E, Domenicucci S, Maggioni A, Vecchio C. Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. *Am J Cardiol* 1998;**81**:822–7.
203. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. *J Am Coll Cardiol* 1998;**31**:1622–6.
204. Kurth T, Moore S, Gaziano J, *et al*. Healthy lifestyle and the risk of stroke in women. *Arch Intern Med* 2006;**166**:1403–9.
205. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002;**360**:1903–13.
206. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet* 2000;**356**:1955–64.
207. Staessen JA, Fagard R, Thijs L, *et al*. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet* 1997;**350**:757–64.
208. Gueyffier F, Bulpitt C, Boissel JP, *et al*. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. *Lancet* 1999;**353**:793–6.
209. *Mancia G, De Backer G, Dominiczak A, *et al*. The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2007;**28**:1462–536.
210. *Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro- and microvascular events. *J Hypertens Suppl* 2007;**25**(Suppl. 1):S7–12.
211. Black HR, Elliott WJ, Grandits G, *et al*. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. *JAMA* 2003;**289**:2073–82.
212. Dahlof B, Devereux RB, Kjeldsen SE, *et al*. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;**359**:995–1003.
213. Kizer JR, Dahlof B, Kjeldsen SE, *et al*. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. *Hypertension* 2005;**45**:46–52.
214. ALLHAT investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002;**288**:2998–3007.
215. Ekblom T, Linjer E, Hedner T, *et al*. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. *Blood Press* 2004;**13**:137–41.
216. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;**281**:2005–12.
217. Colhoun HM, Betteridge DJ, Durrington PN, *et al*. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004;**364**:685–96.

218. Sever PS, Poulter NR, Dahlof B, *et al.* Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). *Diabetes Care* 2005;**28**:1151–7.
219. *Kearney PM, Blackwell L, Collins R, *et al.* Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008;**371**:117–25.
220. *Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. *Stroke* 2004;**35**:2902–9.
221. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;**360**:7–22.
222. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988;**259**:1025–9.
223. Abbott RD, Yin Y, Reed DM, Yano K. Risk of stroke in male cigarette smokers. *N Engl J Med* 1986;**315**:717–20.
224. Colditz GA, Bonita R, Stampfer MJ, *et al.* Cigarette smoking and risk of stroke in middle-aged women. *N Engl J Med* 1988;**318**:937–41.
225. Kawachi I, Colditz GA, Stampfer MJ, *et al.* Smoking cessation and decreased risk of stroke in women. *JAMA* 1993;**269**:232–6.
226. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. *JAMA* 1995;**274**:155–60.
227. Iso H, Date C, Yamamoto A, *et al.* Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. *Am J Epidemiol* 2005;**161**:170–9.
228. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Cigarette smoking among spouses: another risk factor for stroke in women. *Stroke* 2005;**36**:e74–6.
229. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989;**298**:789–94.
230. Ong MK, Glantz SA. Cardiovascular health and economic effects of smoke-free workplaces. *Am J Med* 2004;**117**:32–8.
231. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. *JAMA* 2003;**289**:579–88.
232. Mukamal KJ, Ascherio A, Mittleman MA, *et al.* Alcohol and risk for ischemic stroke in men: the role of drinking patterns and usual beverage. *Ann Intern Med* 2005;**142**:11–9.
233. Bazzano LA, Gu D, Reynolds K, *et al.* Alcohol consumption and risk for stroke among Chinese men. *Ann Neurol* 2007;**62**:569–78.
234. Lee C, Folsom A, Blair S. Physical activity and stroke risk: a meta-analysis. *Stroke* 2003;**34**:2475–81.
235. Deplanque D, Masse I, Lefebvre C, Libersa C, Leys D, Bordet R. Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. *Neurology* 2006;**67**:1403–10.
236. Joshipura KJ, Ascherio A, Manson JE, *et al.* Fruit and vegetable intake in relation to risk of ischemic stroke. *JAMA* 1999;**282**:1233–9.
237. He K, Song Y, Daviuglus M, *et al.* Fish consumption and incidence of stroke: a meta-analysis of cohort studies. *Stroke* 2004;**35**:1538–42.
238. Mellen PB, Walsh TF, Herrington DM. Whole grain intake and cardiovascular disease: a meta-analysis. *Nutr Metab Cardiovasc Dis* 2007;**85**:1495–502.
239. Umesawa M, Iso H, Date C, *et al.* Dietary intake of calcium in relation to mortality from cardiovascular disease: the JACC Study. *Stroke* 2006;**37**:20–6.
240. He K, Merchant A, Rimm EB, *et al.* Dietary fat intake and risk of stroke in male US healthcare professionals: 14-year prospective cohort study. *BMJ* 2003;**327**:777–82.
241. Howard BV, Van Horn L, Hsia J, *et al.* Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 2006;**295**:655–66.
242. Kurth T, Gaziano JM, Berger K, *et al.* Body mass index and the risk of stroke in men. *Arch Intern Med* 2002;**162**:2557–62.
243. Kurth T, Gaziano JM, Rexrode KM, *et al.* Prospective study of body mass index and risk of stroke in apparently healthy women. *Circulation* 2005;**111**:1992–8.
244. Hu G, Tuomilehto J, Silventoinen K, Sarti C, Mannisto S, Jousilahti P. Body mass index, waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. *Arch Intern Med* 2007;**167**:1420–7.
245. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2003;**42**:878–84.
246. Curioni C, Andre C, Veras R. Weight reduction for primary prevention of stroke in adults with overweight or obesity. *Cochrane Database Syst Rev* 2006;(4):CD006062.
247. Marniemi J, Alanen E, Impivaara O, *et al.* Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. *Nutr Metab Cardiovasc Dis* 2005;**15**:188–97.

248. Hsia J, Heiss G, Ren H, *et al.* Calcium/vitamin D supplementation and cardiovascular events. *Circulation* 2007;**115**:846–54.
249. Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Albanes D, Huttunen JK. Postintervention effect of alpha tocopherol and beta carotene on different strokes: a 6-year follow-up of the Alpha Tocopherol, Beta Carotene Cancer Prevention Study. *Stroke* 2004;**35**:1908–13.
250. *Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005;**142**:37–46.
251. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 2002;**288**:2015–22.
252. Yang Q, Botto LD, Erickson JD, *et al.* Improvement in stroke mortality in Canada and the United States, 1990 to 2002. *Circulation* 2006;**113**:1335–43.
253. Wang X, Qin X, Demirtas H, *et al.* Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. *Lancet* 2007;**369**:1876–82.
254. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. *Ann Intern Med* 2001;**135**:1–8.
255. Grady D, Herrington D, Bittner V, *et al.* Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA* 2002;**288**:49–57.
256. *Gabriel S, Carmona L, Roque M, Sanchez G, Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev* 2005;(2):CD002229.
257. Brunner RL, Gass M, Aragaki A, *et al.* Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. *Arch Intern Med* 2005;**165**:1976–86.
258. Rossouw JE, Prentice RL, Manson JE, *et al.* Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007;**297**:1465–77.
259. Peto R, Gray R, Collins R, *et al.* Randomised trial of prophylactic daily aspirin in British male doctors. *Br Med J (Clin Res Ed)* 1988;**296**:313–6.
260. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1989;**321**:129–35.
261. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. *JAMA* 1992;**268**:1292–300.
262. Hansson L, Zanchetti A, Carruthers SG, *et al.* Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet* 1998;**351**:1755–62.
263. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. *Lancet* 2001;**357**:89–95.
264. Iso H, Hennekens CH, Stampfer MJ, *et al.* Prospective study of aspirin use and risk of stroke in women. *Stroke* 1999;**30**:1764–71.
265. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. *Am J Cardiol* 2006;**98**:746–50.
266. *Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. *JAMA* 2006;**295**:306–13.
267. Ridker PM, Cook NR, Lee IM, *et al.* A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005;**352**:1293–304.
268. *Bhatt DL, Fox KA, Hacke W, *et al.* Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* 2006;**354**:1706–17.
269. Hobson RW 2nd, Krupski WC, Weiss DG. Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. *J Vasc Surg* 1993;**17**:257–63, discussion 263–255.
270. Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. *Cochrane Database Syst Rev* 2003;(3):CD001458.
271. *Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med* 2007;**146**:857–67.
272. *Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). *Age Ageing* 2007;**36**:151–6.
273. Mant J, Hobbs FD, Fletcher K, *et al.* Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet* 2007;**370**:493–503.

274. Connolly S, Pogue J, Hart R, *et al.* Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006;**367**:1903–12.
275. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N Engl J Med* 1995;**333**:11–7.
276. *Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. *Cochrane Database Syst Rev* 2005;(4):CD001923.
277. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. *JAMA* 1995;**273**:1421–8.
278. *Halliday A, Mansfield A, Marro J, *et al.* Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet* 2004;**363**:1491–502.
279. *North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med* 1991;**325**:445–53.
280. Baker WH, Howard VJ, Howard G, Toole JF. Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators. *Stroke* 2000;**31**:2330–4.
281. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. *JAMA* 2002;**288**:1388–95.
282. The European Carotid Surgery Trialists Collaborative Group. Risk of stroke in the distribution of an asymptomatic carotid artery. *Lancet* 1995;**345**:209–12.
283. Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group. *Mayo Clin Proc* 1992;**67**:513–8.
284. Derdeyn C. Carotid stenting for asymptomatic carotid stenosis: trial it. *Stroke* 2007;**38**:715–20.
285. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. *Stroke* 2003;**34**:2741–8.
286. Group P. Post-stroke antihypertensive treatment study. A preliminary result. *Chin Med J (Engl)* 1995;**108**:710–7.
287. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;**342**:145–53.
288. Bosch J, Yusuf S, Pogue J, *et al.* Use of ramipril in preventing stroke: double blind randomised trial. *BMJ* 2002;**324**:699–702.
289. PROGRESS collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001;**358**:1033–41.
290. Chobanian AV, Bakris GL, Black HR, *et al.* The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003;**289**:2560–72.
291. Schrader J, Luders S, Kulschewski A, *et al.* Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). *Stroke* 2005;**36**:1218–26.
292. Wilcox R, Bousser MG, Betteridge DJ, *et al.* Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone Clinical Trial In macroVascular Events 04). *Stroke* 2007;**38**:865–73.
293. *Amarenco P, Bogousslavsky J, Callahan A, *et al.* High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;**355**:549–59.
294. *Blanco M, Nombela F, Castellanos M, *et al.* Statin treatment withdrawal in ischemic stroke: a controlled randomized study. *Neurology* 2007;**69**:904–10.
295. Vivekananthan D, Penn M, Sapp S, Hsu A, Topol E. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003;**361**:2017–23.
296. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. *Arch Intern Med* 2004;**164**:1552–6.
297. *Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* 2007;**297**:842–57.
298. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ* 2002;**325**:1202.
299. Toole JF, Malinow MR, Chambless LE, *et al.* Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004;**291**:565–75.
300. Bonna KH, Njolstad I, Ueland PM, *et al.* Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* 2006;**354**:1578–88.

301. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA* 2006;**296**:2720–6.
302. VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. *Cerebrovasc Dis* 2002;**13**:120–6.
303. *Bassetti CL. Sleep and stroke. *Semin Neurol* 2005;**25**:19–32.
304. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. *N Engl J Med* 2007;**357**:2262–8.
305. Overall JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. *Neurology* 2000;**55**:1172–9.
306. Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. *J Am Coll Cardiol* 2007;**49**:797–802.
307. Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. *J Am Coll Cardiol* 2006;**47**:440–5.
308. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. *N Engl J Med* 2001;**345**:1740–6.
309. Wahl A, Krumdordf U, Meier B, et al. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. *J Am Coll Cardiol* 2005;**45**:377–80.
310. Windecker S, Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. *J Am Coll Cardiol* 2004;**44**:750–8.
311. *Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Swissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. *N Engl J Med* 2001;**345**:1243–9.
312. *Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;**324**:71–86.
313. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. *J Neurol Neurosurg Psychiatry* 1996;**60**:197–9.
314. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. *N Engl J Med* 1991;**325**:1261–6.
315. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry* 1991;**54**:1044–54.
316. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. *JAMA* 2007;**297**:2018–24.
317. *Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med* 2005;**352**:1305–16.
318. *CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996;**348**:1329–39.
319. *Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci* 1996;**143**:1–13.
320. *Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. *Cochrane Database Syst Rev* 2005;(3):CD004296.
321. *Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet* 2006;**367**:1665–73.
322. Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. *Cerebrovasc Dis* 2006;**22**:258–62.
323. Diener H, Davidai G. Dipyridamole and headache. *Future Neurology* 2007;**2**:279–83.
324. *Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004;**364**:331–7.
325. Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K, and the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. *N Engl J Med* 2001;**345**:494–502.
326. *Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med* 2001;**345**:1444–51.
327. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. *Ann Neurol* 1997;**42**:857–65.
328. *Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT):

- a randomised controlled trial. *Lancet Neurol* 2007;**6**:115–24.
329. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet* 1993;**342**:1255–62.
330. Visser CA, Kan G, Meltzer RS, Lie KI, Durrer D. Long-term follow-up of left ventricular thrombus after acute myocardial infarction. A two-dimensional echocardiographic study in 96 patients. *Chest* 1984;**86**:532–6.
331. Flaker GC, Gruber M, Connolly SJ, *et al.* Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. *Am Heart J* 2006;**152**:967–73.
332. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. *J Am Coll Cardiol* 1998;**31**:134–8.
333. Echiverri HC, Rubino FA, Gupta SR, Gujrati M. Fusiform aneurysm of the vertebrobasilar arterial system. *Stroke* 1989;**20**:1741–7.
334. Engelter ST, Brandt T, Dobbie S, *et al.* Antiplatelets versus anticoagulation in cervical artery dissection. *Stroke* 2007;**38**:2605–11.
335. *Rothwell PM, Eliasziw M, Gutnikov SA, *et al.* Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. *Lancet* 2003;**361**:107–16.
336. *European Carotid Surgery Trialists' Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European carotid surgery trial. *Lancet* 1996;**347**:1591–3.
337. *Cina C, Clase C, Haynes R. Carotid endarterectomy for symptomatic carotid stenosis. *Cochrane Database Syst Rev* 1999;(3):CD001081.
338. *Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. *Lancet* 2004;**363**:915–24.
339. Bond R, Rerkasem K, AbuRahma AF, Naylor AR, Rothwell PM. Patch angioplasty versus primary closure for carotid endarterectomy. *Cochrane Database Syst Rev* 2004;(3):CD000160.
340. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Sex difference in the effect of time from symptoms to surgery on benefit from carotid endarterectomy for transient ischemic attack and nondisabling stroke. *Stroke* 2004;**35**:2855–61.
341. Inzitari D, Eliasziw M, Sharpe BL, Fox AJ, Barnett HJ. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. *Neurology* 2000;**54**:660–6.
342. Streifler JY, Eliasziw M, Benavente OR, *et al.* Prognostic importance of leukoariosis in patients with symptomatic internal carotid artery stenosis. *Stroke* 2002;**33**:1651–5.
343. *Mas JL, Chatellier G, Beyssen B, *et al.* Ducrocq X, for the EVA-3S Investigators: endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med* 2006;**355**:1660–71.
344. *Ringleb PA, Allenberg JR, Berger J, *et al.* 30-day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. *Lancet* 2006;**368**:1239–47.
345. Yadav JS, Wholey MH, Kuntz RE, *et al.* Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med* 2004;**351**:1493–501.
346. *CAVATAS Group. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. *Lancet* 2001;**357**:1729–37.
347. Kastrup A, Groschel K. Carotid endarterectomy versus carotid stenting: an updated review of randomized trials and subgroup analyses. *Acta Chir Belg* 2007;**107**:119–28.
348. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. *N Engl J Med* 1985;**313**:1191–200.
349. Kasner SE, Chimowitz MI, Lynn MJ, *et al.* Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. *Circulation* 2006;**113**:555–63.
350. Jiang WJ, Xu XT, Du B, *et al.* Long-term outcome of elective stenting for symptomatic intracranial vertebrobasilar stenosis. *Neurology* 2007;**68**:856–8.
351. Jiang WJ, Xu XT, Du B, *et al.* Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis. *Neurology* 2007;**68**:420–6.
352. Marks MP, Wojak JC, Al-Ali F, *et al.* Angioplasty for symptomatic intracranial stenosis: clinical outcome. *Stroke* 2006;**37**:1016–20.
353. Fiorella D, Levy EI, Turk AS, *et al.* US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. *Stroke* 2007;**38**:881–7.
354. *Bose A, Hartmann M, Henkes H, *et al.* A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. *Stroke* 2007;**38**:1531–7.
355. *SSYLVIA Study investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. *Stroke* 2004;**35**:1388–92.

356. Lindstrom E, Boysen G, Christiansen L, Nansen B, Nielsen P. Reliability of Scandinavian neurological stroke scale. *Cerebrovasc Dis* 1991;1:103–7.
357. Sulter G, Elting JW, Langedijk M, Maurits NM, De Keyser J. Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study. *Stroke* 2003;34:101–4.
358. Cavallini A, Micieli G, Marcheselli S, Quaglioni S. Role of monitoring in management of acute ischemic stroke patients. *Stroke* 2003;34:2599–603.
359. Ronning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. *Stroke* 1999;30:2033–7.
360. Bamford J, Dennis M, Sandercock P, Burn J, Warlow C. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project. *J Neurol Neurosurg Psychiatry* 1990;53:824–9.
361. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. *Stroke* 1992;23:1250–6.
362. Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ. Elevated troponin levels are associated with sympathoadrenal activation in acute ischaemic stroke. *Cerebrovasc Dis* 2007;23:260–6.
363. Bhalla A, Sankaralingam S, Dundas R, Swaminathan R, Wolfe CD, Rudd AG. Influence of raised plasma osmolality on clinical outcome after acute stroke. *Stroke* 2000;31:2043–8.
364. Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). *Lancet Neurol* 2007;6:397–406.
365. Asplund K, Marke LA, Terent A, Gustafsson C, Wester P. Costs and gains in stroke prevention: European perspective. *Cerebrovasc Dis* 1993;3(Suppl.):34–42.
366. Castillo J, Leira R, Garcia MM, Serena J, Blanco M, Davalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. *Stroke* 2004;35:520–6.
367. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. *Stroke* 2002;33:1315–20.
368. Blood pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke. *Cochrane Database Syst Rev* 2001;(44):CD000039.
369. Nazir FS, Overell JR, Bolster A, Hilditch TE, Lees KR. Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial. *Cerebrovasc Dis* 2005;19:77–83.
370. COSSACS investigators. COSSACS (Continue or Stop post-Stroke Antihypertensives Collaborative Study): rationale and design. *J Hypertens* 2005;23:455–8.
371. Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. *Drugs Aging* 2006;23:131–55.
372. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? *JAMA* 1996;276:1328–31.
373. Kiers L, Davis SM, Larkins R, et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. *J Neurol Neurosurg Psychiatry* 1992;55:263–70.
374. van Kooten F, Hoogerbrugge N, Naarding P, Koudstaal PJ. Hyperglycemia in the acute phase of stroke is not caused by stress. *Stroke* 1993;24:1129–32.
375. Baird TA, Parsons MW, Phan T, et al. Persistent post-stroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. *Stroke* 2003;34:2208–14.
376. Baird TA, Parsons MW, Barber PA, et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. *J Clin Neurosci* 2002;9:618–26.
377. Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. *Ann Neurol* 2002;52:20–8.
378. Huff JS. Stroke mimics and chameleons. *Emerg Med Clin North Am* 2002;20:583–95.
379. Fukuda H, Kitani M, Takahashi K. Body temperature correlates with functional outcome and the lesion size of cerebral infarction. *Acta Neurol Scand* 1999;100:385–90.
380. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. *Lancet* 1996;347:422–5.
381. Castillo J, Davalos A, Noya M. Aggravation of acute ischemic stroke by hyperthermia is related to an excitotoxic mechanism. *Cerebrovasc Dis* 1999;9:22–7.
382. Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. *Stroke* 2000;31:410–4.
383. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). *Lancet* 1998;352:1245–51.
384. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute stroke. *JAMA* 1995;274:1017–25.
385. *Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. *Cochrane Database Syst Rev* 2009;(4):CD000213.

386. *Hacke W, Donnan G, Fieschi C, *et al.* Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet* 2004;**363**:768–74.
387. Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rTPA Stroke Study. *Stroke* 2005;**36**:2110–5.
388. Hacke W, Kaste M, Bluhmki E, *et al.* Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *New England Journal of Medicine* 2008;**359**:1317–29.
389. Wahlgren N, Ahmed N, Davalos A, *et al.* Thrombolysis with alteplase 3–4 center dot 5h after acute ischaemic stroke (SITS-ISTR): an observational study. *Lancet* 2008;**372**:1303–9.
390. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. *J Neurol Neurosurg Psychiatry* 2006;**77**:826–9.
391. van Oostenbrugge RJ, Hupperts RM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. *J Neurol Neurosurg Psychiatry* 2006;**77**:375–7.
392. Ringleb PA, Schwark C, Köhrmann M, *et al.* Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. *J Neurol Neurosurg Psychiatry* 2007;**78**:690–3.
393. Elkind MS, Prabhakaran S, Pittman J, Koroshetz W, Jacoby M, Johnston KC. Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke. *Neurology* 2007;**68**:842–8.
394. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study (CASES). *CMAJ* 2005;**172**:1307–12.
395. Bateman BT, Schumacher HC, Boden-Albala B, *et al.* Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. *Stroke* 2006;**37**:440–6.
396. *Wahlgren N, Ahmed N, Davalos A, *et al.* Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. *Lancet* 2007;**369**:275–82.
397. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. *Stroke* 2003;**34**:799–800.
398. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. *Stroke* 2003;**34**:2847–50.
399. Alexandrov AV, Molina CA, Grotta JC, *et al.* Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. *N Engl J Med* 2004;**351**:2170–8.
400. Molina CA, Ribo M, Rubiera M, *et al.* Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. *Stroke* 2006;**37**:425–9.
401. Köhrmann M, Jüttler E, Fiebach JB, *et al.* MRI versus CT-based thrombolysis treatment within and beyond the 3h time window after stroke onset: a cohort study. *Lancet Neurol* 2006;**5**:661–7.
402. Schellinger PD, Thomalla G, Fiehler J, *et al.* MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. *Stroke* 2007;**38**:2640–5.
403. *Lansberg MG, Thijs VN, Bammer R, *et al.* Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. *Stroke* 2007;**38**:2275–8.
404. The Multicenter Acute Stroke Trial – Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. *N Engl J Med* 1996;**335**:145–50.
405. (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial – Italy. *Lancet* 1995;**346**:1509–14.
406. *Hacke W, Albers G, Al-Rawi Y, *et al.* The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke* 2005;**36**:66–73.
407. *Furlan AJ, Eydind D, Albers GW, *et al.* Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. *Stroke* 2006;**37**:1227–31.
408. Ogawa A, Mori E, Minematsu K, *et al.* Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. *Stroke* 2007;**38**:2633–9.
409. Nedeltchev K, Fischer U, Arnold M, *et al.* Long-term effect of intra-arterial thrombolysis in stroke. *Stroke* 2006;**37**:3002–7.
410. IMS investigators. The Interventional Management of Stroke (IMS) II Study. *Stroke* 2007;**38**:2127–35.
411. Macleod MR, Davis SM, Mitchell PJ, *et al.* Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior

- circulation ischaemic stroke. *Cerebrovasc Dis* 2005;**20**:12–7.
412. Brandt T, von Kummer R, Muller Kupperts M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. *Stroke* 1996;**27**:875–81.
413. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. *Stroke* 1988;**19**:1216–22.
414. *Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. *Stroke* 2006;**37**:922–8.
415. *Smith WS, Sung G, Starkman S, *et al.* Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. *Stroke* 2005;**36**:1432–8.
416. *International-Stroke-Trial-Collaborative-Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. *Lancet* 1997;**349**:1569–81.
417. *CAST-Collaborative-Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. *Lancet* 1997;**349**:1641–9.
418. Rödén-Jülig A, Britton M, Malmkvist K, Leijl B. Aspirin in the prevention of progressing stroke: a randomized controlled study. *J Intern Med* 2003;**254**:584–90.
419. *AbESST investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. *Stroke* 2005;**36**:880–90.
420. *Adams HP Jr, Effron MB, Torner J, *et al.* Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial. Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). *Stroke* 2008;**39**:87–99.
421. *Kay R, Wong KS, Yu YL, *et al.* Low-molecular-weight heparin for the treatment of acute ischemic stroke. *N Engl J Med* 1995;**333**:1588–93.
422. *Wong KS, Chen C, Ng PW, *et al.* Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. *Lancet Neurol* 2007;**6**:407–13.
423. *Diener HC, Ringelstein EB, von Kummer R, *et al.* Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. *Stroke* 2001;**32**:22–9.
424. *Bath PM, Lindenstrom E, Boysen G, *et al.* Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *Lancet* 2001;**358**:702–10.
425. *Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. *Lancet* 2000;**355**:1205–10.
426. *The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. *JAMA* 1998;**279**:1265–72.
427. *Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. *Cochrane Database Syst Rev* 2008;(4):CD000024.
428. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. *Stroke* 2005;**36**:2415–20.
429. Chamorro A, Busse O, Obach V, *et al.* The rapid anticoagulation prevents ischemic damage study in acute stroke – final results from the writing committee. *Cerebrovasc Dis* 2005;**19**:402–4.
430. Chamorro A. Immediate anticoagulation for acute stroke in atrial fibrillation: yes. *Stroke* 2006;**37**:3052–3.
431. Sandercock P. Immediate anticoagulation for acute stroke in atrial fibrillation: no. *Stroke* 2006;**37**:3054–5.
432. *Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. *Stroke* 2007;**38**:423–30.
433. *Shuaib A, Lees KR, Lyden P, *et al.* NXY-059 for the treatment of acute ischemic stroke. *N Engl J Med* 2007;**357**:562–71.
434. *Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. *Lancet* 2004;**363**:439–45.
435. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. *Stroke* 2007;**38**:2173–5.
436. Davalos A, Castillo J, Alvarez-Sabin J, *et al.* Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. *Stroke* 2002;**33**:2850–7.
437. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. ‘Malignant’ middle cerebral artery territory infarction: clinical course and prognostic signs. *Arch Neurol* 1996;**53**:309–15.

438. Qureshi AI, Suarez JI, Yahia AM, *et al.* Timing of neurologic deterioration in massive middle cerebral artery infarction: a multicenter review. *Crit Care Med* 2003;**31**:272–7.
439. Unterberg AW, Kiening KL, Hartl R, Bardt T, Sarrafzadeh AS, Lanksch WR. Multimodal monitoring in patients with head injury: evaluation of the effects of treatment on cerebral oxygenation. *J Trauma* 1997;**42**:S32–7.
440. Righetti E, Celani MG, Cantisani TA, Sterzi R, Boysen G, Ricci S. Glycerol for acute stroke: a Cochrane systematic review. *J Neurol* 2002;**249**:445–51.
441. Berezcki D, Liu M, do Prado GF, Fekete I. Mannitol for acute stroke. *Cochrane Database Syst Rev* 2001;(1):CD001153.
442. Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. *Stroke* 2002;**33**:136–40.
443. *Qizilbash N, Lewington SL, Lopez-Arrieta JM. Corticosteroids for acute ischaemic stroke. *Cochrane Database Syst Rev* 2002;(2):CD000064.
444. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. *Stroke* 1998;**29**:2461–6.
445. Steiner T, Ringleb P, Hacke W. Treatment options for large hemispheric stroke. *Neurology* 2001;**57**(5 Suppl. 2):S61–8.
446. Els T, Oehm E, Voigt S, Klisch J, Hetzel A, Kassubek J. Safety and therapeutical benefit of hemicraniectomy combined with mild hypothermia in comparison with hemicraniectomy alone in patients with malignant ischemic stroke. *Cerebrovasc Dis* 2006;**21**:79–85.
447. *Vahedi K, Hofmeijer J, Jüttler E, *et al.* Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. *Lancet Neurol* 2007;**6**:215–22.
448. Jüttler E, Schwab S, Schmiedek P, *et al.* Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. *Stroke* 2007;**38**:2518–25.
449. Gupta R, Connolly ES, Mayer S, Elkind MS. Hemicraniectomy for massive middle cerebral artery territory infarction: a systematic review. *Stroke* 2004;**35**:539–43.
450. Weimar C, Roth MP, Zillessen G, *et al.* Complications following acute ischemic stroke. *Eur Neurol* 2002;**48**:133–40.
451. Horner J, Massey EW, Riski JE, Lathrop DL, Chase KN. Aspiration following stroke: clinical correlates and outcome. *Neurology* 1988;**38**:1359–62.
452. Prass K, Meisel C, Höflich C, *et al.* Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by post-stroke T helper cell type 1-like immunostimulation. *J Exp Med* 2003;**198**:725–36.
453. Chamorro A, Amaro S, Vargas M, *et al.* Interleukin 10, monocytes and increased risk of early infection in ischemic stroke. *J Neurol Neurosurg Psychiatry* 2006;**77**:1279–81.
454. Chamorro A, Horcajada JP, Obach V, *et al.* The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. *Stroke* 2005;**36**:1495–500.
455. *Mazzone C, Chiodo GF, Sandercock P, Miccio M, Salvi R. Physical methods for preventing deep vein thrombosis in stroke. *Cochrane Database Syst Rev* 2004;(4):CD001922.
456. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. *J Thromb Haemost* 2005;**3**:1187–94.
457. *Diener HC, Ringelstein EB, von Kummer R, *et al.* Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. *Stroke* 2006;**37**:139–44.
458. *Sherman DG, Albers GW, Bladin C, *et al.* The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischemic stroke (PREVAIL Study): an open-label randomised comparison. *Lancet* 2007;**369**:1347–55.
459. Reddy M, Gill SS, Rochon PA. Preventing pressure ulcers: a systematic review. *JAMA* 2006;**296**:974–84.
460. Forster A, Young J. Incidence and consequences of falls due to stroke: a systematic inquiry. *BMJ* 1995;**311**:83–6.
461. Mackintosh SF, Goldie P, Hill K. Falls incidence and factors associated with falling in older, community-dwelling, chronic stroke survivors (>1 year after stroke) and matched controls. *Aging Clin Exp Res* 2005;**17**:74–81.
462. Mackintosh SF, Hill KD, Dodd KJ, Goldie PA, Culham EG. Balance score and a history of falls in hospital predict recurrent falls in the 6 months following stroke rehabilitation. *Arch Phys Med Rehabil* 2006;**87**:1583–9.
463. Lamb SE, Ferrucci L, Volapto S, Fried LP, Guralnik JM. Risk factors for falling in home-dwelling older women with stroke: the Women's Health and Aging Study. *Stroke* 2003;**34**:494–501.
464. Aizen E, Shugaev I, Lenger R. Risk factors and characteristics of falls during inpatient rehabilitation of elderly patients. *Arch Gerontol Geriatr* 2007;**44**:1–12.
465. Teasell R, McRae M, Foley N, Bhardwaj A. The incidence and consequences of falls in stroke patients during inpatient rehabilitation: factors associated with high risk. *Arch Phys Med Rehabil* 2002;**83**:329–33.
466. Vassallo M, Vignaraja R, Sharma JC, *et al.* The effect of changing practice on fall prevention in a rehabilitative hos-

- pital: the Hospital Injury Prevention Study. *J Am Geriatr Soc* 2004;**52**:335–9.
467. Oliver D, Connelly JB, Victor CR, *et al.* Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. *BMJ* 2007;**334**:82.
468. Rannemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y. Fractures after stroke. *Osteoporos Int* 1998;**8**:92–5.
469. Rannemark A, Nilsson M, Borssen B, Gustafson Y. Stroke, a major and increasing risk factor for femoral neck fracture. *Stroke* 2000;**31**:1572–7.
470. *Pang MY, Eng JJ, Dawson AS, Gylfadottir S. The use of aerobic exercise training in improving aerobic capacity in individuals with stroke: a meta-analysis. *Clin Rehabil* 2006;**20**:97–111.
471. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. *Cerebrovasc Dis* 2005;**20**:187–92.
472. Sato Y, Asoh T, Kaji M, Oizumi K. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. *J Bone Miner Res* 2000;**15**:2487–94.
473. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. *Cochrane Database Syst Rev* 2004;(3):CD001255.
474. Gerberding JL. Hospital-onset infections: a patient safety issue. *Ann Intern Med* 2002;**137**:665–70.
475. Thomas L, Cross S, Barrett J, *et al.* Treatment of urinary incontinence after stroke in adults. *Cochrane Database Syst Rev* 2008;(1):CD004462.
476. Jorgensen L, Engstad T, Jacobsen BK. Self-reported urinary incontinence in noninstitutionalized long-term stroke survivors: a population-based study. *Arch Phys Med Rehabil* 2005;**86**:416–20.
477. Thomas LH, Barrett J, Cross S, *et al.* Prevention and treatment of urinary incontinence after stroke in adults. *Cochrane Database Syst Rev* 2005;(3):CD004462.
478. Meijer R, Ihnenfeldt DS, de Groot IJ, van Limbeek J, Vermeulen M, de Haan RJ. Prognostic factors for ambulation and activities of daily living in the subacute phase after stroke. A systematic review of the literature. *Clin Rehabil* 2003;**17**:119–29.
479. Dumoulin C, Korner-Bitensky N, Tannenbaum C. Urinary incontinence after stroke: does rehabilitation make a difference? A systematic review of the effectiveness of behavioral therapy. *Top Stroke Rehabil* 2005;**12**: 66–76.
480. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. *Stroke* 2005;**36**:2756–63.
481. Mann G, Hankey GJ, Cameron D. Swallowing function after stroke: prognosis and prognostic factors at 6 months. *Stroke* 1999;**30**:744–8.
482. Dennis MS, Lewis SC, Warlow C. Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomised controlled trial. *Lancet* 2005; **365**:755–63.
483. Axelsson K, Asplund K, Norberg A, Alafuzoff I. Nutritional status in patients with acute stroke. *Acta Med Scand* 1988;**224**:217–24.
484. Axelsson K, Asplund K, Norberg A, Eriksson S. Eating problems and nutritional status during hospital stay of patients with severe stroke. *J Am Diet Assoc* 1989;**89**: 1092–6.
485. Finestone HM, Greene-Finestone LS, Wilson ES, Teasell RW. Malnutrition in stroke patients on the rehabilitation service and at follow-up: prevalence and predictors. *Arch Phys Med Rehabil* 1995;**76**:310–6.
486. Finestone HM, Greene-Finestone LS, Wilson ES, Teasell RW. Prolonged length of stay and reduced functional improvement rate in malnourished stroke rehabilitation patients. *Arch Phys Med Rehabil* 1996;**77**:340–5.
487. Dávalos A, Ricart W, Gonzalez-Huix F, *et al.* Effect of malnutrition after acute stroke on clinical outcome. *Stroke* 1996;**27**:1028–32.
488. Food Trial Collaboration. Poor nutritional status on admission predicts poor outcomes after stroke: observational data from the FOOD trial. *Stroke* 2003;**34**:1450–6.
489. *Dennis MS, Lewis SC, Warlow C. Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled trial. *Lancet* 2005;**365**:764–72.
490. Norton B, Homer-Ward M, Donnelly MT, Long RG, Holmes GK. A randomised prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke. *BMJ* 1996;**312**: 13–6.
491. Hamidon BB, Abdullah SA, Zawawi MF, Sukumar N, Aminuddin A, Raymond AA. A prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding in patients with acute dysphagic stroke. *Med J Malaysia* 2006;**61**:59–66.
492. Callahan CM, Haag KM, Weinberger M, *et al.* Outcomes of percutaneous endoscopic gastrostomy among older adults in a community setting. *J Am Geriatr Soc* 2000;**48**: 1048–54.
493. Rickman J. Percutaneous endoscopic gastrostomy: psychological effects. *Br J Nurs* 1998;**7**:723–9.
494. WHO. *International Classification of Functioning Disability and Health*. Geneva: World Health Organisation, 2001.

495. Langhorne P, Dennis MS. *Stroke Units, an Evidence Based Approach*. London: BMJ Publishing group, 1998.
496. Lincoln NB, Husbands S, Trescoli C, Drummond AE, Gladman JR, Berman P. Five-year follow up of a randomised controlled trial of a stroke rehabilitation unit. *BMJ* 2000;**320**:549.
497. Indredavik B, Slordahl SA, Bakke F, Rokseth R, Haheim LL. Stroke unit treatment. Long-term effects. *Stroke* 1997;**28**:1861–6.
498. Early Supported Discharge Trialists. Services for reducing duration of hospital care for acute stroke patients. *Cochrane Database Syst Rev* 2005;(2):CD000443.
499. Langhorne P, Taylor G, Murray G, et al. Early supported discharge services for stroke patients: a meta-analysis of individual patients' data. *Lancet* 2005;**365**:501–6.
500. Ronning OM, Guldvog B. Outcome of subacute stroke rehabilitation: a randomized controlled trial. *Stroke* 1998;**29**:779–84.
501. *Legg L, Langhorne P. Rehabilitation therapy services for stroke patients living at home: systematic review of randomised trials. *Lancet* 2004;**363**:352–6.
502. Baron JC, Cohen LG, Cramer SC, et al. Neuroimaging in stroke recovery: a position paper from the First International Workshop on Neuroimaging and Stroke Recovery. *Cerebrovasc Dis* 2004;**18**:260–7.
503. Barbay S, Plautz E, Friel KM, et al. Delayed rehabilitative training following a small ischaemic infarct in non-human primate primary cortex. *Soc Neurosci Abstr* 2001;**27**:931–4.
504. Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. *J Neurosci* 2004;**24**:1245–54.
505. Paolucci S, Antonucci G, Grasso MG, et al. Early versus delayed inpatient stroke rehabilitation: a matched comparison conducted in Italy. *Arch Phys Med Rehabil* 2000;**81**:695–700.
506. Salter K, Jutai J, Hartley M, et al. Impact of early vs delayed admission to rehabilitation on functional outcomes in persons with stroke. *J Rehabil Med* 2006;**38**:113–7.
507. Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a multicenter study. *Stroke* 2000;**31**:1223–9.
508. Diserens K, Michel P, Bogousslavsky J. Early mobilisation after stroke: review of the literature. *Cerebrovasc Dis* 2006;**22**:183–90.
509. Bernhardt J, Dewey H, Thrift A, Donnan G. Inactive and alone: physical activity within the first 14 days of acute stroke unit care. *Stroke* 2004;**35**:1005–9.
510. *Aziz N, Leonardi-Bee J, Walker M, Phillips M, Gladman J, Legg L. Therapy based rehabilitation services for patients living at home more than one year after stroke – A Cochrane review. *Cochrane Database Syst Rev* 2008;(2):CD005952.
511. *Kwakkel G, van Peppen R, Wagenaar RC, et al. Effects of augmented exercise therapy time after stroke: a meta-analysis. *Stroke* 2004;**35**:2529–39.
512. *Langhorne P, Wagenaar R, Partridge C. Physiotherapy after stroke: more is better? *Physiother Res Int* 1996;**1**:75–88.
513. *van der Lee JH, Snels IA, Beckerman H, Lankhorst GJ, Wagenaar RC, Bouter LM. Exercise therapy for arm function in stroke patients: a systematic review of randomized controlled trials. *Clin Rehabil* 2001;**15**:20–31.
514. Evans A, Perez I, Harraf F, et al. Can differences in management processes explain different outcomes between stroke unit and stroke-team care? *Lancet* 2001;**358**:1586–92.
515. Kalra L, Dale P, Crome P. Improving stroke rehabilitation. A controlled study. *Stroke* 1993;**24**:1462–7.
516. *Stroke Unit Trialists' Collaboration. How do stroke units improve patient outcomes? A collaborative systematic review of the randomized trials. Stroke Unit Trialists Collaboration. *Stroke* 1997;**28**:2139–44.
517. *van Peppen RP, Kwakkel G, Wood-Dauphinee S, Hendriks HJ, Van der Wees PJ, Dekker J. The impact of physical therapy on functional outcomes after stroke: what's the evidence? *Clin Rehabil* 2004;**18**:833–62.
518. *Pollock A, Baer G, Langhorne P, Pomeroy V. Physiotherapy treatment approaches for the recovery of postural control and lower limb function following stroke: a systematic review. *Clin Rehabil* 2007;**21**:395–410.
519. *Pomeroy VM, King LM, Pollock A, Baily-Hallam A, Langhorne P. Electrostimulation for promoting recovery of movement or functional ability after stroke. Systematic review and meta-analysis. *Stroke* 2006;**37**:2441–2.
520. *Moseley AM, Stark A, Cameron ID, Pollock A. Treadmill training and body weight support for walking after stroke. *Cochrane Database Syst Rev* 2005;(4):CD002840.
521. Mehrholz J, Werner C, Kugler J, Pohl M. Electromechanical-assisted training for walking after stroke. *Cochrane Database Syst Rev* 2007;(4):CD006185.
522. de Wit DC, Buurke JH, Nijlant JM, Ijzerman MJ, Hermens HJ. The effect of an ankle-foot orthosis on walking ability in chronic stroke patients: a randomized controlled trial. *Clin Rehabil* 2004;**18**:550–7.
523. Gordon NF, Gulanick M, Costa F, et al. Physical activity and exercise recommendations for stroke survivors: an American Heart Association scientific statement from the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention; the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and the Stroke Council. *Stroke* 2004;**35**:1230–40.

524. Wolf SL, Winstein CJ, Miller JP, *et al.* Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. *JAMA* 2006;**296**:2095–104.
525. *Legg LA, Drummond AE, Langhorne P. Occupational therapy for patients with problems in activities of daily living after stroke. *Cochrane Database Syst Rev* 2006;(4):CD003585.
526. *Walker MF, Leonardi-Bee J, Bath P, *et al.* Individual patient data meta-analysis of randomized controlled trials of community occupational therapy for stroke patients. *Stroke* 2004;**35**:2226–32.
527. Sackley C, Wade DT, Mant D, *et al.* Cluster randomized pilot controlled trial of an occupational therapy intervention for residents with stroke in UK care homes. *Stroke* 2006;**37**:2336–41.
528. Bath PMW, Bath-Hextall FJ, Smithard DG. Interventions for dysphagia in acute stroke. *Cochrane Database Syst Rev* 2007;(8):19.
529. DePippo KL, Holas MA, Reding MJ, Mandel FS, Lesser ML. Dysphagia therapy following stroke: a controlled trial. *Neurology* 1994;**44**:1655–60.
530. Engelter ST, Gostynski M, Papa S, *et al.* Epidemiology of aphasia attributable to first ischemic stroke: incidence, severity, fluency, etiology, and thrombolysis. *Stroke* 2006;**37**:1379–84.
531. *Sellars C, Hughes T, Langhorne P. Speech and language therapy for dysarthria due to non-progressive brain damage. *Cochrane Database Syst Rev* 2005;(3):CD002088.
532. *Greener J, Enderby P, Whurr R. Speech and language therapy for aphasia following stroke. *Cochrane Database Syst Rev* 2000;(2):CD000425.
533. Robey RR. The efficacy of treatment for aphasic persons: a meta-analysis. *Brain Lang* 1994;**47**:582–608.
534. Robey RR. A meta-analysis of clinical outcomes in the treatment of aphasia. *J Speech Lang Hear Res* 1998;**41**:172–87.
535. Pulvermuller F, Neining B, Elbert T, *et al.* Constraint-induced therapy of chronic aphasia after stroke. *Stroke* 2001;**32**:1621–6.
536. Bhogal SK, Teasell R, Speechley M. Intensity of aphasia therapy, impact on recovery. *Stroke* 2003;**34**:987–93.
537. *Stroke Liaison Workers Collaboration. Meta-analysis of stroke liaison workers for patients and carers: results by intervention characteristic. *Cerebrovasc Dis* 2006;**21**:120.
538. O'Mahony PG, Rodgers H, Thomson RG, Dobson R, James OF. Satisfaction with information and advice received by stroke patients. *Clin Rehabil* 1997;**11**:68–72.
539. *Forster A, Young J, Langhorne P. Medical day hospital care for the elderly versus alternative forms of care. *Cochrane Database Syst Rev* 2008;(4):CD001730.
540. Kalra L, Evans A, Perez I, *et al.* Training carers of stroke patients: randomised controlled trial. *BMJ* 2004;**328**:1099.
541. Johansson BB. Brain plasticity and stroke rehabilitation. The Willis lecture. *Stroke* 2000;**31**:223–30.
542. Nair RD, Lincoln NB. Cognitive rehabilitation for memory deficits following stroke. *Cochrane Database Syst Rev* 2007;(3):CD002293.
543. Lincoln NB, Majid MJ, Weyman N. Cognitive rehabilitation for attention deficits following stroke. *Cochrane Database Syst Rev* 2000;(4):CD002842.
544. Bowen A, Lincoln NB. Cognitive rehabilitation for spatial neglect following stroke. *Cochrane Database Syst Rev* 2007;(2):CD003586.
545. Cicerone KD, Dahlberg C, Malec JF, *et al.* Evidence-based cognitive rehabilitation: updated review of the literature from 1998 through 2002. *Arch Phys Med Rehabil* 2005;**86**:1681–92.
546. Marinkovic S, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. *J Urol* 2001;**165**:359–70.
547. Sjogren K, Fugl-Meyer AR. Adjustment to life after stroke with special reference to sexual intercourse and leisure. *J Psychosom Res* 1982;**26**:409–17.
548. Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. *Am J Cardiol* 2000;**86**:14F–8F.
549. McLean DE. Medical complications experienced by a cohort of stroke survivors during inpatient, tertiary-level stroke rehabilitation. *Arch Phys Med Rehabil* 2004;**85**:466–9.
550. Paolucci S, Antonucci G, Pratesi L, Traballese M, Lubich S, Grasso MG. Functional outcome in stroke inpatient rehabilitation: predicting no, low and high response patients. *Cerebrovasc Dis* 1998;**8**:228–34.
551. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. *Stroke* 2005;**36**:2296–301.
552. Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V. The Italian multicenter observational study on post-stroke depression (DESTRO). *J Neurol* 2006;**253**:556–62.
553. Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients: a case-control study. *Stroke* 2007;**38**:1860–3.
554. Thomas SA, Lincoln NB. Factors relating to depression after stroke. *Br J Clin Psychol* 2006;**45**:49–61.
555. Kauhanen M, Korpelainen JT, Hiltunen P, *et al.* Poststroke depression correlates with cognitive impairment and neurological deficits. *Stroke* 1999;**30**:1875–80.
556. *van de Meent H, Geurts AC, Van Limbeek J. Pharmacologic treatment of poststroke depression: a systematic review of the literature. *Top Stroke Rehabil* 2003;**10**:79–92.

557. *Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. *Stroke* 2005;**36**:1098–103.
558. *Bhagal SK, Teasell R, Foley N, Speechley M. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. *J Am Geriatr Soc* 2005;**53**:1051–7.
559. *Anderson CS, Hackett ML, House AO. Interventions for preventing depression after stroke. *Cochrane Database Syst Rev* 2008;(3):CD003689.
560. *House AO, Hackett ML, Anderson CS, Horrocks JA. Pharmaceutical interventions for emotionalism after stroke. *Cochrane Database Syst Rev* 2010;(2):CD003690.
561. Lindgren I, Jonsson AC, Norrving B, Lindgren A. Shoulder pain after stroke: a prospective population-based study. *Stroke* 2007;**38**:343–8.
562. Vuagnat H, Chantraine A. Shoulder pain in hemiplegia revisited: contribution of functional electrical stimulation and other therapies. *J Rehabil Med* 2003;**35**:49–54.
563. *Price CI, Pandyan AD. Electrical stimulation for preventing and treating post-stroke shoulder pain: a systematic Cochrane review. *Clin Rehabil* 2001;**15**:5–19.
564. Ada L, Foongchomcheay A, Canning C. Supportive devices for preventing and treating subluxation of the shoulder after stroke. *Cochrane Database Syst Rev* 2005;(1):CD003863.
565. *Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. *Cochrane Database Syst Rev* 2005;(2):CD001133.
566. *Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. *CMAJ* 2003;**169**:1173–9.
567. Lannin NA, Herbert RD. Is hand splinting effective for adults following stroke? A systematic review and methodologic critique of published research. *Clin Rehabil* 2003;**17**:807–16.
568. Brashear A, Gordon MF, Elovic E, *et al.* Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. *N Engl J Med* 2002;**347**:395–400.
569. van Kuijk AA, Geurts AC, Bevaart BJ, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. *J Rehabil Med* 2002;**34**:51–61.
570. Pittock SJ, Moore AP, Hardiman O, *et al.* A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. *Cerebrovasc Dis* 2003;**15**:289–300.
571. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. *Arch Phys Med Rehabil* 2001;**82**:1155–63.
572. Shah S, Vanclay F, Cooper B. Efficiency, effectiveness, and duration of stroke rehabilitation. *Stroke* 1990;**21**:241–6.
573. Wyller TB, Sodring KM, Sveen U, Ljunggren AE, Bautz-Holter E. Are there gender differences in functional outcome after stroke? *Clin Rehabil* 1997;**11**:171–9.
574. Chae J, Zorowitz RD, Johnston MV. Functional outcome of hemorrhagic and nonhemorrhagic stroke patients after inpatient rehabilitation. *Am J Phys Med Rehabil* 1996;**75**:177–82.
575. Falconer JA, Naughton BJ, Strasser DC, Sinacore JM. Stroke inpatient rehabilitation: a comparison across age groups. *J Am Geriatr Soc* 1994;**42**:39–44.
576. Katz N, Hartman-Maeir A, Ring H, Soroker N. Functional disability and rehabilitation outcome in right hemisphere damaged patients with and without unilateral spatial neglect. *Arch Phys Med Rehabil* 1999;**80**:379–84.
577. Ween JE, Alexander MP, D'Esposito M, Roberts M. Factors predictive of stroke outcome in a rehabilitation setting. *Neurology* 1996;**47**:388–92.
578. Gladman JR, Sackley CM. The scope for rehabilitation in severely disabled stroke patients. *Disabil Rehabil* 1998;**20**:391–4.
579. Rodgers H. The scope for rehabilitation in severely disabled stroke patients. *Disabil Rehabil* 2000;**22**:199–200.
580. van Peppen RP, Hendriks HJ, van Meeteren NL, Helders PJ, Kwakkel G. The development of a clinical practice stroke guideline for physiotherapists in The Netherlands: a systematic review of available evidence. *Disabil Rehabil* 2007;**29**:767–83.
581. Kalra L, Eade J. Role of stroke rehabilitation units in managing severe disability after stroke. *Stroke* 1995;**26**:2031–4.
582. Schmidt JG, Drew-Cates J, Dombrov ML. Severe disability after stroke: outcome after inpatient rehabilitation. *Neuro-rehab Neural Repair* 1999;**13**:199–203.
583. Brainin M, Barnes M, Baron JC, *et al.* Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. *Eur J Neurol* 2004;**11**:577–81.
584. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. *Lancet* 1999;**354**:1457–63.
585. Ringleb PA, Hacke W. [Stent and surgery for symptomatic carotid stenosis. SPACE study results]. *Nervenarzt* 2007;**78**:1130–7.